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Abstract 
Squamous cell carcinoma of tissues of the head and neck (HNSCC) continues 
to be a major cause of morbidity and mortality in many parts of the world, and 
survival is not improving. Much research has been devoted to the identification 
of molecular markers characteristic of the development and progression of 
HNSCC. Alterations in many molecular markers in HNSCC have been 
demonstrated, including genes related to proliferation, differentiation, adhesion 
and others such as those that control invasion and metastasis. Some of these 
single markers may indicate poor prognosis or risk of recurrence, but none has 
been found to be robust enough for clinical use. 
Limitless replicative potential, or immortality, has been identified as one of the 
six basic "hallmarks" of cancer. Clinical follow-up data from our HNSCC 
cultures, and other studies, show a correlation between the ability of HNSCCs 
to establish as cell lines in culture (i. e. become immortal) and poorer patient 
survival. In addition, 40% of primary cell cultures derived from dysplastic 
premalignant oral lesions are immortal in culture. Thus, the acquisition of 
immortality and invasion may be independent events. Previous work has 
demonstrated a specific pattern of four biological markers associated with oral 
SCC or dysplasia immortality in cell culture: namely p16 and RARP loss, p53 
mutation, and telomerase activation. The changes in p16, p53 and hTERT 
were found in the dysplasia biopsies from which the cultures were derived, 
however the in vitro changes in RAR-, 8 expression were not reproduced in the 
biopsy tissues. 
Microarray analysis was performed on 32 head and neck keratinocyte cultures 
using Affymetrix U133A/B genechips. The panel of cultures included normal 
cells, mortal and immortal cultures of dysplastic keratinocytes and mortal and 
immortal cultures from carcinomas, all grown to a standard protocol. 
The overall GEP revealed that many of the well-established HNSCC molecular 
markers associated with motility and invasion were up-regulated in the mortal 
cells, particularly in the mortal carcinomas. Immortal HNSCC cells showed 
elevated expression of cell-cycle markers and loss of differentiation markers. 
In addition, a small number of common changes in gene expression in all the 
carcinomas, regardless of replicative fate, were identified. This included several 
transcription factors. 
A series of 49 novel gene expression changes consistently associated with 
immortality in dysplastic keratinocytes and SCCs were identified. The list 
included genes involved in cell cycle control, signalling, cellular metabolism and 
maintenance of cellular structure. Validation of the expression of these genes 
by western blot demonstrated that, in general, the protein expression of genes 
agreed with the RNA expression level from the microarray data. However, 
some heterogeneity was evident. 
The mortal and immortal gene expression signatures were validated by IHC in 
the turnours from which the cultures were derived. The turnours that gave rise 
to immortal cell cultures demonstrated a relatively uniform pattern of staining in 
relation to the novel markers of immortality. However, those tumours which 
gave rise to mortal cultures exhibited significant heterogeneity of gene 
expression pattern, with areas characteristic of both the mortal and immortal 
phenotype present. 
The patterns of gene expression characteristic of mortal and immortal cells may 
reflect the differing origin of these populations, relating to different mechanisms 
involved in the generation of HNSCC subtypes. The differences may also 
indicate that the mortal and immortal cells utilise different mechanisms of 
invasion. In some cases, mortal and immortal cells exist in adjacent areas 
within the same tumour, but it is not clear whether the immortal HNSCCs derive 
from the adjacent mortal cells. However, the presence of intermediate features 
in vivo and in vitro raises the possibility that inter-conversion between the two 
HNSCC types may be possible, with mortal neoplastic keratinocytes gaining the 
immortal phenotype 
These novel markers give us further insight into the mechanisms and 
importance of keratinocyte immortalization. Surrogate markers of immortality 
could therefore be valuable for assessment of prognosis and therapy if 
confirmed in larger in vivo studies. 
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1 
Chapter One: Clinical and pathological aspects of head and neck 
squamous cell carcinoma and related premalignant lesions. 
1.1 General introduction 
Squamous cell carcinoma of tissues of the head and neck (HNSCC) continues 
to be a major cause of morbidity and mortality in many parts of the world. 
Indeed, head and neck cancer (90% of which is HNSCC) is the sixth most 
common cancer worldwide, with a much higher incidence in particular 
subpopulations, especially in areas of France, the Indian sub-continent and Far 
East. This disease can have devastating effects on the sufferer, as treatment 
often involves mutilating surgery that compromises the functions of the upper 
aero-digestive tract, in addition to the unfortunate social stigma of the facial 
disfigurement that treatment often involves. Patients, particularly if at advanced 
stage on presentation, often follow a protracted clinical course involving 
repeated recurrences with a requirement for long-term multi-disciplinary care. 
This is distressing for the patient and their family and places a significant 
financial and logistical burden on the treating healthcare institution. 
1.2 Epidemiology 
1.2.1 Incidence 
HNSCC is a heterogeneous group comprising cancers of the lip, oral cavity, 
oropharynx, hypopharynx and larynx, each having clinically and biologically 
distinctive features, but clearly linked by common risk factors (Takes et al., 
1998). In the United Kingdom, approximately 8000 new cases of HNSCC are 
diagnosed each year, with oral cancer comprising 1.6% of all new malignant 
disease. Historically, the sex ratio has shown a male predominance (5: 1), but 
this has decreased as the female incidence rate has risen (now 1.9: 1). Patients 
over 50 years of age comprise 85% of cases. (ISID at www. isdscotland. o[g). 
The incidence of HNSCC in the UK as a whole has been stable over the last 25 
years at around 16 per 100,000 population. However, this headline figure is 
misleading and conceals important trends. In Scotland, head and neck cancer 
incidence increased by 16.3% over the period 1990-2000 (Table 1.1 shows 
individual male and female rates). There was also an increase in the incidence 
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of cancers of the oral cavity, both in the UK as a whole, but particularly in 
Scotland, where data from the Scottish Cancer Registry (ISID at 
www. isdscotland. o[g) reveals an increase of 34% in males and 43% in females 
over a similar period (Table 1.2). This contrasts with the 20% reduction in male 
lung cancer incidence in Scotland over 1990-2000, an intriguing phenomenon 
as HNSCC and lung cancer share many common risk factors. Similar rises in 
HNSCC incidence have been seen in many areas of the world, particularly in 
Central and Eastern Europe, Japan and Australia (La Vecchia et al., 2004; La 
Vecchia et al., 1997). However, in the USA, the incidence of HNSCC amongst 
whites (especially males) is failing (Ries et al., 2004). A reduction has also 
been seen in some areas of high incidence such as India, Hong Kong and 
Brazil (Sankaranarayanan et al., 1998). 
Another worrying feature hidden in the headline data is the rise in HNSCC 
incidence in young patients (younger than 45 years at diagnosis) in many high 
incidence and European countries (Boyle et al., 1995). Many of these patients 
fall into the traditional high risk factor groups, but an increasing proportion do 
not (Llewellyn et al., 2003; Llewellyn et al., 2004; Rodriguez et al., 2004). Such 
patients without the traditional HNSCC risk factors may constitute a distinct 
clinical and biological group (Koch et al., 1999). The notion that these young 
patients have a poor prognosis with a low five-year survival is not supported by 
studies in Scotland, as recent data revealed that the 15-44 year age group had 
a substantially higher five-year survival than any other age group (ISD at 
www. isdscotland. org). A recent study in Scandinavia also reported higher five 
year survival rates in young patients (Annertz et al., 2002). 
Mortality 
Headline figures for the overall five-year survival of patients with HNSCC are 
also misleading as they conceal trends in particular subgroups of patients. 
These summary statistics do not take into account the diversity of stage and 
anatomical subsites involved. Aggressive surgical treatment of early disease at 
some subsites, for example lip, can produce five-year survival figures of 80-90% 
(McCombe et al., 2000; Veness et al., 2001). However, in many parts of the 
world, including Scotland, despite progress in the understanding of the disease, 
the headline survival rates for head and neck cancer have not changed 
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markedly over the last few decades (ISID at www. isdscotland. o[g). The five- 
year survival rate is 54.3% for males and 56.6% for females (Table 1.1). 
Indeed, in Scottish males, the five-year survival from head and neck cancer has 
fallen slightly over the period 1977-2001. Many reasons have been proposed, 
including a less favourable case mix and an increase in the proportion of 
patients from deprived areas (Macfarlane et al., 1996). In contrast, over the 
same period, five-year survival from oral cavity cancer improved by 15%, in 
both males and females (ISID at www. isdscotland. onq). 
The recent overall worsening of HNSCC survival in Scottish males is 
disappointing. Whilst developments in primary surgical and oncological 
treatment have resulted in better apparent control of primary disease, there has 
been little improvement in the management of metastatic disease. This is 
becoming a problem, as an increasing proportion of patients now survive long 
enough to present with distant metastases (Taneja et al., 2002). Thus, it has 
become clear that the way forward in tackling this devastating disease must be 
on two fronts. Emphasis must be placed on prevention and early detection of 
HNSCC lesions and the careful clinical and pathological monitoring of any 
lesions that may harbour an increased risk of development of HNSCC. The 
Health Education Board for Scotland (HEBS) has highlighted this in recent 
media campaigns. Additionally, advancement in the knowledge of the biology 
and pathogenesis of HNSCC may result in the development of molecular based 
prognosis assessment tools and therapies, which may help to reduce the 
burden of continued disease, foremost for the patient, but also on the 
healthcare system. 
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Summary statistics Period Males Females 
Rank 2001 4 10 
Relative frequency 2001 5.6% 2.4% 
Registrations 2001 687 313 
Deaths 2003 252 113 
Change in incidence 
N 
1992-2001 +11.6% +21.80% 
Relative survival 
1 year 
5 years 
1997-2001 78.7 
54.3 
77.3 
56.6 
Table 1.1 Summary statistics for cancer of the head and neck in Scotland 
This Table comprises the most recent data from Scottish Health statistics, ISID 
Scotland, released on 26 November 2004 (ISD at www. isdscotland. org). This 
covers IARC classification codes ICD-9 140-149,160-161; ICD-10 COO-C14, 
C30-C32. 
Summary statistics Period Males Females 
Relative frequency 1999 1.9% 0.9% 
Registrations 1999 222 113 
Deaths 2001 81 35 
Change in incidence 
N 
1989-99 +35.4% +43.5% 
Relative survival 
-1 year 
-5 years 
1995-99 72.8 
43.1 
71.1 
51.3 
Table 1.2 Summary statistics for oral cavity cancer in Scotland 
This Table comprises data collected for IARC classification codes ICD-9 143- 
145; ICD-10 C03-CO6. Data from Scottish Health statistics, ISD Scotland (ISD 
at www. isdscotland. org). 
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1.3 Risk factors 
1.3.1 Tobacco and alcohol 
The main risk factors for HNSCC are tobacco usage (in any form) and alcohol 
consumption, but this varies significantly between subsites. A recent report 
found a 20 fold increased risk of oral and pharyngeal cancer below age 46 for 
heavy smokers, with a five-fold increase for heavy drinkers. The combination of 
heavy smoking and drinking led to an increased risk of almost 50 fold 
(Rodriguez et al., 2004). In Western populations, the most common sites for 
small, asymptomatic SCC lesions within the oral cavity are the ventral aspect of 
the tongue and floor of the mouth, presumably because this is where such 
carcinogens collect. Oral cancer is also prevalent in particular communities, 
such as in the Indian subcontinent, where other forms of tobacco consumption, 
such as betel quid chewing, are prevalent: indeed, in some Indian 
subpopulations, HNSCC accounts for almost half of all cancers in males 
(Sanghvi, 1981; Saranath et al., 1993). 
Carcinogens produced by tobacco, for example benz-(a)-pyrene and 
nitrosamines, are known to produce the precise types of guanine nucleotide 
transversions found in critical genes involved in HNSCC development, such as 
p53 (Burns et al., 1993; Chang et al., 1994). The role of alcohol is less clear, 
but it appears to act as a co-carcinogen by being metabolised to acetaldehyde. 
This can damage DNA and trap glutathione, an important peptide in 
detoxification of carcinogens (reviewed in Poschl & Seitz, 2004; Seitz et al., 
2001). Alcohol can also induce CYP2E1, an enzyme involved in activation of 
various pro-carcinogens found in alcoholic beverages and tobacco smoke. 
1.3.2 Human papilloma virus 
Human papilloma virus (HPV) has also been implicated in HNSCC development 
(Gillison et al., 2000), but this has proved controversial (Ha et al., 2002a). One 
case control study found an increased risk of HNSCC with the presence of high 
risk HPV types (HPV16) in exfoliated oral cells, in concert with heavy alcohol 
consumption and tobacco use (Smith et al., 2004). However, the concordance 
between oral HPV status and HPV positivity of the tumour in this study was 
weak and thus the data is open to other interpretation. Much of the data on the 
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role of HPV in HNSCC carcinogenesis is semiquantitative and hampered by 
difficulties in interpretation. The recent study by Ha and co-workers utilised 
quantitative PCR in assessment of HPV DNA copy number in oral 
carcinogenesis. This study concluded that sufficient copy numbers of HPV to 
allow a causal association to be inferred were only present in 1 of 102 
premalignant oral lesions and 1 of 34 oral SCCs (Ha et al., 2002a). 
Recent evidence more convincingly implicates HPV in a less aggressive form of 
HNSCC, particularly in tonsillar and oropharyngeal cancers, but to a lesser 
extent in oral cancer (Herrero et al., 2003; Ringstrom et al., 2002). These HPV- 
positive oropharyngeal cancers are clinically and biologically distinct and such 
patients had an improved prognosis (Gillison et al., 2000). Braakhuis and co- 
workers have shown that HNSCC with transcriptionally active HPV DNA fail to 
show the pattern loss of heterozygosity (LoH) at chromosomes 3p, 9p and 17p 
normally associated with HNSCC (Braakhuis et al., 2004b). The implications of 
this will become apparent in later discussion of the importance of such 
chromosomal loci. 
1.3.3 Other risk factors 
A multitude of other factors has been implicated. The development of lip cancer 
is primarily related to exposure to UV irradiation (Ju, 1973). Marijuana has also 
been postulated to play a role by increasing mutagen sensitivity (Zhang et al., 
1999), but the evidence from cohort studies does not support such a link 
(Hashibe et al., 2002; Rosenblatt et al., 2004). Poor diet, particularly a low 
consumption of fruit and vegetables has been implicated (Macfarlane et al., 
1995). This has been pinpointed as a potential cause of the increase in HNSCC 
incidence in young people, although it is likely that such an effect is additive to 
that of high tobacco and alcohol consumption (Llewellyn et al., 2004; Mackenzie 
et al., 2000). These collective risk factors may account for the higher incidence 
of HNSCC in socially and economically deprived communities, notably in the 
West of Scotland (Macfarlane et al., 1996). Nutrients, such as folic acid, may be 
protective (Pelucchi et al., 2003). A small number of patients may have an 
increased susceptibility to oral cancer because of inherited genetic defects 
(Prime et al., 2001). In disorders of DNA repair mechanisms, such as 
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xeroderma pigmentosurn, these is an increased incidence of secondary 
malignancies, including oral cancer (Patton & Valdez, 1991). 
Genetic susceptibility and environmental risk factors often interact. About 40% 
of Japanese carry a mutant allele of the acetaldehyde dehydrogenase-2 
(ALDI-12) gene that encodes an inactive enzyme. This mutant ALDI-12 allele is a 
strong risk factor for head and neck cancer and oesophageal cancer among 
heavy alcohol drinkers in Japan (Yokoyama et al., 2002). Polymorphisms in 
alcohol dehydrogenase-2 (AIDI-12) also affects risk of head and neck cancer in 
alcoholics (Yokoyama et al., 2001). Indeed, it has been calculated that the 
polymorphisms in the ALID2 and ALIDI-12 genes account for 82% of the 
population attributable risks for HNSCC in Japanese alcoholics (Yokoyama et 
al., 2001). 
There is some variation in the risk factors associated with different subsites 
within the upper aero-digestive tract. Smoking and alcohol in combination is a 
higher risk factor for oral cavity and pharyngeal cancer than for larynx (Baron et 
al., 1993). The differences may lie in the presence of unspecified factors in the 
oral cavity and pharynx, but not in the other upper aero-digestive tract sites, 
which potentiates the effects of alcohol and smoking in the oral cavity and 
pharynx. Separate analysis of smoking and alcohol in relation to risk at the 
various subsites also reveals that the highest risk for either factor is in the oral 
cavity and lowest in the larynx (Franceschi et al., 1990; La Vecchia et al., 1990). 
Various dietary factors have been reported as having differential effects in terms 
of risk including red chilli and tea drinking (pharynx) (Notani & Jayant, 1987). 
Patients who present with none of the traditional risk factors predominantly have 
oral cavity cancers (Wiseman et al., 2003). 
1.4 Prognostic factors in HNSCC 
Many clinical prognostic factors in SCC are well established. These include 
anatomical site, tumour size, lymph node status, the presence of distant 
metastases and certain histological subtypes (Quon et al., 2001; Tralongo et al., 
1999; Woolgar et al., 1999). Histological examination also adds tumour grade 
(a measure of differentiation), depth of invasion and the presence of invasion 
related to nerves or lympho-vascular channels. Much of this information is 
summarised in the TNM classification (Sobin & Wittekind, 2002). Whilst useful 
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at a population level, these prognostic factors may be limited in their predictive 
value for the identification of patients who have a high risk of recurrence, 
relapse or death (Fries et al., 1976). As a result, many other clinico-pathological 
staging and prognosis systems have been developed, with varying degrees of 
success, and with limited acceptance (Groome et al., 2001). 
As is often the case for lung cancer patients, the risk of the development of 
continued or subsequent malignant disease in patients with HNSCC is high. 
Many patients will develop either synchronous or metachronous second (or 
subsequent) upper aero-digestive tract turnours. The probability of developing 
a second, metachronous HNSCC in the five years after initial treatment is 
approximately 22% (de Vries et al., 1986; Schwartz et al., 1994). 
1.5 Field cancerization 
There is evidence that primary HNSCC and subsequent disease (and 
premalignant lesions) are derived by additional mutations acquired within a 
'field' of genetically altered cells within the mucosa (Bedi et al., 1996). The 
mucosa affected may be clinically and/or histologically normal. This has been 
termed 'field cancerization', (Slaughter et al., 1953). These alterations arise 
from exposure of large areas of the epithelium of the upper aero-digestive tract 
to carcinogens and/or growth promoters in tobacco or alcohol (Bedi et al., 
1996). Thus, whilst these tumours are ultimately clonally divergent, they share 
certain common cytogenetic features with the rest of the field (Braakhuis et al., 
2003). The abnormalities may be due to epigenetic or genetic changes induced 
in the field of exposed cells. Jang and co-workers have also suggested that, in 
a minority of cases, there may be mucosal spread of malignant or premalignant 
cells within the oral cavity, resulting in multiple, discrete tumours that are truly 
clonal in origin (Jang et al., 2001). The mechanism of this effect has not been 
elucidated. 
Consequently, some of the genetic changes characteristic of a particular 
primary HNSCC can often be found in clinically and histological normal mucosa 
up to a distance of 7 cm away from the primary tumour (Braakhuis et al., 2003; 
Tabor et al., 2002a). This has obvious repercussions for decisions relating to 
the size of excision margins required at the time of primary surgical 
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management. Thus, second or subsequent HNSCCs may be of three types: 
they may be: 
* "True" recurrence; derived from incomplete eradication of the primary 
scc 
9 Second "field cancers"; these may have a different, but overlapping, 
spectrum of genetic changes having developed from an intervening field 
of abnormal oral mucosa (Braakhuis et al., 2002). 
9 Second primary tumours, with a clonally independent origin. 
1.6 Premalignant lesions 
The presence of extensive areas of genetically abnormal epithelium raises the 
possibility of precursor lesions, which may be amenable to preventative 
intervention. These lesions may be clinically evident, and are often referred to 
as premalignant lesions (PMLs). Clinically evident mucosal lesions that 
possess an increased risk of progression to HNSCC predominantly appear as 
white patches (leukoplakia) or, less commonly, as red patches (erythroplakia). 
These lesions are illustrated in Figure 1.1A and C. Other conditions, such as 
lichen planus, may have premalignant potential (Epstein et al., 2003). 
1.6.1 Malignant transformation in PMLs 
The evidence that oral leukoplakia has premalignant potential is mainly based 
on cohort studies in hospital-based populations. This introduces an element of 
case selection bias into the assessment of the proportion of these patients who 
develop HNSCC within their PML. The consequence of this is a large range of 
malignant transformation rates from multiple studies, whose populations are not 
readily comparable (Table 1.3). Recent studies estimated the prevalence of 
homogeneous oral leukoplakia in the general population of the USA at 0.37% 
(Scheifele et al., 2003). Extrapolation of this, in conjunction with the incidence 
of HNSCC in European countries where there is reasonable integrity of cancer 
registry data, indicates that the true malignant transformation rate of oral 
leukoplakia is probably less than 1% per year (Scheifele & Reichart, 2003). 
Malignant transformation may be higher in the small proportion of leukoplakias 
that are dysplastic, but regression of dysplastic changes may also be seen, 
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particularly where there is cessation of the precipitating risk factor(s) (Pindborg 
et al., 1977). 
Various clinical parameters alter the malignant transformation rate of 
leukoplakia. In Western populations, lesions located on the floor of the mouth 
and ventral surface of the tongue have been shown to have a higher malignant 
potential than other areas of the mouth (Kramer et al., 1978), although 
Schepman and co-workers could not substantiate this in a later study 
(Schepman et al., 1998). Thus, the concept of high-risk sites is not well 
supported in the literature. However, it is surely significant that the proposed 
"high-risk" PML sites are also those that are most commonly associated with 
early oral cancer lesions. Erythro-leukoplakia or 46 speckled" leukoplakia, a form 
of non-homogenous leukoplakia (Figure 1.113) also has a higher malignant 
transformation rate (Mehta et al., 1981), presumably related to the presence of 
areas of erythroplakia within the lesion. The concurrent presence of infection 
with Candida species also correlates with the presence of oral epithelial 
dysplasia (McCullough et al., 2002). 
In contrast, the malignant transformation rate of erythroplakia is much higher. 
Erythroplakia is much rarer than leukoplakia, but often reveals carcinoma-in-situ 
or frank carcinoma at the time of original diagnosis (Mashberg, 1977; 
Mashberg, 1978; Shafer & Waldron, 1975). Subsequently, a substantial 
proportion of patients will develop a SCC over the following five-year period. 
The reasons for the high prevalence of dysplasia in erythroplakias are not clear. 
It has been suggested this may due to a greater frequency of p53 mutations in 
erythroplakias (Qin et al., 1999), but once smoking status has been taken into 
account, this does not seem to be the case (Lazarus et al., 1995; Lazarus et al., 
1996). 
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Figure 1.1 . Clinically premalignant lesions 
A 
B 
C 
A. leukoplakia of anterior floor of mouth/ventral tongue 
B. erythro-leukoplakia of soft palate complex 
erythroplakia of right anterior pillar of fauces 
Photographs courtesy of Professor DG MacDonald (A and C) and Dr John 
Eveson, @ Bristol Biomedical Image Archive, University of Bristol (B) 
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Study/year Country No of 
patients 
follow- 
Up 
(years) 
% malignant 
transformation 
(Pindborg et al., 1968) Denmark 248 3.9 4.4 
(Silverman & Rosen, 
1968) 
USA 117 1-11 6.0 
(Kramer et al., 1970) UK 187 unclear 4.8 
(Mehta et al., 1972) India 117 10 0.9 
(Silverman et al., 1976) India 4762 2 0.9 
(Banoczy, 1977) Hungary 670 9.8 6.0 
(Silverman et al., 1984) USA 257 7.2 17.5 
(Lind, 1987) Norway 157 9.3 8.9 
(Lummerman et al., 
1995) 
USA 240 20 13.8 
(Schepman et al., 1998) Netherlands 166 2.5 12 
(Shiu et al., 2000) Taiwan 435 10 14 
(Cowan et al., 2001) N. Ireland 165 20 15 
(Sudbo et al., 2001 a) Norway 150 9 24 
Table 1.3 Selected studies on malignant transformation of dysplastic oral 
leukoplakia. 
The table is adapted from a review by Reibel (Reibel, 2003), with some added 
information from more recent studies. 
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1.7 The relationship between PMLs and HNSCC 
It is impossible to be precise as to the fraction of HNSCC that are preceded by 
PIVII-s. Indeed, in some patients, the precursor lesion may not be clinically 
evident. Certainly, many patients present initially with advanced HNSCC, but it 
is unclear to what extent previous PMLs may have been missed due to 
infrequent intraoral examinations. However, as the risk factors for the 
development of oral premalignant lesions are very similar to those for HNSCC 
itself (Hashibe et al., 2003), it seems reasonable that a proportion of patients 
will develop their SCC within a histopathologically evident precursor lesion, 
whether or not it is clinically visible. Histological studies indicate that, as a 
minimum estimate, in the region of 36% of SCCs have adjacent dysplastic 
areas (Bouquot et al., 1988). This clearly leaves a large proportion of SCCs 
that either have developed in epithelium that was not previously dysplastic, or 
have completely subsumed the original dysplastic lesion. Pindborg found that a 
proportion of carcinomas developed in lesions that had not shown dysplasia in 
previous biopsies (Pindborg et al., 1977). Another study concluded that 
leukoplakia was associated with 48% of oral SCCs (Hogewind et al., 1989). 
This indicates that whilst commonly associated with HNSCC, PMLs are not 
obligatory precursor lesions. 
1.8 Epithelial dysplasia and PML prognosis 
Assessment of epithelial dysplasia on histological sections has been the 
traditional method of judging the potential for malignant change. Dysplasia is 
the sum of atypical structural and cytological features within the epithelium and 
is traditionally graded as mild, moderate or severe (Figure 1.2 A-C). Once the 
histopathological features of dysplasia affect the full thickness of the epithelium, 
but with no evidence of invasion, the term carcinoma-in-situ is used (Figure 1.2 
D). Despite WHO guidelines to standardise assessment (Pindborg et al 1997), 
evaluation of changes within the epithelium remains subjective (Pindborg et al., 
1985) and poorly reproducible (Abbey et al., 1995; Onofre et al., 1997). 
Some studies have demonstrated a relationship between increased histological 
grade and increased risk of malignant transformation (Schepman et al., 1998; 
van der Waal et al., 1997) but others have failed to corroborate this (Partridge et 
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al., ; Saito et al., 2001). The disparity most likely arises from a combination of 
the subjectivity of dysplasia assessment and a lack of knowledge of the relative 
importance of the individual histopathological features (Warnakulasuriya, 2001). 
Indeed, the morphological changes seen in a dysplastic epithelium may merely 
be surrogate features that are additional and superfluous to the important 
changes occurring in the genome and transcriptome of the progressing 
precancerous oral lesion i. e. epiphenomena (Partridge et al., 2000b). It is clear 
that although certain histological features of dysplasia are associated with risk 
of malignant transformation in oral leukoplakia in general, there is a poor 
correlation between the histological grade of dysplasia (as mild, moderate or 
severe) and the prognosis of an individual lesion. Such confusion clearly 
demonstrates the inadequacies of the present predictive methodologies for a 
patient. 
1.9 Treatment of PMLs 
Despite initial promise, medical treatment of PMLs with the aim of reducing the 
malignant transformation rate has proven disappointing. Vitamin A (retinyl 
palmitate) or its synthetic retinoid derivatives have been used for treatment of 
oral leukoplakia and prevention of second primary cancers (Hong & Doos, 
1985; Hong et al., 1986; Koch, 1978). Retinol/retinoids are known to play an 
important role in regulating keratinocyte differentiation and high dose retinoids 
can reverse epithelial dysplasia and precipitate resolution of oral leukoplakia 
(Hong et al., 1986). However, they cause significant toxicity and the beneficial 
effect is transient, as the clinical lesion often returns after cessation of treatment 
(Lodi et al., 2004). The initial promise that retinoids might prevent second 
cancers developing (Hong et al., 1986) has not been confirmed in recent trials 
(van Zandwijk et al., 2000). The biology of retinoids will be discussed in more 
detail later. 
Based on promising preclinical data, inhibition of cyclooxygenase 2 (COX2) is 
one of the novel treatments currently being actively tested in various cancer 
models. This includes upper aero-digestive tract turnours, either for cancer 
prevention or treatment (reviewed in Altorki et al., 2004; Dannenberg & 
Subbaramaiah, 2003). Antioxidants are another class of agents that may offer 
promise for treatment of oral PMLs. For example, oral administration of N- 
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acetyl-L-cysteine reduced the frequency of DNA adducts and abnormal 
micronuclei in oral mucosa in healthy smokers (Van Schooten et al., 2002) and 
oral dysplasias showed a clinical and histological response to lycopene, a 
naturally occurring carotenoid (Singh et al., 2004). 
For many patients, surgery provides the only available method for control of 
their disease, but multifocal lesions are not amenable to curative surgical 
intervention. Indeed, recent studies have suggested that surgical removal of 
leukoplakias with chromosomal aneuploidy may be futile (Sudbo et al., 2004). 
Allied to this, the failures of medical treatment and the uncertainty in 
assessment of these lesions have led to the search for other predictors of 
prognosis in HNSCC and malignant transformation in PIVII-s. It is hoped that 
these markers may also reveal promising targets for therapy, both in malignant 
and premalignant disease. 
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Figure 1.2 Oral epithelial clysplasia 
Features assessed after the method of Kramer et al (Kramer et al., 1978). 
Generally, in mild dysplasia (A) abnormal tissue and cytological features are 
confined to the deep third of the epithelium, moderate (B) to middle and deep 
thirds and severe dysplasia (C) extends into the superficial third of the 
epithelium. This can be modified up or down depending on cytological features. 
Carcinoma in situ (CIS) (D) refers to similar features to severe dysplasia 
affecting the whole thickness of the epithelium. 
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Chapter Two: Carcinogenesis 
Over the past three decades, much evidence has accumulated that 
carcinogenesis is a multi-step process in which various genetic and epigenetic 
alterations in normal cells cooperate in the generation of highly malignant 
derivatives. Despite the complexity of cancer genomes and the large number of 
possible cellular pathways to target, Hanahan and Weinberg have suggested 
that alterations in six basic cellular functions are required (Hanahan & 
Weinberg, 2000). The six "hallmarks" of cancer are illustrated in Figure 2.1. 
These features involve not only the neoplastic cell population per se, but also 
interactions with the tumour stroma. 
Figure 2.1 The "hallmarks" of cancer. 
The Figure shows the six consistent features or "hallmarks" of most cancers, as 
described by Hanahan and Weinberg. Reproduced from the review by 
Hanahan and Weinberg (Hanahan & Weinberg, 2000) 
The "hallmarks" comprise some of the most complex basic cellular control 
mechanisms and as such, there are multiple points of intervention that may lead 
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to similar effects. Conversely, one particular defect may have a different effect 
in different cell types and the effect may even differ within cells of the same type 
under different environmental contexts. Thus limiting such If capabilities" to six in 
number does not predicate against multiple pathways which cells may take on 
their way to becoming malignant. Thus, certain common alterations (e. g. p53 
mutation) may only be present in a proportion of a particular cancer type, but 
defects in the p53 pathway may be more common (Save et al., 1998). 
Similarly, the timing and the order in which these capabilities are acquired may 
vary extensively. 
2.1 Invasion and metastasis 
The defining feature of malignant disease is its ability to escape normal 
biological constraints and invade into surrounding tissues. These invasive cells 
may then travel to locoregional or distant sites, either by direct spread or 
dissemination in the lymphatic or vascular systems. Secondary tumours 
(metastases) may then develop. The process has been likened to a cascade 
with barriers to be overcome at each stage (Pantel & Brakenhoff, 2004). 
Consequently, it has now become apparent that it is too simplistic to regard 
malignant disease solely in terms of the neoplastic cell population (Hanahan & 
Weinberg, 2000). Cellular (fibroblasts, endothelial and inflammatory cells) and 
non-cellular elements (matrix proteins) within the microenvironment play 
important roles in establishing a suitable environment for the development of a 
malignant neoplasm. In certain tumour types such as the basal cell carcinoma, 
development of the tumour is very dependent on the correct microenvironment 
as removal from this results in involution of the tumour (Pollack et al., 1982). 
In normal mucosa, the architecture and function of the epithelium is maintained 
by a complex interaction between the epithelial cells and their 
microenvironment. The dynamic interplay with the extracellular matrix (ECM) 
controls various functions within the epithelial cell such as differentiation, 
proliferation and apoptosis. These functions are vital in the control of growth 
and development, healing and the tissue response to injury (Streuli, 1999). 
Multiple cellular products and components of the ECM, including adhesion 
molecules, such as the integrins, and the transforming growth factor-beta (TGF- 
fl) signalling pathway, mediate this control. Alterations in the microenvironment 
19 
of a tumour may result from similar genetic damage to that which precipitated 
the neoplastic growth in the epithelial cells (Park et al., 2000). Alternatively, 
tumour cells can induce the formation of a "tumour stroma" via the aberrant 
secretion of growth factors or induction of growth factor receptors (Mueller & 
Fusenig, 2002). Certain haernopoietic growth factors, such as G-CSF and GM- 
CSF in addition to tumour derived TGF-, 8 may be important in this regard 
(Obermueller et al., 2004). The cellular components of the tumour stroma may 
then reciprocally influence the tumour cells. 
TGF-fl plays a double-edged role in carcinogenesis (Akhurst & Derynck, 2001). 
In the early stages, TGF-fl acts as a potent tumour suppressor, as it inhibits 
growth and induces apoptosis (Derynck et al., 2001; Tang et al., 1998). Further 
effects may include suppression of telomerase activity and the induction of 
senescence (Katakura et al., 1999; Zhao et al., 2003). However, later in the 
carcinogenic process, this growth inhibitory effect is lost and TGF-fl acts to 
promote the malignant phenotype (Barrack, 1997). This results in increased 
angiogenesis and motility, promotion of epithelial-mesenchymal transition 
(EMT) and escape from apoptosis (Lu et al., 2004; Prime et al., 2004). The 
alteration in the effect of TGF-, 8 has been related to defects in the receptors and 
their signalling pathways, particularly via the SMAD transcription factors 
(Maliekal et al., 2003). Defects in TGF-, 8 signalling in HNSCC have been 
demonstrated, but many HNSCC cell lines maintain a full or partial inhibitory 
response to TGF-, 8 (Malliri et al., 1996). However, even a partial defect in TGF- 
fl signalling through the receptor T, 8R-11, has been shown to result in the 
emergence of the malignant phenotype, with increased proliferation and 
invasion in vitro (Huntley et al., 2004). 
Further functions of TGF-, 8 may include the acquisition of a motile phenotype 
that allows neoplastic cells to disseminate locally and to distant sites. This may 
be possible via a partial epithelial-mesenchymal transition (EMT). In normal 
embryogenesis, this fundamental process governs morphogenesis (Shook & 
Keller, 2003), but in tumours, it promotes loss of intercellular adhesion and 
induces cell motility (Mueller & Fusenig, 2004). The TGF-, 8 pathway is one of 
many that have been implicated in induction of EMT. In breast carcinoma, the 
transcription factor TWIST is suppressed and this allows EMT to occur, due to 
loss of E-cadherin mediated effects (Kang & Massague, 2004). Loss of E- 
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cadherin expression by promoter methylation has been reported in HNSCC 
(Chang et al., 2002; Chow et al., 2001). The main consequence of loss of E- 
cadherin is nuclear accumulation of fl-catenin, but whilst this has been 
described in gastric adenocarcinoma, there is no convincing evidence that this 
occurs to any significant degree in HNSCC in vivo (Chow et al., 2001; 
Patturajan et al., 2002). However, it is possible that other modulators of EMT, 
such as certain receptor tyrosine kinases, will play a role. However, HNSCC 
cell lines showing decreased E-Cadherin expression also have higher levels of 
vimentin and other markers of EMT (Taki et al., 2003). 
Many turnours show changes in the spectrum of cell adhesion molecule (CAM) 
expression including alteration in E-Cadherin and various integrins. These 
CAMs mediate adhesion to the ECM and are involved in a variety of functions 
such as motility, proliferation and differentiation via various intracellular 
pathways, such as activation of focal adhesion kinase (FAK) (Akiyama, 1996). 
Numerous studies have demonstrated changes in the expression, distribution 
and functions of integrins in tumour cells. Aberrant expression and function 
promotes cell migration, invasion and angiogenesis (Brooks et al., 1994) in 
cancer and may suppress apoptosis (Thomas & Speight, 2001). Consistent 
upregulation of certain integrin subunits, such as aV, 86, in oral cancer suggests 
that this may play a more active role in oral carcinogenesis (Thomas et al., 
2001 a; Thomas et al., 2001 b). 
Alterations in stromal remodelling can also contribute to the tumour-stroma 
interaction and may modulate the activity of the neoplastic cell population. 
Many enzymes, including the matrix metal loprotei nases (MMPs), remodel the 
extracellular matrix. This family of zinc-dependent endopeptidases plays a 
crucial role in ECM turnover, but alterations in the expression of various MMPs 
and/or their inhibitors have been reported in many cancers. The levels of 
various MMPs may be increased by many signals including TGF-, B, epithelial 
growth factor receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) 
(Hiratsuka et al., 2002; O-Charoenrat et al., 2000b; Rougier et al., 1997). 
MMPs promote carcinogenesis by multiple mechanisms, including cell growth, 
migration and angiogenesis (Pepper, 2001), due not solely to ECM turnover, but 
also to the release of matrix-bound growth factors (Belotti et al., 2003) and 
interaction with various classes of cell adhesion molecules (Coussens et al., 
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2002). Alterations in many MMP family members and some of their inhibitors 
have been found in HNSCC including MMP2, MMP9 and TIMP2 (Katayama et 
al., 2004; O-Charoenrat et al., 2001; Ruokolainen et al., 2004). High levels of 
MMP9 in HNSCCs has been correlated with advanced T stage, an infiltrative 
pattern of growth and poor prognosis (0-Charoenrat et al., 2001; Ruokolainen 
et al., 2004). However, this has not been reproduced in vitro, perhaps due to 
difficulties in fully reconstituting the ECM in tissue culture (Robinson et al., 
2003). 
Analysis of tumour cell motility by a combination of methods has led to the 
conclusion that there are many different mechanisms of tumour cell motility. 
(Friedl & Wolf, 2003; Sahai, 2005) The two main types, with subgroups, are 
illustrated in Figure 2.2. Collective type motility involves the movement of 
clusters of cells and is dependent on the production of MMPs at the invasive 
front to clear a path for the tumour to move (Nabeshima et al., 2002). This 
method, although common in epithelial malignancy, is poorly understood, as it is 
difficult to model in vitro. There are also two types of individual motility. 
Mesenchymal motility is related to EMT, and requires the production of MMPs 
to degrade the ECM (reviewed in Friedl & Wolf, 2003). On the other hand, 
amoeboid movement, which is characteristically seen in haematological 
malignancy, demonstrates no such requirement, nor an EMT. It is very similar 
to the rounded Rho- and Rock-dependent form of motility that has been 
described (Sahai & Marshall, 2003). This allows the cell to squeeze through the 
ECM, rather than degrading it. It also is likely that cells are able to switch their 
mechanism of motility in response to different environments (Wolf et al., 2003). 
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Figure 2.2 Mechanisms of invasion 
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The figure illustrates the present understanding of the different mechanisms of 
invasion of cancer cells and their varying dependence on different molecular 
programmes (triangles). From individual (top) to collective (bottom) movements 
integrins and proteases play an increasing role in cell-ECM interaction. The 
most common pattern of invasion in epithelial cancers is collective movement 
as clusters. Reproduced from (Friedl & Wolf, 2003). 
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2.2 Angiogenesis 
Tumour angiogenesis is another vital component of lisuccessful" malignant 
neoplasia. The ability to stimulate the development of new blood vessel growth 
allows a tumour to continue to grow without the potential hindrance of hypoxia 
and consequent ischaemic necrosis. Growth factors such as Vascular 
Endothelial Growth Factor (VEGF) and various Fibroblast Growth Factors 
(FGFs) may initiate the development of tumour vasculature (Compagni et al., 
2000; Giavazzi et al., 2003). The increase in activity may be due to increased 
production of such factors by the tumour cells under stimulation by the EGFR 
family (0-Charoenrat et al., 2000c), but alternatively may be due to release of 
stores of ECM-bound growth factors by increased ECM turnover (Whitelock et 
al., 1996). Increased numbers of particular VEGF receptor subtypes have been 
associated with the initiation of malignant disease (reviewed in Mueller & 
Fusenig, 2002) and VEGF overexpression is associated with poor overall 
prognosis (Uehara et al., 2004). Various integrin subunit complexes and MMPs 
are also pro-angiogenic (Brooks et al., 1994; Pepper, 2001). 
Assessment of angiogenesis in tumours is difficult, but microvascular density 
has often been used as a surrogate marker. This is dependent on the 
immunohistochemical identification of endothelial lined channels, but some 
turnours, including HNSCC may construct a pseudo-vasculature using tumour- 
lined channels for blood supply (Folberg & Maniotis, 2004; Shieh et al., 2004). 
In HNSCC carcinogenesis, some groups have demonstrated that the vascularity 
of oral tissues increased with disease progression from normal mucosa to 
through the grades of dysplasia to carcinoma (Macluskey et al., 2000; Pazouki 
et al., 1997), whilst others have found no such increase (Tae et al., 2000). An 
increase in VEGF has been noted in HNSCC and this is related to EGFR 
overexpression (0-charoenrat et al., 2002). In particular, increases in VEGF-A 
and VEGF-C have been correlated with the presence of lymph node 
metastases (Shintani et al., 2004). 
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2.3 Self sufficiency in growth signals 
Normal cells require mitogenic stimuli to initiate and sustain proliferation. Many 
of these signals are mediated by autocrine or paracrine signals that are relayed 
to the nucleus from the cell surface by various classes of transmembrane 
receptor. Alterations in several of these critical pathways were originally 
identified as a consequence of research into oncogenic viruses (Harvey, 1964). 
Such viruses have sequences in their genome that are similar to genes found in 
normal human cells. These sequences were aberrantly expressed subsequent 
to integration into the host genome. These genes, termed oncogenes, have 
subsequently been shown to belong to several functional groups of genes, 
many of which are involved in the transmission of mitogenic stimuli from the cell 
surface to the nucleus. 
2.3.1 Growth factors and their receptors 
Many of the alterations in oncogenes involve growth factors and their receptors. 
Tumours may produce their own growth factors to act in an autocrine/paracrine 
manner on the tumour cell population (e. g. FGF-1, Myoken et al., 1994). This 
obviates the normal control exercised by the microenvironment. 
Overexpression of growth factor receptors will also increase the intensity of the 
signal. One example is overexpression of the epidermal growth factor receptor 
(EGFR), a member of the EGFR/c-erbB family of growth factor receptors. This 
family of receptors binds six major ligands, namely, epidermal growth factor 
(EGF), transforming growth factor-alpha (TGF-a), betacellulin, heparin-binding 
epidermal growth factor-like growth factor (HB-EGF), amphiregulin and 
heregulin (O-Charoenrat et al., 2000a; Prigent & Lemoine, 1992). Ligand 
binding promotes dimerisation of receptor subunits and activation of the intrinsic 
tyrosine kinase activity of the cytoplasmic domain of the receptor. The signal is 
then propagated to the nucleus via a cascade of intracellular kinases. These 
include the Stat family of signal transducers, which may also show altered 
expression in tumours (Grandis et al., 1998b). 
EGF is required for proliferation of oral keratinocytes in culture, which illustrates 
the dependence of these cells upon this signalling pathway. Thus, it is not 
surprising that alterations of EGF signalling are seen in many epithelial cancers 
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(Cheng et al., 2002; Cowley et al., 1986; Hendler & Ozanne, 1984; Ito et al., 
2001; Perry et al., 1998). Overexpression of EGFR may allow the neoplastic 
keratinocytes to respond inappropriately to low levels of ligand in the 
extracellular environment. EGFR upregulation has been demonstrated in many 
cancers including HNSCC (Ozanne et al., 1986), although it does not seem to 
be a ubiquitous alteration. Inhibition of EGFR or TGF-a expression using 
antisense oligonucleotides leads to a decrease in the proliferation of HNSCC 
cells lines, with limited effects on normal cells in culture (Grandis et al., 1998a; 
Rubin Grandis et al., 1997). 
However, Stanton and co-workers noted that the relative overexpression of 
EGFR was higher in primary HNSCC cell cultures than in their matched tumour 
samples (Stanton et al., 1994). Indeed, the expression of EGFR in the turnours; 
was higher than normal tissue in only two of ten samples. Whilst this suggests 
that there is potential for EGFR overexpression in at least a subset of cells 
within most HNSCC lesions, it does not explain why some tumours over- 
express EGFR and others do not. The same work also suggested that 
overexpression of EGFR is a late event in HNSCC carcinogenesis, since cells 
derived from two premalignant lesions that progressed to SCC over a short 
period did not have high levels of EGFR expression (Stanton et al., 1994). The 
small number of premalignant lesions analysed may be a limiting factor in this 
conclusion, as much larger studies have concluded that EGFR is upregulated in 
dysplastic oral tissues (Shin et al., 1994b). Even in these studies, the EGFR 
upregulation demonstrated in dysplastic lesions is somewhat modest (in some 
cases 2 fold, assessed by immunohistochemistry), compared to the much larger 
increase in EGFR expression which occurs in HNSCC (Shin et al., 1994b). 
Alterations in the other family members (c-erbB2, c-erbB3 and c-erbB4) have 
also been reported, but their role in HNSCC carcinogenesis is less clear (0- 
Charoenrat et al., 2002). 
Nevertheless, clinicopathological studies found that high levels of EGFR and 
TGF-a in HNSCC were a statistically significant predictor of recurrent disease 
and poor overall survival (Grandis et al., 1998c). Similar data in other epithelial 
malignancies has lead to the development of novel anti-EGFR therapies for use 
in many cancers, including HNSCC. Initial preclinical and phase 1/11 trials 
appeared promising (Bonner et al., 2002), but the results of recent larger trials 
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of EGFR inhibition with chemotherapy and radiotherapy have shown limited 
improvements in disease free survival, with only a minority of patients 
responding (reviewed in Raben et al., 2004). 
2.3.2 Signal transduction 
Components of various intracellular signal transduction pathways have also 
been implicated as oncogenes. Such signalling networks include the Ras-Raf- 
MAPKinase pathway, which is downstream of many growth factor receptors. 
The Ras proteins were amongst the first to be assigned a function related to cell 
growth and proliferation (Yuspa et al., 1983). This family of proteins controls 
the activity of several key signalling pathways. Three members of the family 
HRAS, KRAS and NRAS are mutated in 20% of human tumours (Bos, 1989). 
Point mutations in RAS lead to constitutive activation by compromising the 
GTPase activity of RAS, leading to accumulation of RAS in an active form 
(Tabin et al., 1982). This increases the signalling traffic in several pathways, 
resulting in loss of control over cell growth and an increase in invasiveness and 
angiogenesis (reviewed by (Shields et al., 2000). 
The reported frequency of RAS alterations in HNSCC varies in the literature 
(reviewed in Downward, 2003). Several studies have documented a very low 
frequency of RAS mutation in HNSCC in the UK, despite the high proportion of 
tobacco smokers (Chang et al., 1991; Yarbrough et al., 1994; Yeudall et al., 
1993). A similar pattern has been found in premalignant lesions (Matsuda et al., 
1996). However, in populations where tobacco is chewed, or used in 
association with betel quid (pan), the prevalence of activating RAS point 
mutations may be as high as 35% (Chang et al., 1991). Alterations in targets 
downstream of RAS, such as BRAF, are also rare in HNSCC (Weber et al., 
2003). 
2.3.3 Targets in the cell cycle 
The cell cycle comprises a highly regulated series of steps that result in the 
duplication of the cellular DNA and subsequent cytokinesis (Figure 2.3). The 
machinery of the cell cycle is thus intimately involved in the control of cell 
proliferation. The regulatory elements of the cell cycle includes Cyclins, Cyclin 
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dependent kinases (CDKs) and various negative regulators, including inhibitors 
of Cyclin/CDK complexes. 
One of the ultimate targets of the mitogenic cell-surface signals is Cyclin D1 
(Loyer et al., 1996; Quelle et al., 1993). This is a member of the family of D- 
type Cyclins and is involved in control of the transition from G1 to S phase of 
the cell cycle (Figure 2.4). Upon induction by mitogeneic stimuli, Cyclin D1 
expression increases forming transient functional complexes with cdk4 and 
cdk6. Interaction of this complex with retinoblastoma protein (Rb) results in Rb 
phosphorylation (Kato et al., 1993). This removes the inhibitory effect of Rb on 
certain transcription factors, such as E2F, which allows transcription of proteins 
required for G1/S phase transition (Figure 2.4). 
Investigations in many different cancers, including breast carcinomas, 
lymphomas and SCCs have demonstrated frequent amplification of 
chromosome locus 11q13 (Schuuring, 1995). This locus contains several 
putative oncogenes, including Cyclin D1, also known as PRAD1 (Motokura et 
al., 1991). Loss of control of Cyclin D1 expression may be attained by 
chromosomal translocation, DNA amplification, abrogation of controls in 
mitogenic signalling pathways and retroviral integration. The resulting 
overexpression accelerates passage of the cell through G1 phase and reduces 
the requirement for mitogens (Quelle et al., 1993). 
A number of workers have demonstrated that Cyclin D1 overexpression is a late 
change in HNSCC carcinogenesis (Schoelch et al., 1999) and have related 
such overexpression to poor prognosis (Bova et al., 1999). The proportion of 
patients with Cyclin D1 overexpression varies greatly, particularly in those 
studies based on immunohistochernistry (Lam et al., 2000). The subjectivity in 
assessment of Cyclin D1 by lHC may account in part for the great variation in 
proportion of tumours and subsequent conclusions. Detection of Cyclin D1 
amplification may be a more sensitive measure of deregulation of Cyclin D1 
expression, but it does not account for all possible routes by which deregulation 
may be achieved. Amplification has been described in 30-50% of primary 
tumours, but in virtually all HNSCC cell lines (Callender et al., 1994; Jares et al., 
1994; Okami et al., 1999; Rousseau et al., 2001; Sartor et al., 1999). The 
presence of amplification of Cyclin D1 has been related to aneuploidy, which 
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has also been related to poor prognosis (Callender et al., 1994; Nimeus et al., 
2004). However, work in our own group did not identify any consistent 
overexpression of Cyclin D1 expression in cell cultures from dysplastic lesions 
or HNSCC (McGregor et al., 2002). Thus, whilst it seems likely that 
deregulation of Cyclin D1 does play a role in the development of at least subset 
of HNSCC there are other points in the machinery controlling G1/S transition 
that may also be altered in the process of carcinogenesis. 
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2.4 Insensitivity to anti growth signals 
The abrogation of inhibitors of the cell cycle may also contribute to the loss of 
tight control of cycle progression. Other possible targets, which may render 
Cyclin D1 overexpression redundant, include alterations in Rb itself, or in 
p16 INK4a , an 
inhibitor of the Cyclin D1/CDK4/6 complex. 
2.4.1 Retinoblastoma protein 
In its hypophosphorylated form, Rb acts to block G1/S transition. It may also be 
involved in the promotion of terminal differentiation and permanent exit from the 
cell cycle (Adams, 2001). Rb also regulates the expression of p16 INK4a via a 
negative feedback loop (Li et al., 1994). Inactivation of Rb, by point mutation or 
by interaction with HPV protein E7, deregulates the G1/S transition and allows 
the cell a selective growth advantage. In HNSCC, Rb mutation appears to be a 
rare event (Ambrosch et al., 2001). Alterations in Rb expression have been 
reported in some cancers, including non-small cell lung cancer (Jin et al., 2001), 
oesophageal SCC (Xing et al, 1999), and to a variable extent in HNSCC 
(Ambrosch et al., 2001; Pande et al., 1998; Schoelch et al., 1999). When 
alteration in Rb expression occurs, this may be early in the carcinogenic 
process (Pande et al., 1998). 
2.4.2 Cyclin dependent kinase inhibitors 
It is more common for the alteration within the Rb pathway to involve inhibitors 
of the Cyclin/CDK complexes, such as p16 INK4a (hereafter referred to as p16) or 
p27 KIP1 (hereafter referred to as p27). Inhibitors of the cell cycle belong to two 
main families - the ink4 family which includes p14, p15, p16 and p18 or the 
Cip/Kip family, which includes p2l, p27 and p57. 
2.4.2.1 The INK4 family of Cyclin dependent kinase inhibitors 
The INK4 proteins are products of the complex INK4a locus on chromosome 
9p2l. p16 transcripts include exons la, 2 and 3 whilst an alternate reading 
frame (ARF) uses exon1fl, which is located upstream from exon la (Quelle et 
al., 1995). This comprises the first exon of p14ARF, with exons 2 and 3 the 
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same as p16. These alternative products have separate promoters and perform 
very different actions within the cell. 
2.4.2.2 pl 6 
p16 was initially identified in co-immunoprecipitation experiments with CDK4 
(Xiong et al., 1993). Subsequent investigation has demonstrated it to be a 
specific inhibitor of the Cyclin D kinases, CDK4 and CDK6 (Serrano et al., 1993) 
and to be able to destabilise cdk4/Cyclin D1 complexes in vitro (Sandhu et al., 
2000). Thus, Rb phosphorylation is inhibited and the G1/S transition of the cell 
cycle does not proceed. Regulation of p16 expression is primarily at the 
transcriptional level and increased p16 levels have been related to a number of 
stimuli including replicative senescence (discussed later), oncogenic RAS 
(Serrano et al., 1997) and inactivation of Rb, presumably due to the loss of 
negative feedback (Parry et al., 1995). 
Alterations in p16 were initially described in many cancer cell lines, including 
those derived from bladder, lung, pancreas and head and neck cancer (Cairns 
et al., 1995; Liu et al., 1995). Abnormalities reported include homozygous 
deletion (often of small segments) or point mutation. The linkage with cancer 
was further strengthened by the identification of germline mutations of p16 in 
patients with a familial form of malignant melanoma (Ranade et al., 1995). 
Epigenetic silencing of p16 expression by promoter methylation has been 
identified as another method of transcriptional loss (Merlo et al., 1995). In cell 
lines demonstrating this phenomenon, re-establishment of p16 expression was 
possible by treatment with a demethylating agent, such as 5-aza-2- 
deoxycytidine (McGregor et al., 2002; Merlo et al., 1995). 
In HNSCC, the predominant mechanisms of p16 inactivation are homozygous 
deletion and promoter methylation. The prevalence of p16 mutations is low 
(Jefferies et al., 2001; Tsai et al., 2001). Promoter methylation may be 
concurrent with homozygous deletion indicating that initial epigenetic 
inactivation may be made permanent by subsequent deletion (Shintani et al., 
2001). From many different studies, it has been estimated that around 60-80% 
of all primary HNSCCs have either a genetic or epigenetic alteration in p16 
(Reed et al., 1996; Shintani et al., 2001). There is however, much variation as 
studies based solely on immunohistochemical detection of p16 expression have 
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found a lower prevalence of alteration (Tsai et al., 2001). Discrepancies in the 
frequency of deletions and mutations detected in primary tumours when 
compared to cell lines has also been reported (Sartor et al., 1999; Zhang et al., 
1994). These studies concluded that the difference in p16 alterations might be 
the result of adaptation to tissue culture. However, the presence of normal cells 
within the mixed tumour samples, which may have masked small deletions, was 
not investigated in either study. 
Loss of p16 expression in various SCCs has been linked with poor prognosis. 
For example, p16-negative lung SCC patients having a significantly lower five 
year survival than those with p16-positive turnours (Huang et al., 2000; Jin et 
al., 2001). In HNSCC, loss of p16 has been related to a poorer prognosis in 
patients with SCC of anterior tongue (Bova et al., 1999). Yuen and coworkers 
found a link with more locally advanced disease, but not with overall survival 
(Yuen et al., 2002), a finding confirmed by other studies (Geisler et al., 2002; 
Ogi et al., 2002). 
Many clinical studies have also found p16 alterations in dysplastic oral 
epithelium (Ambrosch et al., 2001; Papadimitrakopoulou et al., 1997; 
Shahnavaz et al., 2001). Papadimitrakopoulou and coworkers described loss of 
p16 protein expression in 38% of oral leukoplakias and a good correlation was 
found with LOH at 9p2l (Papadimitrakopoulou et al., 2001). This work, along 
with similar studies in Barrett's oesophagus, indicates that alterations in p16 are 
common, early abnormalities in SCC (Wong et al., 2001). Interestingly, 
hype rmethylatio n has been reported as the predominant mechanism of loss of 
pl 6 expression in severely dysplastic lesions, especially in lesions of the floor of 
the mouth (Kresty et al., 2002). In terms of assessment of the risk of malignant 
transformation, loss of p16 expression appears to have predictive value only in 
combination with other markers, such as p53 overexpression (Gallo et al., 
1997). 
Work previously conducted in the Beatson Institute for Cancer Research has 
focused on p16 alterations in HNSCC and oral dysplastic lesions in vitro. Loss 
of p16 expression was found in all 19 immortal carcinoma and six of seven 
immortal dysplasia cultures, but only in one of six mortal carcinoma and one of 
eight mortal dysplasia cultures (Loughran et al., 1996; McGregor et al., 2002; 
34 
McGregor et al., 1997). In the carcinoma cultures, p16 was inactivated by 
homozygous deletion in 8 of 18 cultures and by transcriptional silencing in the 
remaining 10 (Loughran et al., 1996). In two of these cell lines, p16 transcripts 
were readily detectable after treatment with demethylating agents. In addition 
to this, we have previously demonstrated p1 6 re-expression after treatment with 
5-aza-2- deoxycytidine in 2 of 5 immortal dysplasia cultures, but in none of the 
immortal carcinomas (McGregor et al., 2002). These results confirm the 
importance of homozygous deletion and DNA methylation as mechanisms of 
p16 inactivation, consistent with that described elsewhere in the literature. 
Additionally, they suggest a relationship between p16, replicative senescence 
and the acquisition of immortality, rather than with the malignant phenotype per 
se. This issue will be discussed in detail later. 
2.4.2.3 pl4ARF 
p14 has a role in the p53 signalling pathway, as it binds to MDM2, targeting it 
for degradation (Zhang et al., 1998b). This results in blockage of MDM2- 
mediated p53 degradation and stabilisation of p53 (see later). The 
consequence of this is p53 dependent cell cycle arrest or apoptosis. p14ARF 
has also been implicated in non-p53 mediated events, such as an ability to 
inhibit rRNA processing and other effects on gene expression (Ayrault et al., 
2004). Expression of p14ARF is under the control of E2F (Dimri et al., 2000), 
thus the Rb and p53 pathways are linked (Bates et al., 1998; Robertson & 
Jones, 1998). Increased expression of ARF has also been related to sustained 
oncogenic signals, such as those resulting from Myc overexpression or Ras 
mutation (Zindy et al., 1998). Such effects may be unrelated to p53 function. 
Loss of p19ARF (the mouse homologue of human p14ARF) expression has 
been shown to predispose to cancer early in life (Kamijo et al., 1997). However, 
despite this and the high frequency of alterations reported in the INK4 locus, 
specific p14ARF abnormalities have been found with much less regularity than 
those in p16. As all of the cell cycle inhibitory functions of p14ARF are 
contained within the sequence of the unique 1fl exon, the significance of 
mutations in exon 2, which is shared with p16, is disputed (Quelle et al., 1997). 
The frequency of either mutations in, or deletion of, exon 1fl in oral 
carcinogenesis has been reported to be very low (Kresty et al., 2002; Munro et 
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al., 1999; Shahnavaz et al., 2001). However, epigenetic abnormalities in the 
p14ARF promoter have been reported in oesophageal cancer (Smeds et al., 
2002) and oral SCC (Shintani et al., 2001). Interestingly, the study by Smeds 
and coworkers found no relation between p14ARF promoter methylation with 
p53 status, indicating that the non-p53 mediated effects of p14ARF may be of 
greater importance (Smeds et al., 2002). Despite this, at present, there is no 
convincing evidence that abnormalities in p14ARF play an important role in the 
development of oral cancer. 
2.4.3 The cip/kip family of Cyclin dependent kinase inhibitors 
This family of CDKNs includes p27, p2l WAF1 and p57. These inhibit a wider 
spectrum of Cyclin/CDK complexes including Cyclin E/cdk2, Cyclin A/cdk2 and 
Cyclin D/cdk4. This results in cell cycle arrest by intervention at various points 
in the cell cycle (see Figure 2.3). 
2.4.3.1 p27 
KIPI 
The cellular level of p27 is responsive to a wide variety of growth inhibitory and 
stimulatory signals, including TGF-fl and growth factors (Polyak et al., 1994). In 
various cell types, including fibroblasts, epithelial cells and T lymphocytes, 
downregulation of p27 in response to mitogenic stimulation allows the cell to 
progress from a quiescent to a dividing state (Eblen et al., 1995; Malek et al., 
2001). The main regulation of p27 expression is post-transcriptional, as 
mitogen-stimulated cells degrade p27 in an ubiquitin-dependent manner via the 
proteosome (Kawada et al., 1997). This complex regulation of quiescent and 
dividing cells demonstrates the importance of p27 in cell differentiation and 
development (Zhang et al., 1998a), but functions in the control of cellular 
senescence (Munro et al., 2001), susceptibility to apoptosis and cell adhesion 
have also been demonstrated (reviewed in Sgambato et al., 2000). 
Many cancer studies have demonstrated poor prognosis related to loss of p27 
expression (summarised in Slingerland & Pagano, 2000). The mechanism of 
such an effect is probably enhanced degradation of p27, although other 
mechanisms, such as sequestration by Cyclins D1 and D2 cannot be 
discounted (Bouchard et al., 1999). In HNSCC, low p27 expression in tongue 
tumours is associated with an increased risk of lymph node metastases and 
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poor overall survival (Mineta et al., 1999). This loss of p27 immunoreactivity 
has also been demonstrated in clysplastic oral lesions (Jordan et al., 1998). 
2.4.3.2 p2l wm' 
Inhibition of several Cyclin/CDK complexes by p2l WAR (p2l) results in cell cycle 
arrest. p2l is one of the main downstream effectors of p53 mediated cell cycle 
arrest in either G1 or G2 (Waldman et al., 1995). p2l also binds to PCNA, 
which may interrupt DNA replication (McCormick & Hall, 1992). 
Loss of expression or mutation of p2l are infrequent in HNSCC (Ibrahim et al., 
2003). Indeed, Van Oijen and co-workers found increased p2l expression in 
HNSCC and dysplastic tissue and this can occur in HNSCCs with no functional 
p53 (van Oijen et al., 1998). Others have substantiated this, by showing that 
p53 mutation did not necessarily lead to deregulation of downstream targets 
such as p2l, Bax and BcI-2, (Lavieille et al., 1998 2272). Thus, p53 
independent functions of p2l may be advantageous to the neoplastic cell, 
including resistance to apoptosis (Javelaud & Besancon, 2002; Wang & Walsh, 
1996). In dysplastic oral lesions, p2l was increased in 60% of samples, the 
intensity and amount of parabasal staining increasing with a more advanced 
histological grade (van Oijen et al., 1998). However, others have found no 
differences in p2l level when comparing lesions which progressed to SCC and 
those which did not (Hogmo et al., 1998). These conflicting findings indicate 
that loss of p2l is not useful as a marker of progression in HNSCC. 
2.4.4 p53 
The ability of the cell to delay DNA synthesis and mitosis in order to allow repair 
of DNA damage due to various injurious stimuli is an important mechanism in 
the protection of the integrity of the cell and its genome. Signals arising from 
DNA damage, mitotic spindle damage, hypoxia, nucleotide deprivation and 
oncogene activation, amongst others, represent stresses to which the cell must 
respond. The p53 tumour suppressor protein sits at this pivotal point in control 
of the cell cycle and other cellular responses to such stresses. The two main 
responses of the cell, namely cell cycle arrest and apoptosis, are mediated, at 
least in part, by the activity of p53. 
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p53 is a transcription factor, whose activity is regulated primarily at the post- 
translational level. The half-life of wild type p53 is very short under normal 
conditions. This is due to its interaction with the mouse double minute 2 protein 
(MDM2). This interaction interferes with the p53 transactivation domain, thus 
rendering p53 unable to assemble fully the machinery required for 
transcriptional activation (Oliner et al., 1993). The interaction with MDM2 also 
leads to the degradation of p53 by the ubiquitin-proteasome pathway, as MDM2 
has been demonstrated to act as a p53-specific E3 ubiquitin protein ligase 
(Honda et al., 1997). One of the genes targeted by activated p53 is MDM2, 
thus forming the basis of a negative feedback loop (Wu et al., 1993). 
Stimulation of p53 stabilisation and activation can be achieved via several 
signalling pathways that form the primary responses to cellular stresses (Figure 
2-5). Injurious stimuli, such as ionising or ultraviolet radiation and certain 
chemotherapeutic agents, such as adriamycin, elicit a rapid induction of p53 
activity via non-transcriptional means. The DNA damage caused by such 
agents is relayed via signalling pathways such as ataxia telangiectasia-mutated 
(ATM) and ataxia telangiectasia-related (ATR) proteins (Enoch & Norbury, 
1995; Tibbetts et al., 1999). These signal via the protein kinases Chk2 and 
Chk1 (Liu et al., 2000) respectively, with the result being phosphorylation of p53 
(Hirao et al., 2000; Liu et al., 2000). A schematic representation of these 
pathways is seen in Figure 2.5. Other cellular stresses are mediated via other 
intracellular signalling pathways (reviewed in Giaccia & Kastan, 1998). For 
example, deregulated expression of various oncogenic signals, such as ElA, 
Ras, Myc and fl catenin leads to a p53 response via the induction of p14ARF 
(de Stanchina et al., 1998; Zindy et al., 1998). ARF can bind to MDM2, 
reducing binding to p53 and thus inducing p53 stabilisation (Honda & Yasuda, 
1999) Thus, the response of p53 to oncogenic stimuli may be an important 
direct tumour suppressive role. 
The phosphorylation of p53 is one of the major mechanisms for regulation of its 
activity. The protein can be phosphorylated on many amino acid residues, 
including serine 15 and 20, which are the main targets for the ATMATR 
pathways (Dumaz & Meek, 1999; Fiscella et al., 1993; Tibbetts et al., 1999). 
These residues lie in the transactivation domain that regulates binding to 
MDM2. Phosphorylation within this domain reduces affinity for MDM2 and thus 
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reduces p53 degradation. However, p53 activity can also be modified by 
acetylation (Li et al., 2002) or glycosylation of various amino acid residues 
(reviewed by Brooks & Gu, 2003). This may lead to increased DNA binding. 
Activation of p53 induces many genes including p2l (Figure 2.5). This, at least 
in part, is responsible for cell cycle arrest in G1 (Waldman et al., 1995). 
Participation of p53 in other cell cycle checkpoints, such as at G2/M and GO/G1 
has also been described, but the molecular mechanisms have not been 
established (Itahana et al., 2002; Taylor & Stark, 2001). The functions of p53 in 
replicative senescence may also be mediated via these pathways (Shay et al., 
1991). This will be discussed in a subsequent section. 
The other cellular response that may be elicited is apoptosis, mediated in some 
cells by Bax, a member of the bc12 family of apoptosis promoters (Miyashita & 
Reed, 1995). Induction of other genes, such as PUMA, is also pro-apoptotic 
(Nakano & Vousden, 2001). The appropriate cellular response depends on the 
context in which p53 stimulation is achieved. If p53 signalling co-exists with 
stimulation of factors related to cell survival, cell cycle arrest may predominate. 
2.4.4.1 p53 in cancer 
Loss of p53 function is well documented in many cancers, including HNSCC. In 
rodents, homozygous disruption of p53 results in predisposition to malignancy, 
with an increased cancer risk also present in p53 heterozygous animals (Harvey 
et al., 1993; Jacks et al., 1994). Disruption of p53 function is often achieved by 
point mutation, but p53 function can also be inactivated by interaction with viral 
proteins such as HPV16 E6 (Shay et al., 1993). Mutation of p53 most 
frequently occurs in the DNA binding domain (Olivier et al., 2002), a 
consequence of which is reduced DNA binding and transcriptional activation 
capacity, in addition to inhibition of MDM2 binding. This results in stabilisation 
of p53, explaining the increased levels of mutated protein often reported by 
immunohistochemical studies. Often the remaining wild type allele also 
becomes deleted. Patients with mutant p53 show defects in cell cycle control 
and apoptosis, but also have an increased tendency to genomic instability 
(Shao et al., 2000; Shin et al., 2001 a). 
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DNA damage signals to p53, resulting in the activation of various intracellular 
responses. p53 exerts its control on cell cycle progression mainly through p2l 
and its inhibitory effect on CyclinA/cdk4. The activity of p53 is regulated 
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A high proportion of patients who inherit mutated p53 (i. e. are heterozygous for 
the wild type allele) develop cancer, often at an early age (Srivastava et al., 
1990). Sporadic mutations in p53 have also been noted with an overall 
frequency in cancer of 50-55% (Hollstein et al., 1991). The importance of 
tobacco in the prevalence of guanine nucleotide transversions in p53 in 
smoking related cancers, such as lung, bladder and HNSCC, was mentioned 
earlier. The low prevalence of p53 mutations in lesions from never-smokers 
bears witness to this (Lazarus et al., 1995). Most of the mutations are in the 
DNA binding domain encoded by exons 5-8. These have been termed the 
"hotspot", regions in which mutations are claimed to account for in excess of 
90% of the total (Hollstein et al., 1991). We have previously shown that two of 
seven immortal dysplasia cultures have mutations outwith this area (McGregor 
et al., 2002). Thus, emphasis solely on sequencing exons 5-8 in many studies 
may have resulted in under-reporting of the prevalence of p53 mutation in vivo. 
The link between p53 mutation and protein stabilisation has resulted in a 
plethora of immunohistochemically based studies of p53 malfunction. However, 
the complexity of the regulation of p53 protein level makes interpretation of this 
data difficult, particularly when no attempt is made to analyse the DNA 
sequence. Additionally, the large number of variables in methodology and 
assessment of p53 staining, together with the use of many different p53 
antibodies, makes drawing clear conclusions problematic. A poor correlation of 
p53 mutation with increased immunoreactivity has been demonstrated in some 
studies (Burns et al., 1993). The effect of particular mutations on p53 protein 
structure may explain this, for example, the creation of a premature stop codon, 
or a frameshift, which creates a truncated protein. In addition, some tumours 
express elevated levels of p53 without mutation (Bradley et al., 2001). Such 
difficulties have resulted in many, often contradictory studies relating p53 level 
to outcome, including overall survival and freedom from recurrence. 
The reported frequency of p53 mutation in HNSCC varies from study to study 
and is dependent on the methodology utilised. Most of these studies confine 
sequencing to exons 5-8/9 (Kashiwazaki et al., 1997; Koch et al., 1996; 
Matsuda et al., 1996; Rowley et al., 1998). However, in a study by Kropveld 
and co-workers, p53 was mutated in 91 % of HNSCC, with 33% of these outwith 
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the core domain of exons 5-8/9 (Kropveld et al., 1999). This is considerably 
higher than in most other studies. Overall, p53 sequencing consistently 
demonstrates that 50-55% of HNSCC have mutations in exons 5-8/9, with 
approximately 20% present in the other exons (2-4 and 10-11). This gives an 
approximate overall prevalence of p53 mutation in HNSCC of 75%. The 
mutations found in the primary tumours have also been found in metastatic 
lesions (Burns et al., 1994; Tabor et al., 2002b), indicating that p53 mutated 
clones may be positively selected during HNSCC progression. The difficulties 
outlined above with immunohistochemical prognosis have resulted in 
contradictory conclusions about p53 (reviewed in (Nylander et al., 2000), but 
mutations, particularly in the DNA binding domain, have been associated with 
poor prognosis (Mineta et al., 1998; Yamazaki et al., 2003). 
The prevalence of p53 mutations in some precancerous lesions of the head and 
neck indicates that this may be an early step in HNSCC carcinogenesis (Boyle 
et al., 1993). The reported rate of mutation is less than that for invasive 
disease, with the highest rate recorded in severe dysplasia within erythroplakia 
(50%, Qin et al., 1999). Other workers have even suggested that p53 mutation 
is the initiating event in HN carcinogenesis (Braakhuis et al., 2004a). However, 
in a study of sequential biopsies from patients who eventually developed 
HNSCC within a dysplastic lesion, p53 mutations (in exons 5-8) were only found 
in pre-invasive lesions in two of ten patients (Shahnavaz et al., 2000). The 
conclusion drawn from this was that p53 mutations occur late in disease 
progression, but this assumes that any p53-mutated clone present in the tissue 
would be present in the portion of the premalignant lesion actually analysed. 
Tissue heterogeneity within the epithelium, as demonstrated later in this thesis, 
probably dictates that this is not necessarily so. 
Increased p53 immunoreactivity has been described in dysplastic oral lesions, 
often variably related to the grade of dysplasia (Lippman et al., 1995; Sauter et 
al., 1994; Shin et al., 1994a). This may be a genuinely early change, as 
increased immunoreactivity is seen in all grades of dysplasia (Regezi et al., 
1995). Alterations in the spatial distribution of p53 staining have been 
suggested as of more value than staining intensity. The presence of suprabasal 
p53 staining in high-grade dysplasia is associated with an increased risk of 
malignant transformation (Cruz et al., 2002). However, some groups have found 
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that the link between p53 expression and HNSCC carcinogenesis is less robust 
(Murti et al., 1998) and that the link may reduce with long term follow-up (Lee et 
al., 2000). However, the prognostic value of the combined p53 and p16 status 
is more powerful than for either alone (Gallo et al., 1997). 
2.5 Evasion of apoptosis 
As seen earlier in the discussion of p53 function, one of the possible responses 
of the cell to damage and stress, is the activation of programmed cell death or 
apoptosis. Apoptosis is an energy dependent process of II cell suicide", and can 
be induced by activation of receptors on the cell surface, such as FAS and TNF- 
a receptor (the Is extrinsic" pathway, Wajant, 2002). Additionally the DNA 
damage signalling pathways via p53 result in the upregulation of pro-apoptotic 
mediators, such as Bax (an example of the "intrinsic" pathways Wajant, 2002). 
Bax in turn stimulates mitochondria to release cytochrome C (Jurgensmeier et 
al., 1998). Signalling via FAS, or release of cytochrome C, results in the 
activation of the caspase cascade, via the initiation caspases, such as caspase 
9 (Figure 2.6). The product of this is activation of several effector caspases, 
such as caspases 3,6 and 7 (Slee et al., 2001). These effect the cell death 
programme, by destruction of the organelles and dissolution of the genome 
(reviewed in Okada & Mak, 2004). 
The abrogation of apoptosis in cancer generally was confirmed by the finding 
that the oncogene bcl 2, which is overexpressed by translocation in follicular 
lymphoma, has profound anti-apoptotic effects (Tsujimoto et al., 1984a; 
Tsujimoto et al., 1984b). It is also a transcriptional target of p53, with activated 
p53 reducing bcl 2 expression (HaIdar et al., 1994). Overexpression of bcl 2 
has been described in the early stages of various epithelial malignancies, 
including lung, breast and bladder, but this is often followed by loss of 
expression in advanced disease (Ghosh et al., 1999; Mauri et al., 1999; 
Nakopoulou et al., 1998). However, whilst this has not been found to be a 
consistent effect in HNSCC (Piattelli et al., 2002), a general trend towards a 
reduced bax/bcl 2 ratio has been found in tumour samples, but not in pre- 
invasive lesions (Lavieille et al., 1998). 
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The most common defect in pro-apoptotic signalling reported in HNSCC is loss 
of p53 function by mutation. Mice with p53 deficiency show defects in apoptosis 
in vivo (Lotem & Sachs, 1993). In terms of human tumour biology, this may 
manifest itself as resistance to chemotherapy. There have been clear links 
made between specific p53 mutations and resistance to doxorubicin in breast 
cancer (Aas et al., 1996), and response to chemotherapy in HNSCC 
(CabeIguenne et al., 2000). 
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Figure 2.6 Apoptosis - an overview 
The graphic shows some of the various pathways to apoptosis including 
signalling via p53 (DNA damage response), FAS receptor and c-myc. The 
pathways converge on the release of cytochrome c from mitochondria. Once 
released, cytochrome c interacts with apoptotic protease activating factor 1 
(APAF1) and procaspase 9. In the presence of ATP, caspase 9 is activated, 
leading to the activation of downstream effector caspases. Survival signals, 
such as those mediated by IGF1 may reduce the pro-apoptotic signalling in 
some pathways. 
This figure has been reproduced from (Pelengaris et al., 2002). 
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2.6 Limitless replicative potential 
The genetic changes described above allow proliferation of cancer cells outwith 
the strict controls placed on normal cells. Such unrestricted growth should 
allow tumours to develop unhindered. However, there are further multiple 
barriers to the limitless proliferation of cells. Hayflick originally demonstrated 
that cells have a finite replicative potential (Hayflick, 1965). The concept of the 
96 repl ico meter' was then introduced (Hayflick, 1997), this being a method for the 
cell to count the number of divisions and cease dividing after the maximum limit 
had been reached. This cessation of growth and division has been termed 
replicative senescence. 
2.6.1 Barrier 1: Replicative senescence 
Normal diploid embryonic cells, including fibroblasts and epithelial cells undergo 
approximately 40-70 population doublings before entering the stable, but viable 
state of replicative senescence (Hayflick, 1965). There is now much 
accumulated evidence that senescence is controlled, at least in part, by attrition 
of telomeric DNA. The observation that telomeres shorten both in vivo and in 
vitro suggests that telomeric attrition is the most likely "counting" mechanism for 
cell divisions (Allsopp et al., 1995). Other cellular clocks have been proposed, 
including a progressive increase in DNA methylation as senescence 
approaches (Machwe et al., 2000). The cellular signals that elicit senescence 
include activation of the DNA damage response (d'Adda di Fagagna et al., 
2003). 
Telomeres are repetitive DNA sequences (TTAGGG) on the ends of 
chromosomes. A complex of proteins binds the telomeric DNA, which is 
important in the maintenance of the complex structure of the telomere (Figure 
2.7 A). The 96 end replication problem" dictates that some of these repeats are 
lost when DNA is copied (Levy et al., 1992), although larger portions may also 
be lost through homologous recombination at the telomere (Wang et al., 2004). 
Telomerase was first described in yeast (Greider & Blackburn, 1985). It is a 
holoenzyme complex, consisting of a reverse transcriptase component (TERT, 
on chromosome 5p15.33) and a RNA template (TERC/TR) and is responsible 
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Figure 2.7 Telomere structure and the role of telomerase 
A: Schematic diagram of the structure of the telomere, showing the formation of 
D and T loops, in conjunction with various telomere associated proteins. These 
act to protect the telomeric end of the chromosome. 
B: The action of telomerase. hTERT catalyses the addition of new telomere 
repeats, with hTR as the template. 
Reproduced from Mathon and Lloyd, 2001 (Mathon & Lloyd, 2001) 
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for synthesis of the TTAGGG repeats on the end of chromosomes in germline 
cells (Figure 2.7 B). 
In normal somatic tissues, telomerase activity is generally absent, but is present 
at low levels in the proliferative (stem) cells in continually renewing tissues, 
such as epithelia (Hade-Bachor & Boukamp, 1996; Kolquist et al., 1998). In 
these cells, telomerase expression may depend on the proliferative state of the 
tissue. 
Expression of hTERT and hTR have also been described in the basal cells of 
normal oral mucosa (Fujimoto et al., 2001). Such activity may retard, but does 
not abolish telomere attrition (Oh et al., 2004) and is lost if the cells enter 
terminal differentiation or a quiescent state (Sharma et al., 1995). As normal 
oral keratinocytes approach senescence, telomerase expression reduces. This 
may be due to hype rmethyl atio n of the hTERT promoter (Shin et al., 2003). 
The normal regulation of telomerase expression is complex. Transcription of 
hTERT is modulated by multiple signals including members of the Myc family of 
transcription factors, Spl (Park et al., 2001), and human papilloma virus E6 
(Klingelhutz et al., 1996). It is also postulated that alternative splicing of the 
hTERT gene may contribute to control of telomerase activity (Ulaner et al., 
2000), but this has not been confirmed under physiological conditions (Kotoula 
et al., 2002; Liu et al., 1999). Repression of hTERT expression may be under 
the control of various, as yet unidentified transcriptional repressors, such a gene 
from a possible candidate region on chromosome 3p (Cuthbert et al., 1999). Rb 
and E21F may also have hTERT repressive activity, either directly or indirectly 
(Crowe & Nguyen, 2001). 
In cell culture, it has been demonstrated that telomerase activity is closely 
related to hTERT expression and that in alterations of telomerase activity, such 
as those mentioned above in relation to senescence, hTERT reduces, whilst 
hTR remains constant (Shin et al., 2003). However, in a mouse model, 
ha plo insufficiency of hTR disrupted telomere maintenance (Chiang et al., 2004). 
In vivo studies have also shown hTR to be upregulated in some solid tumours, 
including cervical carcinoma and non-small cell lung carcinoma (Soder et al., 
1998; Soder et al., 1997). Additionally, the coordinate upregulation of hTR and 
hTERT has been demonstrated in many tumours in vivo (Stanta et al., 1999), as 
48 
has hTR downregulation upon proliferation in the small number of telomerase- 
positive cells in normal tissue (Sugihara et al., 1999). This clearly supports a 
role for hTR expression in the regulation of telomerase activity in vivo. The 
mechanisms of regulation of hTR expression have not been elucidated. 
Ectopic expression of TERT in human diploid fibroblasts (HDFs) is sufficient for 
immortal isation. This indicates the importance of telomere dependent pathways 
in the establishment of barriers to growth in this type of cell. However, this does 
not apply to mammary epithelial cells or keratinocytes, both of which require 
additional alterations to allow immortalisation to occur (Muntoni et al., 2003). 
The additional alterations that are necessary in human oral keratinocytes most 
likely include loss of p16 expression. In one mortal cell culture, which had lost 
expression of p16, ectopic expression of hTERT was sufficient to result in 
immortal isation, without pressure toward p53 mutation. Mortal cultures which 
had intact pl 6 expression, were not immortalised (Muntoni et al., 2003). 
As mentioned earlier, p16 has been suggested as playing a central role in the 
establishment of replicative senescence. Recent elegant investigations in 
fibroblasts have indicated that p16 does not have an essential role in fibroblast 
senescence (Brookes et al., 2004; Herbig et al., 2004), although this is still 
disputed (Bond et al., 2004). More importantly, the experiments demonstrated 
that the mechanism by which senescence is achieved could vary even between 
cells within the same culture (Herbig et al., 2004). Thus in terms of 
senescence, it seems likely that individual cells may differ in their response to 
multiple signals, resulting in the development of mosaic cultures. Senescence 
triggered by coordinate upregulation of p14 and p16 has been reported in 
murine fibroblasts, but a role for p14 in keratinocyte senescence has not been 
established (Munro et al., 1999). 
In human keratinocytes, senescence is a two-stage phenomenon, with initial 
replicative arrest mediated by p16, and its effect on the Rb pathway (Kiyono et 
al., 1998; Loughran et al., 1994). This has been termed mortality stage 0 (MO). 
The upstream pathways are unclear, but roles for loss of expression of the 
transcription factor Idl (Alani et al., 2001) and increase in the expression of 14- 
3-3a have been suggested (Dellambra et al., 2000; Rheinwald et al., 2002). 
The rise in p16 expression may also be mediated by telomeric attrition (Jacobs 
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& de Lange, 2004), but the effector pathways are yet to be fully elicited (Zheng 
et al., 2004). Some groups have suggested that the accumulation of p16 in 
keratinocyte cell culture is related to inadequate culture environment and that 
only co-culture with feeders prevents the accumulation of p16 (Ramirez et al., 
2001). This has not been borne out by experimentation in mortal cells in our 
laboratory as, despite co-culture with feeders, the accumulation of p16 still 
occurs (McGregor et al., 2002). 
Once the growth arrest mediated by p16 has been overcome, the continued 
telomeric attrition results in the activation of p53, as described earlier. This is 
termed mortality stage 1 (Ml) (Figure 2.8). Shortened telomeres activate p53 
via ATM, as the uncapped telomere is recognised in a similar manner to a 
double strand DNA break. A single short telomere may be sufficient for this 
pathway to be activated (Hemann et al., 2001), and the effect may be mediated 
by alterations in the binding of telomere-related proteins to shortened telomeric 
DNA (Karlseder et al., 2002). It is also possible that senescence can occur in 
the absence of telomere shortening. Some types of cell, including certain 
keratinocytes, may be telomerase positive and yet these cells still undergo 
senescence (Kang et al., 1998). The main effector in this case was reported to 
be p16 (Kang et al., 2004). However, in many instances these results may 
merely reflect whether MO or M1 is being investigated. 
2.6.2 Overcoming senescence 
Escape from senescence can occur in many ways, largely dependent on the 
cell type, but most require alterations at some point in the p53 and Rb pathways 
(Shay et al., 1991). Fibroblasts require loss of signalling via Rb, but not the loss 
of p16 function per se (Wei et al., 2003). This may be because fibroblast 
senescence is maintained primarily by p53 (Beausejour et al., 2003). Other cell 
types, such as normal human mammary epithelia cells, may spontaneously 
escape senescence (Romanov et al., 2001). In human oral keratinocytes, 
inactivation of p16 is invariably associated with the immortal phenotype in 
HNSCC cell cultures (Munro et al., 1999). Inactivation of the DNA damage 
signal is also required and this is most commonly acquired by mutation of p53. 
Cells that have escaped senescence proliferate until a second major replicative 
is barrier is reached, namely crisis 
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Figure 2.8 Barriers to immortalisation 
Schematic representation of the relationship of telomere length and passage 
through senescence and crisis. Human cells must surmount both replicative 
senescence and crisis to become immortal. Replicative senescence is 
controlled by the actions of the pRb, p53 and telomere maintenance pathways. 
Telomere stabilisation permits cells to avoid crisis and become immortal 
Figure adapted from Hahn, 2003 (Hahn, 2003) 
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2.6.3 Barrier 2: Crisis and immortalisation 
Following further cell division, multiple telomeres in each cell become critically 
short and uncapped. This generates dicentric chromosomes and genomic 
instability (Ducray et al., 1999). This barrier to indefinite growth, known as M2 
or crisis, results in cell death rather than cell cycle arrest (Figure 2.8). Crisis 
has been suggested to precipitate tumour development and progression in 
animal models and in human breast cancer via the promotion of genomic 
instability. The presence of anaphase bridges in mitotic cells, either in culture 
or in tumours, has been used as a surrogate marker of telomere dysfunction as 
it demonstrates the presence of chromosome fusions (Gordon et al., 2003; 
Rudolph et al., 2001). Moreover, in mice, such imbalanced chromosomal 
translocations are associated with the immortalisation process (Rudolph et al., 
1999) and cancer (Artandi et al., 2000), including the erosion of telomeres and 
the development of p53 mutations (Shao et al., 2000). Thus, in some 
circumstances, variants emerge from crisis to become immortal. This is 
accomplished by the correction of telomere dysfunction, by either up-regulation 
or reactivation of telomerase or by alternative methods, which involve 
recombination (alternative lengthening of telomeres, ALT) (Bryan et al., 1997). 
Despite telomerase activity in many tumours, it is clear that telomerase 
activation is a double-edged sword (reviewed in Masutomi & Hahn, 2003). 
Absence of telomerase activity results in a limited lifespan, via the activation of 
senescence, but if senescence is bypassed, this can result in genomic 
instability. However, telomerase activation reduces chromosomal instability by 
stabilising the telomere, but allows cells to become immortal. Once telomerase 
has been activated, the telomeres appear to be maintained at a very short 
setting in some tumours. This allows for a measure of continued genomic 
instability (Chin et al., 2004; Gisselsson et al., 2001; Gordon et al., 2003). 
Expression of telomerase is increased in HNSCC, both in cells derived from 
dysplastic oral lesions and from turnours (McGregor et al., 2002; Parkinson et 
al., 1997). The level of activity is related to tumour grade, as the highest levels 
have been demonstrated in poorly differentiated HNSCC (Kannan et al., 1997). 
increases in both hTERT and hTR expression have been described (Downey et 
al., 2001 ; Kim et al., 2001; Zhang & Zhang, 1999). Whilst increased 
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telomerase activity has been noted in dysplastic oral lesions (Mao et al., 
1996a), reports linking the grade of dysplasia with telomerase activity have 
been variable (Miyoshi et al., 1999; Mutirangura et al., 1996; Zhang & Zhang, 
1999). In most studies, a proportion of the turnours are telomerase-negative. 
These findings suggest that the immortal and invasive phenotypes may be 
acquired independently in HNSCC development. This concept will be explored 
more fully below and later in this thesis 
2.6.4 ALT 
Whilst many tumour types have high levels of telomerase activity, some do not. 
There may be several reasons for this. However, the presence of immortal, 
telomerase negative cell lines is indicative of the existence of other telomere 
lengthening mechanisms (Bryan et al, 1995). These cells have very long and 
heterogeneous telomeres, and there is evidence of elongation of these 
telomeres by the alternative lengthening of telomeres (ALT) mechanism (Bryan 
et al., 1997), which involves intratelomeric recombination and copy templating 
for the synthesis of telomeric DNA (Dunham et al., 2000). Whilst ALT has been 
shown to occur in oral keratinocytes under certain circumstances in vitro (Opitz 
et al., 2001), there is presently no evidence that ALT occurs in HNSCC 
carcinogenesis (Henson et al., 2002; Loughran et al., 1997). 
2.6.5 Evidence for senescence and immortalisation in vivo 
In studies from the Beatson Institute for Cancer Research, about 60% of 
primary HNSCCs are immortal, as are all the HNSCC recurrences (although the 
latter are more limited in number) (Burns et al., 1993; Edington et al., 1995). 
Numerous studies link the process of immortality with genetic instability. p53 
mutations, p16 loss, LOH and aneuploidy are all characteristics of cells that 
have escaped senescence and become immortal (Edington et al., 1995; 
Loughran et al., 1997). It is very unlikely that the acquisition of the immortal 
phenotype is merely a culture phenomenon since the genetic signature of 
immortal HNSCC cell lines is also found in a large subset of HNSCC turnours 
and dysplasias in vivo (Loughran et al., 1997; Mao et al., 1996b; Rosin et al., 
2000; Weber et al., 1998). In addition, the presence of unbalanced 
chromosome translocations and anaphase bridges in over 80% of HNSCC 
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tumours in vivo is suggestive of their escape from senescence (Gordon et al., 
2003). 
Despite, the importance of immortality in the generation of the majority of 
HNSCC, it is becoming clear from work conducted in the Beatson Institute and 
others that a subset of tumours may develop into invasive carcinomas without 
acquiring immortality. Furthermore, other published data on uncultured tumour 
samples reveal minor subsets of oral carcinomas that have no detectable LOH 
(Field et al., 1995) or unbalanced translocations (Weber et al., 1998), or are still 
diploid (Sudbo et al., 2003). The conclusion that the ability of SCCs to establish 
as cell lines in culture (i. e. become immortal) correlates with poorer survival is 
supported in the literature (Shimada et al., 2003). This suggests that some 
primary SCCs can still be mortal in vivo; whereas in others an immortal 
population has developed by further mutation and this is responsible for local 
recurrence and metastasis. Offner et al found that disseminated tumour cells in 
bone marrow from a variety of primary tumour types (presumed to be micro- 
metastases) rarely have p53 mutations and are therefore unlikely to be 
immortal, unlike the primary tumours; in contrast, p53 mutations in the primary 
tumour appear to favour lymphatic dissemination of lung carcinoma cells (Offner 
et al., 1999). 
The existence of mortal SCCs is supported by in vivo data that some HNSCC 
are telomerase negative (Mao et al., 1996a) and, as mentioned above, there is 
currently no evidence for ALT mechanisms in head and neck cancer (Henson et 
al., 2002). Additionally, subsets of HNSCC have a low level of fractional allele 
loss and develop without the characteristic genomic changes (LoH at 3p, 9p 
and 17p) that may underpin the development of immortality (Nunn et al., 1999). 
Others have extended this observation to bladder cancer, showing that all 
superficial transitional cell carcinomas (TCCs) were mortal whereas invasive 
TCCs spontaneously bypassed senescence by acquiring genetic alterations 
involving p16/pRb loss and an additional alteration (p53 mutation, changes at 
chromosome 20q, 3p or 8p) (Yeager et al., 1998). Another study on 
glioblastorna divided the turnours into three groups: telomerase positive, 
te Io me rase- negative-ALT positive and telomerase negative ALT negative; they 
concluded that the third group of turnours do not have a telomere maintenance 
mechanism of any kind and that these turnours appeared to have a better 
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prognosis (Hakin-Smith et al., 2003) Given that all data available shows that 
telomere erosion denies mammalian cells an indefinite lifespan (Bodnar et al., 
1998; Niida et al., 1998), this data seems persuasive evidence for the existence 
of mortal tumours in vivo. 
Like HNSCCs, both mortal and immortal dysplasias exist, though the balance is 
in favour of the former (60: 40) (McGregor et al., 2002; McGregor et al., 1997). 
Of the 19 dysplasia biopsies for which we have derived primary cultures, 6 of 7 
of the immortal cultures showed four molecular changes: loss of p16 INMA and 
retinoic acid receptor-beta (RAR-P) expression, p53 mutations and high 
telomerase activity; whereas 11 of 12 mortal cultures lacked these changes 
(McGregor et al., 2002; McGregor et al., 1997; Muntoni et al., 2003). The two 
exceptions have an intermediate phenotype (McGregor et al., 2002; McGregor 
et al., 1997). No evidence of HPV infection was found in any of the cultures. An 
important conclusion from this evidence is that acquisition of immortality and 
invasiveness may be independent events in cancer progression, since some 
dysplasias are immortal and, conversely, some carcinomas are mortal. 
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2.7 Genomic instability 
One further overarching feature may hold all these alterations together and act 
as an enabling backdrop upon which the other abilities may appear. This is 
genomic or chromosomal instability. Genomic instability is characterised by the 
occurrence of losses and gains of chromosomal segments or even whole 
chromosomes. A large proportion of human turnours demonstrate 
abnormalities in both the number and structure of their chromosomes 
(Hittelman, 2001). 
2.7.1 How does genomic instability arise? 
Chromosomal instability may arise by multiple mechanisms. The basis of 
instability consequent to telomeric attrition has been discussed above. 
Abrogation of the DNA damage signal, by loss of signalling via p53 or 
intermediates within the p53 DNA damage pathway (Figure 2.5), results in 
unrepaired damage and this may lead to chromosomal aberrations (Shao et al., 
2000). Loss of the DNA damage recognition signal after the loss of p53, 
together with telomeric attrition, results in the cell entering crisis (Feldser et al., 
2003). The fusion of chromosome ends, seen in tumours as anaphase bridges, 
drives chromosomal instability via breakage-fusion-bridge cycles. 
Amongst the other mechanisms, which may operate in certain tumours, are 
chromosomal segregation defects (Minhas et al., 2003). The cellular machinery 
active in mitosis is complex and alterations detected in tumour cells include 
spindle abnormalities, centrosome amplification (Mayer et al., 2003) and 
abnormal cytokinesis (reviewed by Gollin, 2004). Amplification of certain genes 
which control mitotic spindle activity has been described. One such important 
gene is Aurora A (serine threonine kinase 15). Amplification of this gene has 
been associated with centrosome amplification and the formation of multipolar 
spindles (Jeng et al., 2004; Zhou et al., 1998). In mammary carcinogenesis, 
amplification of Aurora A has been associated with the transition from in situ 
disease to invasive carcinoma (Hoque et al., 2003). 
Investigations in colorectal cancer have demonstrated that defects in single 
genes can result in genomic instability (Rajagopalan et al., 2003). This in turn 
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leads to further loss of genomic material, as assessed by loss of heterozygozity 
(LoH). 
2.7.2 Karyotypic abnormalities 
The largest scale abnormality seen in genetically unstable cells is karyotypic 
alteration, such as tetraploidy and aneuploidy. These may arise from non- or 
partial disjunction of cells in mitosis. Aneuploidy has been reported in many 
cancers, reflecting the complex karyotypes that may result from genomic 
instability. The presence of aneuploid cells in HNSCC carcinogenesis has been 
known for some time (Munck-Wikland et al., 1994; Munck-Wikland et al., 1992). 
The presence of aneuploidy in oral tissues may even precede the development 
of a clinically or histopathologically evident lesion (Ai et al., 2001; Sudbo et al., 
2001b). Analysis of modal chromosome number in a panel of HNSCC cultures 
indicated that almost all, regardless of whether mortal or immortal, showed 
some karyotypic abnormality (Edington et al., 1995). This demonstrates the 
likelihood that multiple pathways to alterations in the karyotype exist, not merely 
those that involve passage through crisis. 
In recent work using DNA image cytometry to assess the DNA content of nuclei 
from HNSCC and various dysplastic lesions, Sudbo and colleagues have shown 
that leukoplakias from the oral cavity containing aneuploid cells are more likely 
to develop into turnours (Sudbo et al., 2001 a). However, the risk of progression 
to SCC did not increase further as the proportion of aneuploid cells in the 
sample increased. Such lesions are also more likely to be aggressive and 
spread to other sites, compared to diploid or tetraploid leukoplakias (Sudbo et 
al., 2001a; Sudbo et al., 2004). However, the malignant transformation rate in 
these studies is high, compared to other reports of leukoplakia progression the 
HNSCC. Thus, it is likely that the study population is biased towards lesions 
that were clinically or histologically more advanced. However, these finding are 
clearly important and merit careful confirmation in independent patient groups 
with a prospective study design. 
2.7.3 Comparative genomic hybridisation and loss of heterozygozity 
Comparative genomic hybridisation (CGH) is a powerful tool for the analysis of 
gains and losses across the whole genome and has therefore been widely used 
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in the analysis of tumours. It appears that particular types of cancer have 
characteristic (although not ubiquitous) patterns of genetic alteration. This may 
now be conducted on a high throughput, genome-wide scale using array CGH, 
which combines microarray technology with the ability to explore chromosomal 
changes. This technique allows detection of single copy number changes. 
Loss of heterozygozity (LoH) indicates consistent loss at specific, predefined 
loci. This tool has been widely used but is less powerful as known markers 
must be used to investigate particular areas of interest in the genome. 
The areas which are consistently altered in HNSCC are gains on 3q, 5p 8q and 
11q13, and losses on 3p, 9p and 17p (Bockmuhl et al., 1996; Brzoska et al., 
1995; Hermsen et al., 1997; Roz et al., 1996; Soder et al., 1995; van der Riet et 
al., 1994), although this varies by subsite to some extent (Huang et al., 2002). 
Late-stage and high grade tumours have large numbers of gains and losses 
(Hermesen et al., 2001 Bockmuhl, 1996). In general, SCCs have more 
alterations than dysplastic, non-invasive lesions (Weber et al., 1998). LoH has 
also been associated with poor prognosis, particularly at distinct regions within 
3p (Partridge et al., 1996) or within 22q (Ashman et al., 2003), but little evidence 
of specific patterns of abnormality related to risk of metastasis per se (Patmore 
et al., 2004). 
Loss of heterozygozity at 3p, 9p and selected other loci, including 17p has been 
associated with development of SCC, even within lesions exhibiting only mild 
dysplasia (Lee et al., 2000; Mao et al., 1996b; Rosin et al., 2000). These areas 
have been mentioned previously in relation to certain markers related to the 
development of HNSCC, namely p53 (17p), pl6ink4a (9p2l) and RAR-fl (see 
next section) or a putative telomerase inhibitor on 3p. Other, yet unidentified 
tumour suppressor genes may reside in other areas that show high prevalence 
of LoH (Partridge et al., 1999). 
Much of the evidence for field cancerization in HNSCC development has come 
from LoH analysis of multiple premalignant and malignant lesions (Taboret al., 
2002a). These lesions often have a common pattern of LoH, indicating a 
common origin, with divergence at other loci later within the field (Jang et al., 
2001). Others have found that other "early" markers, particularly at 9p2l can be 
maintained over a large area of the mucosa (Guo et al., 2001). This analysis 
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can be used to detect abnormal cells in clinically normal mucosa and in the 
resection margins of SCC and dysplastic lesions to assess the subsequent risk 
of development of HNSCC (Partridge et al., 2000a; Rosin et al., 2002; van 
Houten et al., 2004; Zhang et al., 2001). 
The large number of such publications on patterns of LoH has resulted in the 
development of a model of HNSCC development, much along the lines of the 
Fearon & Vogelstein model of colorectal carcinogenesis (Fearon & Vogelstein, 
1990). This model, proposed by Califano and coworkers, is based on a 
progressive accumulation of genetic alterations (assessed by LoH) on 
comparison of normal, dysplastic oral mucosa (of varying grade) and HNSCC 
(Califano et al., 1996). The model is illustrated in schematic form in Figure 2.9. 
However, this model has certain weaknesses, including the apparently false 
assumption that lesions must progress through the various grades of dysplasia 
before development of SCC. Additionally, it is possible that the "early IP 
alterations detected (3p, 9p, 17p) reflect the escape of the cells from the growth 
barrier of senescence (RAR-fl, p16 and p53 loss respectively). The subsequent 
massive increase in LoH detected may be the result of subsequent genomic 
instability during ti crisis 11 , an idea supported by the much greater frequency of 
allele loss reported in immortal HNSCC cultures compared to mortal cultures 
(Edington et al., 1995). This would give rise to LOH at multiple sites, some of 
which may not be associated directly with alterations in any particular gene in 
relation to cancer progression. As described above, HNSCCs and premalignant 
lesions often exhibit aneuploidy, which is another feature in cells that have 
passed through crisis. The ongoing increase in LoH in late stage tumours may 
merely reflect continuing genomic instability, and be a function of the amount of 
time the cell has been immortal, rather than related to the disease process per 
se. In this way, immortality may be related to disease progression and poor 
prognosis in HNSCC- 
2.7.4 Microsatellite instability 
Microsatellites are areas of repetitive DNA scattered randomly throughout the 
genome. Alterations can occur if DNA replication is not conducted carefully. If 
controls on normal DNA replication are lost, as may be the case in mismatch 
repair defects, areas of microsatellite DNA can be added or lost. This is termed 
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microsatellite instability (MI). In HNSCC, MI has been demonstrated with 
increasing frequency as lesions progress from normal to dysplastic and finally to 
carcinoma (Ha et al., 2002b). The technique has also been used to detect 
circulating tumour cells in patients with SCC of the oesophagus (Eisenberger et 
al., 2003). 
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Figure 2.9 A model of the clinical, pathological, and molecular 
progression of oral cancer 
This model was proposed by Califano et al (Califano et al., 1996). 
Panel A shows the possible clinical presentation of oral cancer. Molecular 
approaches have yielded considerable understanding of the field cancerization 
hypothesis originally proposed by Slaughter (Slaughter et al., 1953). Although 
these lesions may have histopathological differences, as shown in B, they are 
often clonally related, arising from the same field of genetic alterations. 
The possible histological features seen in progression from normal-appearing 
mucosa to invasive cancer are depicted in Panel B. Normal-appearing mucosa 
may harbor early genetic changes (Panel C), often with loss of 9p2l (possible 
inactivation of p16). Further clinical progression to dysplasia is associated with 
further genetic changes. Carcinoma-in-situ often harbours most of the genetic 
changes described in invasive carcinoma. 
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2.8 Retinoids and differentiation 
Alterations in differentiation may also be linked with many of the genetic 
alterations described above. Within a stratified squamous epithelium, cells 
undergo an organised series of morphological changes, culminating in the 
presence of flattened cells on the surface of the tissue, which may, or may not, 
proceed to become fully keratinised. Control of the process of differentiation is 
complex and is accompanied by sequential expression of a number of 
cytoskeletal protein families, including the cytokeratins, and involucrin (Presland 
& Dale, 2000). Alterations in differentiation have been described in HNSCC 
(Kannan et al., 1994; Rheinwald, 1982), and the level of differentiation is one of 
the important clinico-pathological assessments of tumours in general. 
Vitamin A and its analogues are known to play an important role in regulating 
the differentiation of epithelial cells (Kautsky et al., 1995), by binding to and 
activating members of the retinoic acid/retinoid receptors, two families of 
transcription factors that are members of the steroid hormone superfamily 
(reviewed in Sun & Lotan, 2002). Vitamin A is normally obtained from the diet 
and is transported and metabolised in the body by a family of transport proteins, 
cellular retinol or retinoic acid binding proteins (reviewed in Harrison & Hussain, 
2001; Noy, 2000; Vieira et al., 1995). In vivo, there is a strong feedback 
mechanism tightly regulating and limiting the serum level of vitamin A at high 
dietary levels. However, synthetic vitamin A analogues ("retinoids") can escape 
this dose limiting mechanism and therefore their administration can result in 
much higher levels of retinoid acid metabolites in vivo. 
Retinoids regulate gene expression and thus modulate differentiation and 
growth in cells (Lotan, 1996). Thus, there has been much interest in the effects 
that deregulation of this system may have in carcinogenesis. There are two 
main classes of retinoid receptor - RAR and RXR, both with several subtypes. 
The RAR family has three main subtypes a, fl and y plus alternatively spliced 
variants. Studies have shown that RARs are present in normal tissue, some 
showing RAR-a and RAR-y present at all sites. Lotan and co-workers found 
RARP was only prominent in normal tissue from non-keratinised intra-oral sites, 
despite the same group earlier finding no site difference in distribution (Lotan, 
1996; Xu et al., 1994). Four isoforms of RAR-, 8 have been described. RAR, 81 
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and RAR, 83 differ from RARfl2 in the 5'UTR and A coding region (see Figure 
4.11). RAP, 84 is generated by alternative splicing in exon 1 (Zelent et al., 
1991). Isoform RAR-, 82 has been specifically linked with mediation of retinoic 
acid inhibition of growth in certain cells (Toulouse et al., 2000). 
In a variety of premalignant lesions the level of RARcc was found to be slightly 
lower than in normal epithelium, but the most dramatic change consistently 
found during oral cancer development is the increasingly large reduction in 
RARP levels on progression from hyperplasia to dysplasia to SCC (Chakravarti 
et al., 2001; Lotan et al., 1995; Xu et al., 1994). Loss of RARP expression has 
been reported in a variety of other epithelial malignancies, including lung, 
prostate, and breast (Kikugawa et al., 2000; Xu et al., 1997). 
In SCC and dysplastic tissue, the close correlation of keratin 19 expression and 
RAR-fl expression is lost, representing aberrations in differentiation (Hu et al., 
1991). It is also associated with acquisition of the immortal phenotype, as is 
loss of p16 (McGregor et al., 1997). The loss of RARP mirrors the change from 
senescence to immortality in culture and work in our laboratory has shown that 
this is an early event in the development of dysplastic lesions (McGregor et al., 
1997). However, Lee and coworkers found that loss of RARP gave a SCC risk 
ratio of 0.9, suggesting that, loss of RAR-, 8 alone was not necessarily 
associated with poor prognosis. This may be due to the modulatory effect of 
other receptors including RAR-y (Lee et al., 2000). 
The mechanism of the loss of RARP expression does not seem necessarily to 
be deletion, since expression of RAR, 8 receptors can often be re-induced by 
retinoids (Kurie et al., 2003; Lotan et al., 1995). However, many studies have 
implicated epigenetic silencing by promoter methylation in the abolition of RARj8 
expression (Virmani et al., 2000), and it has also been linked with aberrant 
histone deacetylation (Sirchia et al., 2000; Suh et al., 2002). Reduction in RAR- 
,8 expression 
in some immortal dysplasia cell cultures can be reversed by the 
use of de-methylating agents such as 5'aza2'deoycytidine (McGregor et al., 
2002). The inducibility of RARP correlates with clinical response in leukoplakia 
(Lotan, 1996). 
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Recently, retinoids have been implicated in the regulation of telomerase. Not 
only does constitutive expression of telomerase inhibit differentiation (Cerezo et 
al., 2003), but Pendino and coworkers also found that during retinoid treatment, 
hTERT is down-regulated and that this occurs by two pathways: an immediate 
RAR-mediated pathway and another indirect pathway (Pendino et al., 2001). In 
normal cells, expression of telomerase components is reduced in response to 
differentiation (Yashima et al., 1998). A link to p53 has also been suggested 
with stabilised p53 marking increased retinoid resistance (Lippman et al., 1995). 
Historically, vitamin A or synthetic retinoid derivatives have been extensively 
tested in terms of reversing leukoplakias and prevention of second primary 
cancers. The rationale for this was initially based on evidence that cancer risk is 
greater in animals or humans with vitamin A deficiency. High dose retinoids can 
reverse histologically evident dysplasia, but have significant skin toxicity 
(reviewed in Lodi et al., 2004). Lower doses of retinoids in combination with 
interferon a and vitamin E are also effective, but genetic abnormalities persist 
(Hong et al., 1986; Papadimitrakopoulou et al., 1999; Shin et al., 2001 b). 
Disappointingly, the initial promise that retinoids might prevent second cancers 
developing has not been confirmed in more recent trials (Hong et al., 1990; 
Khuri et al., 2003; van Zandwijk et al., 2000). 
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2.9 Other markers 
A large number of studies have identified a variety of other gene expression 
changes in HNSCCs compared to normal oral mucosa by analysis of RNA 
extracted from biopsy tissue or by immunohistochernistry. In several studies, 
the expression of a large number of individual markers has been correlated with 
outcome in univariate analysis (Table 2.1). Not surprisingly, these changes 
affect a wide range of cellular processes known to be involved in cancer 
progression in many cancers, such as kinase signalling pathways; cell 
cycle/apoptosis; cell adhesion, motility and invasion; angiogenesis; 
im mortal isation; chemokines and inflammation. 
2.9.1 Cyclooxygenase 2 
Alterations in cyclooxygenase 2 (COX2) have been described in many cancers. 
COX2 involvement was suspected from observations that patients treated with 
long-term non-steroidal anti-inflammatory drugs (NSAIDs) showed a reduced 
incidence of colorectal adenomas and adenocarcinomas (Thun et al., 1991; 
Waddell & Loughry, 1983). Subsequent investigation demonstrated 
overexpression of COX2 in colorectal adenoma and adenocarcinomas 
(Eberhart et al., 1994). 
COXs are members of a family of dual function enzymes, prostaglandin 
endoperoxide synthases, involved in the generation of prostaglandins, an 
important class of biological regulators: COXs catalyse the first stage, the 
formation of prostaglandin H2 from the fatty acid, arachidonic acid. COX1 is 
widely expressed in cells, whereas COX2 is inducible by mitogens and is also 
highly expressed in many cancer types (reviewed by Goodin & Shiff, 2004). 
COX2 expression is increased in high risk oral dysplasias (Sudbo et al., 2003), 
probably as a consequence of EGF receptor overexpression and activation 
(Matsuura et al., 1999). Moreover, normal human mammary epithelia with 
silenced pl 6 overexpress COX2 and show features of premalignancy (Crawford 
et al., 2004). 
Various mechanisms have been proposed to explain how COX2 may contribute 
to cancer progression: by producing reactive oxygen species as a by-product of 
its catalytic activity, stimulating proliferation, inhibiting apoptosis, modulating 
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Pathways affected Changes in expression References 
Signalling pathways EGF receptor & cerbB2 (Ang et al., 2002; Chen et 
al., 2003; Ulanovski et al., 
2004) 
IL13 receptor a2 (Kawakami et al., 2003) 
phosphatidyl i nos itol-3 kinase catalytic (Estilo et al., 2003) 
a peptide 
RASSF1A (Kuroki et al., 2003) 
Smad ubiquitin ligase (Smurf2) (Fukuchi et al., 2002) 
Cell cycle/apoptosis cdc2 (Wada et al., 2004) 
p53 mutation (Geisler et al., 2002; 
Mineta et al., 1998; Nathan 
et al., 2000; Nogueira et 
al., 1998) 
p16 
INMA (Bova et al., 1999; Geisler 
et al., 2002) 
p14 
ARF (Ogi et al., 2002) 
Cyclin D1 (Bova et al., 1999; 
Nogueira et al., 1998) 
polo-like kinase 1 (Knecht et al., 1999) 
surviving (Lo Muzio et al., 2003) 
DAP-kinase (Brock et al., 2003) 
Adhesion/motility E-cadherin (Chang et al., 2002; Chow 
et al., 2001; Lim et al., 
2004) 
S100 Ca ++ regulated protein A4 (Moriyama-Kita et al., 
2004) 
CD44 (Gonzalez-Moles et al., 
2003) 
hyaluronan (Kosunen et al., 2004) 
metalloproteinase (MMP)-9 (Katayama et al., 2004) 
tissue inhibitor of MMPs (TIMPs)1/2/3 
moesin (Kobayashi et al., 2004) 
DCC (Ogi et al., 2002) 
periostin (Bao et al., 2004) 
Angiogenesis VEGF (Shintani et al., 2004; 
Uehara et al., 2004) 
HIF-1a (Beasley et al., 2002) 
Transcription HMGA2 (Miyazawa et al., 2004) 
BRG1/BRM (Reisman et al., 2003) 
Chemokines CXCR4 receptor (Delilbasi et al., 2004) 
CCR7 receptor (Ding et al., 2003) 
Immortalisation telomerase (Liao et al., 2004) 
Others COX2 (Chang et al., 2004) 
MINT1 & MINT 31 (Ogi et al., 2002) 
haern oxygenase (Yanagawa et al., 2004) 
SCC-related oncogene (Estilo et al., 2003) 
Table 2.1 Gene expression changes in HNSCC that have been associated 
with prognosis compared with normal mucosa 
The table includes some genes that are referred to elsewhere in the text. 
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immune surveillance or stimulating angiogenesis (Lin et al., 2002). Moreover, 
inhibition of COX2 overexpression may be one of the mechanisms whereby 
retinoids inhibit dysplasia progression (Subbaramaiah et al., 2002). Such data 
has led to great interest in the utility of specific Cox-2 inhibitors in 
chemoprevention (Koki et al., 2002). However, it is not certain that inhibition of 
growth of oral cancer cells by 'COX-2-selective' inhibitors is entirely mediated 
by reduced prostaglandin E2 synthesis as the magnitude of growth inhibition 
seen can be unrelated to the COX2 expression level (Minter et al., 2003; 
Schroeder et al., 2004). Disappointingly, despite this strong preclinical data, a 
recent randomised, double-blind, placebo-controlled trial of the COX inhibitor, 
ketorolac, as an oral rinse found no effect on response rates of oropharyngeal 
leukoplakia (Mulshine et al., 2004). However, this conclusion should be 
interpreted cautiously since the study lacked any investigation of biological 
endpoints in the target tissue to establish the effectiveness of the treatment on 
COX activity. 
2.9.2 Gene expression profiling 
More recently, several groups have compared the overall gene expression 
profiles of HNSCCs with normal oral mucosa by microarray analysis. In most 
cases, this has been performed using fresh biopsy material (EI-Naggar et al., 
2002; Gonzalez et al., 2003; Mendez et al., 2002; Sok et al., 2003) which 
obviously contains stromal and immune cells in addition to epithelial cells. In a 
few studies, pure epithelial cell material was obtained by laser capture 
microdissection (Alevizos et al., 2001; Leethanakul et al., 2003; Leethanakul et 
al., 2000) or pure epithelial cell cultures were isolated (Al Moustafa et al., 2002). 
Both approaches have their value, given recent work in other models indicating 
that gene expression changes occur in both tumour stromal and epithelial 
compartments of epithelial cancers and together facilitate cancer development 
(reviewed in Mueller & Fusenig, 2002; Park et al., 2000; TIsty, 2001). 
Such studies have identified subgroups of HNSCCs with gene expression 
profiles that correlate with prognosis. One study of 25 primary HNSCCs, 16 
locally recurrent HNSCCs and 13 normal oral mucosa samples found a gene 
expression signature associated with recurrence that included markers of 
proliferation, extracellular matrix proteins, cytokines and chemokines, and 
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immune response (Ginos et al., 2004). No attempt was made to correct for 
smoking status in this study and so this could account for some of the 
differences in gene expression profiles between normal subjects and HNSCC 
patients; however, the prognosis related differences in gene expression profiles 
amongst HNSCCs are likely to be unaffected since 90% of the patients were 
smokers. Another study of 60 HNSCCs (58 of which were from smokers) 
categorized the tumours into four groups associated with statistically significant 
differences in recurrence-free survival. These included a subtype with a 
possible epidermal growth factor (EGF) receptor pathway signature, a 
mesenchymal-enriched subtype, a normal epithelium-like subtype and a 
subtype with high levels of antioxidant enzymes (Chung et al., 2004). 
Although not directly relevant to HNSCC, one study of 24 oesophageal SCCs 
and normal tissues, found a high rate of relapse to correlate with expression of 
molecules associated with cell cycle regulation, gene repair, apoptosis and 
chemoradiotherapy resistance (Ishibashi et al., 2003). Smoking-related changes 
in this study were controlled by comparing paired samples of normal and 
malignant tissues from the same patient. In another oesophageal SCC study, 
the gene expression signature profile associated with nodal metastasis in a 
training set of 36 cases was found to be predictive in an independent validation 
set of 18 cases (Tamoto et al., 2004). 
Gene expression profiling offers one potential approach for better diagnostic 
methods for analysis of dysplasias in relation to prognosis. Ha et al found that 
there were many more differences in gene expression between normal and 
premalignant oral leukoplakias (mainly moderate to severe dysplastic lesions) 
than between these lesions and HNSCCs (Ha et al., 2003). However, no 
information regarding correlation with progression was available in this study. 
Although not directly relevant to squamous cancer, in another premalignant 
model, Barrett's oesophagus, screening of the expression profiles of a panel of 
23 genes revealed that expression of three genes (PITX1, tetraspanin and 
thymidine phosphorylase) could distinguish Barrett's oesophagus from 
adenocarcinoma with an error rate of 28% in a cross validation test (Brabender 
et al., 2004). 
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2.10 Aims and rationale of approach 
The work described in this thesis builds on the basis laid by the earlier 
publications from the group (McGregor et al., 2002; McGregor et al., 1997; 
Muntoni et al., 2003). The existence of mortal and immortal dysplastic and 
carcinoma cells, together with the characterisation of the immortal phenotype in 
vitro, has allowed us to assess the importance of some of the various 
components using functional studies. 
However, sole use of cell culture technology to investigate HNSCC 
carcinogenesis has significant problems and is often subject to criticism 
(Ramirez et al., 2001). Thus, it is vital that the expression pattern of these 
surrogate immortality markers is established in vivo. This is vitally important as 
potential molecular markers, be it for prediction of prognosis or as potential for 
therapeutic intervention, must also show differential expression in the oral 
tissues. 
Thus, this project aims to address the expression of the markers closely 
associated with the immortal phenotype (McGregor et al., 2002) in vivo. The 
further investigation of these cell cultures is also mandated, as it is apparent 
that, at least in terms of dysplasia progression, immortality does not entirely 
explain the presence of a subset of lesions that are at increased risk of 
progression to SCC. Thus, gene expression profiling has a large part to play in 
identification of other markers of immortality and of other important events in 
HNSCC carcinogenesis, such as early/initiating events, markers of high risk of 
dysplasia progression to carcinoma and gene expression profiles related to 
poor prognosis and recurrence/metastasis in HNSCC. 
Studies with a relatively small group of cell cultures, all derived from different 
patients, are only likely to suggest hypotheses for future investigation. 
However, the aim is to identify novel markers potentially important in these 
important events and determine their expression in vivo, especially for mortal 
HNSCC and high risk dysplastic cell cultures. These markers may then be 
assessed in larger retrospective and prospective studies, which will ultimately 
determine the usefulness of these genes and particular patterns of gene 
expression in improving patient care. 
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Chapter Three: Materials and methods 
3.1 Cell culture 
All cell culture work was performed using strict aseptic techniques inside a 
laminar flow hood (Class 11 Microbiological Safety Cabinets, Medical Air 
technology Ltd., Manchester, UK). Epithelial cells were incubated at 370C in 90 
mm Falcon culture dishes in a dry atmosphere containing 5% (V/V) C02 
(Heraeus, Essex, UK). 
The derivation, characterisation and maintenance of the primary human 
keratinocyte cultures have been described previously (Edington et al., 1995; 
McGregor et al., 1997). All cells were maintained on irradiated Swiss 3T3 
feeders (60Gy from a Co60 radiation source). The growth media used were 
flavine adenine dinucleotide (FAD) growth medium, composition 1: 3 Ham's 
F12/Dulbecco's modified Eagles medium (DMEM) (both from Gibco BRL 
Europe Life Technologies, Paisley, UK) supplemented with 10% foetal bovine 
serum (FBS), 0.4 yg/ml hydrocortisone (Sigma-Aldrich, Poole, Dorset, UK), 5 
/jg/ml insulin (Gibco BRL Europe Life Technologies, Paisley, UK ), 5 /ig/ml 
transferrin (Sigma-Aldrich, Poole, Dorset, UK), 10-10 M cholera toxin (Sigma- 
Aldrich, Poole, Dorset, UK), 1.8 x 10-4 M adenine (Sigma-Aldrich, Poole, Dorset, 
UK). For FAD' medium, 10 ng/ml epidermal growth factor (Gibco BRL Europe 
Life Technologies, Paisley, UK) was added. 
The irradiated 3T3 feeders were removed by treatment with phosphate buffered 
saline (PBS)/0.02% EDTA (PE) for 15-20 seconds and vigorous pipetting before 
analysis of the keratinocyte cultures. Swiss 3T3 cells were maintained in 10C 
medium (DMEM plus 10% donor calf serum (Sigma-Aldrich, Poole, Dorset, UK). 
A summary of the clinical and biological features of the cell cultures used in the 
thesis is found in Table 3.1. 
Oral fibroblast cultures were derived from the lamina propria related to one of 
the dysplastic cell cultures (1319). These were maintained in 10C medium. 
HeLa cells were maintained in modified Dulbecco's medium (Beatson 
formulation) (Gibco BRL Europe Life Technologies, Paisley, UK) supplemented 
with 10% foetal bovine serum (Harlan Sera-Lab, Crawley Down, Sussex, UK) 
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culture age sex smoker site 
histology/ 
stage 
PDL 
NT NK M N tongue normal 25 
NB9 53 M Y tongue normal 17 
FNB3 43 M N BM normal 17 
FNB5 38 IF N BM normal 20 
FNB6 33 IF N BM normal 17 
D6 55 M Y tongue moderate 25 
D8 71 M Y tongue mild 9 
D17 61 M Y BM mild/moderate 45 
D25 58 M Y FoM severe 28 
D30 52 M Y FoM mild 30 
D36 35 M Y RM keratosis only 
D41 55 F N Lattongue mild 3.5 
D47 82 IF Y FoM moderate 20 
D48 62 IF Y FoM/VT mod/severe 25.5 
El NK M NK tongue cis 24 
E2 NK M NK alveolus cis 17 
E4 55 IF NK tongue Ci 41 
E5 NK M NK tongue severe 31 
D4 51 M Y tongue/FoM cis immortal 
D9 84 M N tongue mild/moderate immortal 
D19 53 M N lat tongue moderate immortal 
D20 50 M N lat tongue mild immortal 
D34 54 IF Y tongue severe immortal 
D35 68 M N lat tongue mild/moderate immortal 
D38 55 F Y FoM cis immortal 
BICR30 NK M Y larynx T4N1 MO 17 
BICR37 NK M NK node 
metastasis J4 
tongue SCC) 32 
BICR66 55 M Y tongue T2NOMO 37 
BICR80 NK M Y larynx T4N2MO 62 
BICR3 57 IF Y alveolus T2NOMO immortal 
BICR7 43 M Y tongue T4N2cMO crisis 
BICR22 88 M Y tongue 
metastasis 
(Tongue SCC) immortal 
BICR31 M NK tongue T4N2bMO immortal 
BICR56 58 IF Y tongue T4N1MO immortal 
BICR68 74 M Y tongue T4NOMO im mortal 
Table 3.1 Basic clinical and biological features of the primary keratinocyte 
cultures used in this thesis 
Site: BM = Buccal mucosa, FoM = Floor of mouth, VT = ventral tongue, 
lat=lateral, RM = retromolar 
Histology: Mild/moderate/severe refers to the grading of dysplasia in the 
original biopsy. CiS = carcinoma in situ. Carcinoma stage refers to TNM 
classification at diagnosis. 
PDL = population doublings in culture before Senescence. 
In every case, NK = not known 
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and 1mM glutamine (Gibco BRL Europe Life Technologies, Paisley, UK). W138 
cells (source) were maintained in modified Dulbecco's medium, supplemented 
with 5% fetal bovine serum and 1 mM glutamine. 
To freeze cell stocks for storage, serniconfluent cultures were trypsinized, 
pelleted and re-suspended at a concentration of approximately 106 cells/ml in 
chilled medium containing 50% serum and 10% (v/v) dimethylsulfoxide (DMSO) 
(Fisher Scientific, USA). Suspensions were aliquoted into 1 ml cryotubes (Nunc, 
Wiesbaden, Denmark), placed in a polystyrene box and frozen, well insulated, 
at -701C overnight to ensure a slow rate of cooling (11C/min). The ampoules 
were then transferred to a liquid nitrogen tank until required. 
Frozen stocks were recovered by removing the ampoules from liquid nitrogen 
and placing them into a small, covered bucket of water at 37'C. Once thawed, 
the cells were added to 10 ml of the appropriate pre-warmed growth medium, 
centrifuged, resuspended in fresh growth medium and transferred to 90 mm 
Falcon culture dishes (Becton Dickinson, Franklin Lakes, USA). 
All cultures were tested for the presence of mycoplasma infection. This was 
assessed by Hoechst 33258 staining (Chen, 1977). Briefly, NRK cells were 
incubated for 3-4d with medium that had been in contact with the keratinocyte 
culture for at least 2d. These cells were fixed with methanol (3parts) and acetic 
acid (1 part). The fixative was then removed and 5ml of Hoescht 33258 
(Sigma-Aldrich, Poole, Dorset, UK) added and left for 10 mins. The stain was 
then removed and the cells washed with distilled water. The cells were them 
mounted in distilled water and visualised under a fluorescence microscope. 
Extranuclear DNA staining indicated mycoplasma infection. No infected cells 
were identified during the period of this study. 
Organotypic culture 
After initial growth in a 90mm Falcon culture dish, the keratinocytes were grown 
on a collagen/fibroblast gel and raised to the air/medium interface. This allowed 
the development of a stratified squamous epithelium. The gel was mixed (on 
ice) using 8 volumes of 2mg/ml rat tail collagen solution (kindly provided by Dr 
M Edward, Department of Dermatology, University of Glasgow), with 1 volume 
of DMEM (pH adjusted to 7.2 with sterile 1M NaOH) and 1 volume of FBS. To 
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this gel mixture was added 2.5x1O5 oral fibroblasts per ml of gel. The gel was 
mixed well and 1.5ml added to each Millicell-CM 0-4/. im cell culture insert 
(Millpore Corporation, Bedford, MA, USA) in a six-well cell culture plate. This 
was incubated at 370C for 30 min to set the gel. Each gel was then covered 
with 1ml of FAD' medium and incubated overnight at 370C. The next day the 
medium was removed and the gels in the inserts plated with 8xl 05 oral 
keratinocytes in 250/il of FAD+. FAD+ was also added each of the wells in the 
cell culture plate, adjusted to touch the underside of the semipermeable 
membrane on which the collagen/fibroblast gel rested. The medium was 
changed every 2d for 11 d. 
At the end of this period, the stratified epithelium was either scraped into RNA 
lysis buffer, for subsequent extraction of RNA, or placed, with the gel intact, into 
neutral buffered formalin for fixation prior to histological examination. 
73 
3.2 Detection of protein expression 
3.2.1 SDS-PAGE and Western blotting 
To prepare whole cell protein extracts for immunoblotting, cells in the 
proliferative phase of growth were washed twice with ice-cold PBS and then 
scraped off in 0.2ml of lysis buffer (20mM Hepes, pH 6.8,5mM EDTA, 10mM 
EGTA, 5mM NaF, 0.1/jg/ml okadaic acid, 1 mM DTT, OAM KCI, 0.4% Triton X- 
100,10% glycerol, 5/jg/ml leupeptin, 50/ig/ml PMSF, 1mM benzamidine, 5/jg/ml 
aprotinin, 1 mM sodium orthovanadate), incubated on ice for 20 min, followed by 
centrifugation at 13,000 rpm in a microfuge for 20 min and the lysate 
(supernatant) recovered. The supernatant was stored at -700C. Up to 50/. Ig of 
protein sample (quantitated using the bicinchonic acid-copper (11) sulphate 
method, Smith et al., 1985) was mixed with an equal volume of 2x loading 
buffer (187.5 mM Tris-HCI, pH 6.8,30% glycerol, 6.9% SIDS, 2.1M 9- 
mercaptoethanol, 0.1% bromophenol blue), boiled for 10 min before SDS- 
polyacrylamide gel electorphoresis (SIDS-PAGE). 
Gels containing different concentrations of polyacrylamide (i. e. 10%, 12%, and 
15%) were used to resolve proteins according to their molecular weights. The 
resolving gel was made by adding the appropriate volume of 30% (w/v) 
acrylamide: 0.8% (w/v) bis-acrylamide to a solution of 0.45M Tris, 0.1% SDSY 
0.08% TEMED and 0.1% (w/v) APS. The stacking gel comprised of 0.125M 
Tris, pH6.8,0.1% SIDS, 1.7ml 30% (w/v) acrylamide: 0.8% (w/v) bys- 
acrylamide, 0.2% APS and 0.3% TEMED. Proteins were analysed in parallel 
with BenchMarkTm prestained protein ladder (GibcoBRL, UK) and 
electrophoresis was performed o/n prior to transfer onto nitrocellulose using a 
Camlab semi-dry blotter (Camlab, UK), following the manufacturer's protocol. 
The protein electrophoresis for validation of the microarray GEPs used 4-12% 
Bis-Tris Criterion XT precast gels (Bio-Rad Laboratories, Hercules, CA, USA). 
The 18 well format of the gel allowed for analysis of a large number of cultures 
on one gel. A Bio-Rad Criterion wet blotter (Bio-Rad laboratories, Hercules, 
CA, USA) was used for the transfer to nitrocellulose membrane, according to 
the manufacturer's instructions. 
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Western blots were blocked overnight at 40C in the presence of TBST (50mM 
Tris pH 7.5,50mM NaCl, 1 mM EDTA, 0.1 % Tween-20) containing 5% non fat 
dried milk; washed 4x 10min with TBST and then incubated with antibodies 
diluted in TBST containing 5% non fat dried milk or 0.1-1% bovine serum 
albumin (according to antibody manufacturer's instruction) and 0.1% sodium 
azide. The antibodies and their dilutions are shown in Table 3.2. Following 
incubation with the primary antibody the membrane was washed 4x 10 minutes 
with TBST. This was followed by incubation in 20ml of a 1: 3000 dilution of the 
appropriate IgG HRP-linked antibody in blocking buffer for 1.5h. The secondary 
antibody solution was removed and the membrane was washed 3x 10 minutes 
with TBST. After removal of excess surface liquid, bound primary antibody was 
detected using ECL chemiluminescent reagent (Amersham, UK) source 
according to manufacturer's instructions. 
For loading controls, the membranes were reprobed with a polyclonal antibody 
against total p38 MAP kinase to ensure even loading and transfer since it was 
found to be uniformly expressed in all keratinocyte cultures regardless of 
proliferative fate. The blots were stripped by incubation for 30min with 1x 
Stripping buffer (100mM 2-mercaptoethanol, 2% SDS, 62.5mM Tris-HCI pH6.7) 
at 550C. The membrane was washed 3 times with TBST prior to proceeding to 
blocking and subsequent antibody incubation. 
Antigen Clone Source Dilution 
p16 F12 Santa Cruz Biotechnology, Santa 
Cruz, CA, USA 
1: 250 
p53 D01 Santa Cruz Biotechnology 1: 200 
p38 MAPK Cell Signalling Technology, USA 1: 1000 
UBE2C Abcam Limited, Cambridge, UK 1: 500 
Cyclin B1 GNS1 Neomarkers, Fremont, CA, USA 1: 500 
SMC41-i state, Lake Placid, NY, USA 1: 250 
Involucrin Cancer Research UK monoclonal 
antibody service 
1: 5000 
S1 0OA9 C-1 9 Santa Cruz Biotechnology 1: 100 
lGFBP2 H-75 Santa Cruz Biotechnology 1: 200 
Table 3.2 Primary antibodies used for Western blotting 
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3.2.2 Preparation of routine histopathological sections. 
Tissue specimens 5, um in thickness were cut using a Leica 2035 Microtome 
(Leica, Heidelberg, Germany) and then mounted on plain glass sides. These 
were then oven dried for 15 minutes. The sections were deparaffinized for 30 
minutes using Histoclear (Fisher Scientific, USA) followed by xylene for 10 
minutes. Rehydration was carried out sequentially in 100% and 20% ethyl 
alcohols (5 minutes, each step) and finally water. The sections were then 
stained using haematoxylin and eosin (H&E, Surgipath, Peterborough, UK), 
dehydrated, mounted with a coverslip using Histomount (Hughes & Hughes, 
Wellington, UK). 
3.2.3 Immunohistochemistry (IHC) 
For immunohistochernistry, fresh 5/im sections were cut from the relevant 
diagnostic paraffin blocks and mounted on silane-coated slides. The sections 
were rehydrated as described above and then incubated in 0.3% H202 for 20 
minutes followed by a5 minute wash in distilled water. The sections were 
microwaved in 1.51 of citrate buffer for 4.5 minutes at full power (once full 
pressure had been reached). Immunohistochernistry was carried out using the 
Vectastain ABC (avid in-biotin-peroxidase, Vector Laboratories, Burlingame, CA, 
USA) kit for mouse or rabbit IgG, as appropriate, according to manufacturer's 
instructions. The washing buffer used at all stages was PBS pl-17.6 with 0.1% 
BSA fraction V, as this reduces non-specific antibody binding. 
The p53 lHC was performed on a DakoCytomation Autostainer 
(DakoCytomation Denmark). For all other lHC, the sections were incubated 
with primary antibody overnight at 40C in a moist chamber. The antibodies used 
are shown in Table 3.3. Peroxidase substrate DAB (3,3'-diaminobenzidine) kit 
(Vector Laboratories, Burlingame, CA, USA) was used to visualize the primary 
antibody according to manufacturer's instructions. Counterstaining was carried 
out using haematoxylin and the section dehydrated with sequential treatment 
with water, 70% and 100% ethanol, and xylene. Finally the section was 
mounted in Histomount and covered with a coverslip. 
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Antigen Clone Source Dilution 
p16 F12 Santa Cruz Biotechnology, Santa Cruz, 
CA, USA 
1: 200 
p5 D01 Santa Cruz Biotechnology 1: 300 
Involucrin Cancer Research UK monoclonal 
antibody service 
1: 10000 
Cyclin B1 GNS1 Neomarkers, Fremont, CA, USA 1: 800 
S1 0OA9 C-1 9 Santa Cruz Biotechnology 1: 700 
Table 3.3. Primary antibodies used for immunohistochemistry 
3.2.4 Histopathological image capture 
Routine H&E sections and immunohistochernistry were visualised using a Zeiss 
Axioskop 20 microscope (Zeiss, Germany) with an appropriate light source and 
photornicrographs recorded using the AxioVision ver. 3.0.6 software (Zeiss, 
Germany). The images were cropped in Adobe Photoshop Elements (Adobe 
Systems Incorporated, San Jose, CA, USA. 
3.3 Laser capture microdissection (LCM) 
Fresh 6/im sections were cut from the relevant diagnostic paraffin blocks and 
mounted on plain glass slides, a maximum of 24 hours before use. The 
sections were rehydrated and briefly stained with haernatoxylin and eosin. The 
slides were then maintained in a dry environment under a slight vacuum. The 
LCM was conducted using the Arcturus Pixcell@ Ile, according to the 
manufacturer's instructions (Arcturus Bioscience, Mountain View, CA, USA). 
The Arcturus LCM cap was located on the apparatus and then placed on the 
tissue section. The cells required were identified. A pulse laser was then used 
to target these cells and the cap removed with the target cells adherent to the 
cap (see Figure 3.1). 
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Figure 3.1 Laser capture microdissection for sampling of epithelium from 
tissue sections. 
Panels show formalin fixed tissue stained with Haematoxylin and eosin and 
demonstrate the process of laser capture microdissection using the Arcturus 
Pixcell@ Ile. The captured epithelium was subsequently be digested to release 
the DNA for PCR. 
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3.4 DNA extraction from archival tissue 
DNA was extracted from the microdissected material by Proteinase K digestion, 
as outlined by Going (Going, 2003). Briefly, the microdissected tissue was 
digested overnight in 50, ul of proteinase K digestion buffer at 371C. The tube 
was inverted to ensure that the entire surface of the LCM cap was covered. 
Proteinase K was then inactivated by heating at 950C for 10 min. 5/il of this 
digest was used in a standard PCR reaction. The DNA in the digest was 
amplified using GAPDH nested primers to confirm the isolation of DNA from the 
tissue (Table 3.4). 
3.4.1 p53 sequencing. 
This was performed using the proofreading DNA polymerase, Proofstart 
(Qiagen, Crawley, UK) and primers outlined in Table 3.4. These nested primers 
were designed using the Prime program (GCG Wisconsin package, Accelrys 
Ltd, Cambridge, UK). The primers used amplified a short product that covered 
the mutation previously demonstrated in the relevant culture (McGregor et al., 
2002). A small aliquot of cDNA product was assessed by 5% acrylamide gel 
electrophoresis in Tris-borate-EDTA buffer (TBE), to check for the presence of 
product of correct size and the absence of non-specific products. The gel was 
subsequently stained with ethidium bromide (Sigma-Aldrich, Poole, Dorset, UK). 
The UVIdoc gel documentation system (Uvitech, Cambridge, UK) was used to 
visualise the gel. 
Sequencing of fragments in both directions was performed according to the 
manufacturer's protocols (ABI prism big dye terminator reaction kit, Applied 
Biosystems, Foster City, CA, USA). Where a mutation was found by reading the 
traces by eye, the result was confirmed using an independent PCR amplification 
product. 
As the standard sequencing protocol was unsuccessful for DNA from D9 and 
D20, the PCR products were cloned using the TOPO TA cloning kit (Invitrogen 
Ltd, Paisley, UK). A non proofreading Taq polymerase was used for the PCR 
reaction to provide the necessary TA overhang for cloning into the pCR4-TOPO 
constructs. The constructs were transformed into TOP10 competent E-coli. 
Once colonies had formed, they were picked and DNA minipreps prepared. 
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The DNA was then sequenced using T3 and T7 primers, as described above. 
This work was completed by Janis Fleming. 
Sample Sequence Product Annealing 
size (bp) temp (*C) 
5'-ACTTTCAACTCTGTCTCCTTCC-3' 
5'CCATCGCTATCTGAGCAGC-3' 218 57 
D4 & D19 
5'-CCCTGCCCTCAACAAGATG-3' 
5'-ACAACCTCCGTCATGTGC-3' 137 56 
5'-GCTTTTGATCCGTCATAAAGTC-3' 
' 144 53 5 -TGGGCATCCTTGAGTTCC-3' 
D9 
5'-ACTTACTTCTCCCCCTCCTC-3' 
' 77 53 5 -CCTCATTCAGCTCTCGGAAC-3' 
5'-AGGTTGGCTCTGACTGTACC-3' 
' 116 54 5 -TGACCTGGAGTCTTCCAGTG-3' 
D20 
5'-GTGTAACAGTTCCTGCATGG-3' 69 52 5'-GAGTCTTCCAGTGTGATGATG-3' 
5'-ATGCCTTCTTGCCTCTTGTC-3' 145 52 5'-CTCACCATGTAGCACTCACC-3' 
GAPDH 
5'-GATTTGGTCGTATTGGGCG-3' 93 51 5'-TGAGGTCAATGAAGGGGTC-3' 
Table 3.4 Nested oligonucleotide primers used for p53 sequencing 
These primers were used for sequencing of culture and LCM tissue derived 
DNA. Sample refers to the tissue related to the culture indicated. 
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3.5 Semi-quantitative reverse transcription polymerase chain reaction 
(RT-PCR) assay. 
RNA was extracted from the cultured cells using Qiagen RNeasy minikit 
(Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. 
After thawing, the tissue samples were disrupted and homogenised in the 
presence of the RNEasy lysis buffer using Omni-tip disposable generator 
probes in an OMNI TH220 tissue homogeniser (Omni international Inc Marietta, 
GA, USA). On column IDNase digestion was performed during the RNA 
purification, using the RNase-Free IDNase Set (Qiagen GmbH, Hilden, 
Germany). RT-PCR was performed using the GeneAmp RNA PCR core 
reagent kit (Perkin Elmer, Branchberg, NJ, USA) according to the 
manufacturer's protocols. 
The p16 primers used were p16FP and p16RP (Table 3.5). These primers 
were designed to span the intron between exons la and 2, thus giving 
specificity for p16 and avoiding amplification of any contaminating DNA. The 
hTERT primers used were MS1 13 and MS1 14, as described by Dome and co- 
workers (Dome et al., 1999). Primers used in the detection of hTERT deletion 
splice variants (TERT2109 and TERT2531R) were those previously published 
by Yi and coworkers (Yi et al., 2001). The hTR primers were those published 
by Harada and co-workers (Harada et al., 2001). The RARfl2 primers used 
were RARfl2FP and RARfl2RP as described by Sirchia and coworkers (Sirchia 
et al., 2000). In each experiment, the levels of GAPDH mRNA were also 
measured as an internal control. The sequences, product size and optimal 
annealing temperature for each of these oligonucleotide primer sets are set out 
in Table 3.5. The reactions were carried out on a PCT200 DNA engine (MJ 
Research, Massachusetts, USA), according to the manufacturers instructions. 
The cDNA product was assessed by 5% acrylamide gel electrophoresis in TBE 
and subsequent staining of the gel by addition of 50/il of 5mg/ml ethidium 
bromide (Sigma-Aldrich, Poole, Dorset, UK), to 500ml water (final concentration 
0.5/ig/ml). The UVIdoc gel documentation system (Uvitech, Cambridge, UK) 
was used to visualise the gel. The gel images were captured as Aiff files. 
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product annealing Gene Sequence (forward/reverse) 
(bp) temp (*C) 
5'-TGCCCAACGCACCGAATAG-3' 
p16 176 60 
5'-CACCAGCGTGTCCAGGAAG-3' 
5'-AGAGTGTCTGGAGCAAGTTGC-3' 
hTERT 150 60 
5'-CGTAGTCCATGTTCACAATCG-3' 
hTERT 5'-GCCTGAGCTGTACTTTGTCAA-3' 
various* 64 (DV) 5'-AGGCTGCAGAGCAGCGTGGAGAGG-3' 
5'-TTTGTCTAACCCTAACTGAGAAG-3' 
hTR 128 62 
5'-TTGCTCTAGAATGAACGGTGGA-3' 
5'GACTGTATGGATGTTCTGTCAG-3' 
RARfl2 256 62 
5'-ATTTGTCCTGGCAGACGAAGCA-3' 
5'-AAGGCTGAGAACGGGAAGCTTGTCATCAAT-3' 
GAPDH 146 60 
5'-AGCCCCAGCCTTCTCCATGGTGGTGAAGAC-3' 
Table 3.5 Oligonucleoticle primers used for RT-PCR. 
DV = deletion variants. * The size of the products of the hTERT deletion variant 
RT-PCR are seen in Figure 4.7 
The hTERT deletion splice variants were visualised using the Agilent 2100 
Bioanalyzer (Agilent technologies, Germany). RNA was loaded into the RNA 
6000 Nano-chip in a loading gel and with dye concentrate (Agilent technologies, 
Germany). The Bioanalyzer separates the different sizes of RNA in the sample 
by microcapillary electrophoresis. The different components are detected by 
laser induced fluorescence of the dye that intercalates directly with the RNA. 
The output may be viewed as either gel-like images or electropherograms 
(Figure 3.2). 
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3.6 Microarray RNA preparation and quality control 
Total cellular RNA was isolated from the cell cultures using the Qiagen RNeasy 
minikit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's 
instructions. The RNA was homogenized at the appropriate point in the RNeasy 
kit instructions using the QlAshredder homogenizer (Qiagen GmbH, Hilden, 
Germany) according to the manufacturer's instructions. 
Initially, the quality of the RNA was assessed by spectrophotometry. Only RNAs 
with a 260/280nm ratio of >1.9 were of sufficient quality to proceed to the 
labelling stage. At the end of the labelling and fragmentation process, all the 
products were assessed using an RNA denaturing 1.1 % forma Idehyd e/aga rose 
gel electrophoresis in MOPS buffer. Later samples were analysed using the 
Agilent 2100 Bioanalyzer, (see earlier). Samples with 28S/18S ratio <2.0 were 
rejected (Figure 3.2). In either analysis, the integrity of the initial RNA was 
demonstrated and the expected size distributions for the cRNA and fragmented 
cRNA were confirmed. 
3.6.1 Sample labelling and microarray analysis 
Amplification and labelling of the RNA in the pilot and main studies were 
performed using the Affymetrix standard labelling protocol. An outline of this 
protocol is illustrated in Figure 3.3. Briefly, 15/ig total RNA was reverse 
transcribed using the Superscript double stranded clDNA synthesis kit, 
according to manufacturer's instructions (Invitrogen Ltd, Paisley, UK) and 
T7(dT)24 primer (Helena Biosciences, Sunderland, UK). The clDNA was purified 
using buffer saturated phenol/chloroform/isoamyl alcohol (Ambion Inc, Austin 
TX, USA) in Phase lock gel (light) tubes (Helena Biosciences, Sunderland, UK). 
In vitro transcription (IVT) was performed using the Enzo Bioarray high-yield 
transcript-labelling kit (Affymetrix, Santa Clara, CA, USA), according to the 
manufacturer's instructions. Subsequent purification of the cRNA was carried 
out by the RNEasy minikit RNA clean-up protocol (Qiagen, GmbH, Hilden, 
Germany). If the yield from IVT was <40/ig, the reaction was repeated, as it was 
assumed that there had been a problem with the IVT reaction. 
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A 
B 
Figure 3.2 Quality control measures for RNA for microarray analysis 
Total RNA was analysed on Agilent 2100 Bioanalyser using RNA nanochips. 
Panel A shows a "virtual gel" trace of for QC of array samples 
L=Iadder 
Lanes 1-3 BICR30a total RNA, labelled cRNA and fragmented cRNA 
Lanes 4-6 BICR30b total RNA, labelled cRNA and fragmented cRNA 
Panel B shows traces for lanes 1 and 3, showing 18S and 28S peaks. Samples 
with 28S/18S ratio <2.0 were rejected. Further QC was conducted at the PICR 
with test chips used for certain samples. 
84 
TOUW RNA 
AMIOP 
in Mo 
hwmm4ow 
ON&AMMIl 
CRNA 
41*N "IN - "I, %N 
*INN Nv 
AnW 
Iddw 
N 
AMOPIP, 
w- 0- --Ja ý. -0. --0 
wimsh ww Scon and 
Stein 
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Labelled cRNA targets derived from the mRNA (via cDNA) of each experimental 
sample are hybridized to nucleic acid probes attached to the solid support. By 
monitoring the amount of label associated with each oligonucleotide location, it 
is possible to infer the abundance of each mRNA species represented. Figure 
courtesy of Affymetrix. 
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The cRNA was fragmented in buffer containing 200mM Tris-acetate, pH8.1, 
500nM KOAc and 150mM MgOAc for 35mins at 940C. After visualisation of the 
products and quality control as described above, the fragmented cRNA was 
sent on dry ice to the CRUK microarray core facility at the Paterson Institute for 
Cancer Research in Manchester, UK. The cRNA was hybridised to Affymetrix 
U133A genechips for the pilot and tissue/culture comparison experiments and 
U133A and B gene chips for the main study. The cRNA was processed 
according to the method outlined in the GeneChip@ Expression Analysis 
Technical Manual. The hybridisation cocktail was prepared using the 
fragmented target cRNA, with probe array controls, BSA and herring sperm 
DNA. The hybridisation process was then carried out in the GeneChip 
hybridisation oven 640 (Affymetrix, Santa Clara, CA, USA). Immediately after 
hybridisation, the array underwent an automated washing and staining protocol 
on the GeneChip fluidics station 450 (Affymetrix, Santa Clara, CA, USA). The 
genechips were scanned using the GeneChip scanner 3000 with autoloader 
(Affymetrix, Santa Clara, CA, USA) and the resultant raw data returned to BICR 
for analysis. 
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3.7 Microarray data analysis 
The first step in data analysis was quality assessment of the data. A number of 
elements were assessed, two of which are vitally important. Firstly, the number 
of probe sets detected should be similar for the arrays. The second 
assessment concerned the housekeeping genes. The Signal 375' ratio of the 
GAPDH and P-actin probe controls should ideally be 1, but values up to 3 were 
considered acceptable. Higher values indicate either poor quality starting RNA 
or poor 1 st strand cDNA synthesis. This occurred with only one sample, and 
this preparation was repeated. 
The data was analysed in a standard fashion as outlined in Figure 5.1.1. The 
raw data was Iog2 transformed and normalized using the Robust Multi Average 
(RMA) method of Irizzary and coworkers (Irizarry et al., 2003), as implemented 
in RMAExpress. This is available for download from hftp: //stat- 
www. berkeley. edu/users/bolstad/RMAExpress/ RMAExpress. htmi . The data 
was also loaded to the Affymetrix microarray analysis suite (MAS) 6.0. The 
perfect match (PM) and mismatch (MM) oligonucleotides were analyzed and the 
"Absent", "Marginal" or "Present" tags recorded. Only probesets which had 6 or 
more "Present" flags for that particular gene across the whole dataset of 80 
arrays were forwarded to further analysis. Finally, after ascertaining that the 
reproducibility of the two culture replicates was good, the mean of the replicates 
was calculated and this figure was used for further analysis of the expression of 
a particular gene in a sample. 
The expression data for the normalized, filtered genes were loaded in to 
Bioconductor in R (Gentleman et al., 2004), TMeV (http: //www. tiqr. orq/ 
software/tm4/ mev. html, TIGR, Rockville, MID, USA), and Genespring 6.0 
(Silicon Genetics, Redwood City, CA, USA), after conversion to an appropriate 
format. 
3.7.1 Statistical analysis 
Statistical analysis was conducted in TMeV using SAM (original method by 
Tusher et al., 2001). Comparison of the various groups was carried out using all 
possible permutations and the SO factor derived at the 5th percentile (Quon et 
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al., 2001). This is preferable to the original Tusher et al method as this allowed 
for tighter control of the FDR. Genes were considered significantly differentially 
expressed at FDR 1% with fold change ýý 2. Analysis of the data was 
conducted in parallel by Keith Vass in BICR, using ANOVA, implemented in the 
Bioconductor package for R. 
3.7.2 Annotation 
The resultant gene lists were annotated using the Affymetrix Netaffx analysis 
center (hftp: //www. affymetrix. com/analysis/index. affx), and Expression Analysis 
Systematic Explorer (EASE, hftp: //apr)sl. niaid. nih. gov/david/, Hosack et al., 
2003). These tools allow for functional annotation and linkage to multiple 
databases The relative overrepresentation of biological process and molecular 
function Gene Ontology terms (Ashburner et al., 2000) within the gene lists was 
assessed by Fisher exact probability (p<0.05). This algorithm, which is very 
similar to a Chi-square test, assesses the frequency of a particular GO term in 
the given (statistically significant) list relative to the abundance of that term in all 
the annotated genes on the chip. 
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Chapter Four: Comparison of markers previously characterised in 
cultures 
4.1 Introduction 
Our series of primary cultures covers all stages of the development of oral 
cancer and provides a unique opportunity to study each stage within a defined 
system. It has also given us the ability to assess the importance of particular 
molecular changes in functional studies (Muntoni et al., 2003). However, the 
relationship of the pattern of gene expression seen in the cell cultures to that in 
the tissue of derivation had not been evaluated. This question was addressed 
by in vivo analysis of the well-characterised gene expression changes 
associated with the immortal phenotype, which have been previously published 
(McGregor et al., 2002). 
The in vivo material used in these comparisons came from two sources: 
1. Fresh tissue frozen at the time of establishment of the cultures and 
subsequently stored at -80*C. The amount of total RNA recovered from 
the biopsies varied from 1pg to 19yg. Total cellular RNA was extracted 
from this tissue as RNA allowed the widest range of analyses of the 
limited amount of material using techniques and reagents available at the 
time. 
2. Paraffin wax blocks of formalin fixed biopsy tissue. This material was 
used for IHC and extraction of genomic DNA after LCM. 
One caveat in the comparison of the diagnostic biopsy of origin and the culture 
is that it is impossible to be certain of the spatial relation of the portion of the 
biopsy that gave rise to the culture and the relevant wax embedded tissue 
block. This is less of a problem with the fresh tissue left after the establishment 
of the culture. Since these samples were so small, it is reasonable to assume 
that it was in close proximity to the portion of the lesion that gave rise to the 
culture. This chapter assesses the agreement between the original tissue and 
the derived cell culture regarding the expression of p16, telomerase (catalytic 
component, hTERT and RNA template, hTR), p53 and retinoic acid receptor 
beta 2 (RAR82)- 
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Overall methodological approach 
The analysis of the biological material from the cultures and the tissues utilised 
techniques that are inherently semiquantitative in nature. The RNA analysis by 
RT-PCR required careful selection of cycle numbers and experimental 
conditions to ensure that the reaction was limited to the linear part of the PCR 
reaction curve. This allowed for serniquantitative comparison of gene 
expression in the samples. The analyses were conducted at least three times 
using different amounts of RNA from the cultures and varying reaction 
conditions to assess this. Once the conditions were optimised, the material 
from the biopsies was analysed and this was also repeated to ensure a 
representative and repeatable result was obtained. In each case, GAPDH was 
amplified from the same cDNA to ensure an equal amount of material had been 
used in each reaction. GAPDH is useful in the assessment of loading equality, 
as it does not change, regardless of the proliferative fate of the cells. Most of 
the primers used came from established methodologies in the literature. These 
are acknowledged in the appropriate section (see methods). The primers for 
p16 were selected using the primer design program Prime, with care taken to 
ensure that the fragment amplified was part of exon la of the CDKN2a locus, 
thus ensuring p16 specificity. 
Each Western blot was repeated at least once. Total p38 was used to assess 
equality of whole cell extract loading. The activity of this protein, a constituent 
of the MAP kinase signalling pathway, is primarily regulated by phosphorylation. 
The expression of total p38 (regardless of phosphorylation state) is constant 
regardless of the proliferative state and fate of cells in culture, thus it is useful in 
assessment of protein loading in Western blotting. 
The IHC protocol had been developed by Ken Parkinson's group in BICR (see 
methods). This was optimised as appropriate for each different antibody. For 
each tissue sample an unrelated primary IgG control was processed in parallel. 
This allowed for assessment of non-specific binding of antibody. The staining 
was repeated to assess consistency in the intensity and extent of staining. 
However, only sections that had been stained in the same run were directly 
compared. No quantitation of staining was conducted and the resulting 
assessment is descriptive. 
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4.2 p1l 6 
The p16 protein, is an inhibitor of the Cyclin D1/CDK4 complex. This complex 
phosphorylates retinoblastoma protein (Rb), allowing the cell cycle to progress. 
Thus, p16 acts as a cell cycle inhibitor. The gene for p16, CDKN2A, also 
encodes for p14ARF and is found at chromosome 9p2l, a common site of LoH 
in HNSCC (see Figure 4.1). The level of p16 within the cell can be reduced by 
promoter methylation, deletion or mutation (Serrano, 1997; Yoo et al., 2000). In 
HNSCC, deletion of p16 exon la is common and this also occurs in 12% of 
dysplasias (Ali Shahnavaz et al., 2001). Our previous work has demonstrated a 
clear association of loss of expression of p16 and immortality (Loughran et al., 
1996; McGregor et al., 2002; Munro et al., 1999). 
4.2.1 Expression of p16 protein 
Protein was extracted from a panel of mortal and immortal dysplastic cultures 
as previously described. The expression of p16 in the cultures was assessed 
by Western blotting (Figure 4.2). Expression of total p38 was measured to 
assess the equality of loading in the gels. In general, mortal dysplastic cultures 
expressed p16, whilst this was lost in the immortal cultures. There were two 
exceptions to the correlation of loss of p16 expression and the acquisition of 
immortality: D17 and D38. D17 has lost expression of p16 whilst only gaining a 
modest increase in proliferative lifespan, whilst D38 has retained p16 
expression despite having gained the immortal phenotype. This confirmed the 
previously described pattern in the dysplasia cultures (McGregor et al., 2002). 
The expression of p16 in the tissues of origin was assessed by lHC in 5pm 
sections cut from the original diagnostic biopsy tissue blocks (Figure 4.3). For 
each tissue section, an IgG control was used to assess non-specific binding. 
Biopsies that gave rise to mortal cell cultures had nuclear p16 staining 
throughout the viable layers of the epithelium. There was also pl 6 expression in 
the tissue that gave rise to D38, an immortal culture that has retained p16 
expression. On comparison with the Western blots of protein from the cultures, 
the agreement was good; however, heterogeneity was evident in some of the 
tissue samples. This was most obvious in D1 7, where there were small areas of 
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CDKN2A 
p16 mRNA 
Figure 4.1 Genomic organization of the CDKN2A and gene on 9p2l 
The CDKN2A locus encodes two cell cycle regulators, p16 and ARF(p14), 
which are transcribed from separate promoters located upstream (5') of unique 
exons 1a and 1fl respectively, a shared exon 2, with exon 3 present only in 
p16. The primers used for RT-PCR are marked in blue. These were designed 
to span the intron between exons la and 2, giving specificity for p16 and 
avoiding amplification of any contaminating DNA. 
p16 inhibits the Cyclin D-CDK4/6 complex to prevent phosphorylation of Rb. 
ARF inhibits MDM2 mediated degradation of p53 and is induced by various 
oncogenic signals. ARF functions in overlapping pathways and links Rb and 
p53. The stabilization of p53 mediated by ARF can lead to growth arrest via 
p2l, apoptosis and DNA repair. This figure has been adapted from Smeds et al, 
2002 (Smeds et al., 2002). 
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Figure 4.2 p16 immunostaining in mortal and immortal dysplasia cultures. 
The panel shows Western blot of whole cell extract from cultured dysplastic oral 
keratinocytes using p16 antibody (F12). Total p38 was measured to assess 
loading of the samples 
This result confirms that described by earlier work in the group (McGregor et al., 
2002). The mortal dysplastic cultures express p16, except D17 which has an 
extended lifespan. The immortal cultures have lost the expression of p16, 
except D38 which is immortal and which is furthermore unusual in that it has 
also retained wild type p53. 
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Figure 4.3 p16 immunostaining in the tissue of origin of the cultures 
The panels shows p16 immunostaining in formalin fixed biopsy tissue from 
which the culture was derived. Negative controls, using IgG, showed no non- 
specific staining. These images are representative of two experiments. Cultures 
D30 and D48 are mortal and p16 expression is seen throughout the viable 
layers of the epithelium. D17 is also mortal, but has an extended lifespan. p16 
expression is lost from large areas of the biopsy, but some p16 expression is 
retained (see arrow). D4, D19, D34 and show loss of p16 expression. However, 
the heterogeneity is the tissue from which D4 was derived is evident. D38 is 
atypical, having retained p16 expression in the culture and also in the tissue. 
Magnification x2O, except D4 "normal" AO. 
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P16 positivity punctuated along the basement membrane (see arrow in Figure 
4-3). The tissues that yielded immortal cell cultures showed complete loss of 
pl 6 expression in at least part of the biopsy. Tissue related to D4 was the most 
heterogeneous with areas of p16 positivity present alongside areas devoid of 
pl 6 expression (Figure 4.3). This tissue sample is an excision specimen and by 
far the largest piece of tissue examined. Therefore, this may give a realistic 
assessment of the heterogeneity within the lesions generally. 
4.2.2 Expression of p16 mRNA 
The previously published analyses of p1 6 in the cultures assessed the presence 
or absence of p16 protein (McGregor et al., 2002). Analysis of p16 transcription 
was important, as it had not been established if the lack of expression of protein 
seen in the immortal dysplastic cultures was also seen at a transcriptional level. 
Expression of p16 RNA was assessed by semiquantitative RT-PCR of RNA 
extracted from fresh tissue and the cultures (Figure 4.4). In order specifically to 
amplify p16 transcripts, primers were designed to span the intron between 
exons la and 2 (Figure 4.1). GAPDH mRNA levels were also measured to 
ensure comparable amounts of starting RNA were used. The panel of samples 
was smaller, than that seen in Figures 4.6,4.8,4.12 as some of the tissue RNA 
stocks were exhausted. The expression of p16 transcripts showed good 
agreement between the tissues and the cultures, including the atypical cultures 
D17 and D38. 
4.2.3 Summary and discussion 
There was good agreement of the expression of p16 in tissue and cell culture at 
mRNA and protein level. There was some heterogeneity evident, particularly in 
the larger tissue sections. Such differential staining raises the possibility of the 
presence of "mortal 19 and "immortal" keratinocyte clones within the same lesion, 
although the areas of differential staining were quite distinct. Whilst the method 
of Reinwald et al facilitates growth of cells from all stages of the development of 
keratinocyte neoplasia (Rheinwald & Green, 1975), the factors that dictate 
which cells from a biopsy grow in culture are unknown. It is possible that factors 
such as the doubling time of the cells, which is related to the time to establish in 
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Figure 4.4 Comparison of p16 exon la expression in primary oral 
keratinocytes and their tissue of origin. 
Expression of p16 was demonstrated by RT-PCR in a panel of mortal and 
immortal dysplasia cultures for which there was matched tissue RNA available. 
The figure shows 5% Acrylamide gel electrophoresis of p16 exon la RT-PCR 
products stained with ethidium bromide. GAPDH mRNA levels were also 
measured as a control. This data is representative of two experiments. 
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culture, will be important. However, since the portions of the biopsies used to 
establish the cultures were very small, the amount of heterogeneity therein may 
not have been significant. 
Previously, it has been suggested that the high levels of p16 seen in cell culture 
are due to limitations of the culture system, and may be a response to the 
stress of inadequate conditions (Ramirez et al., 2001). However, this current 
work does not support that conclusion, as high levels of pl 6 were present in the 
tissues of origin and the corresponding culture, indicating that the p16 
expression pattern seen in cultures is not merely the result of inadequate 
culture conditions 
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4.3 Telomerase 
Increased levels of telomerase activity have been described in many cancers, 
including HNSCC. Previous work within the group has demonstrated that 
increased telomerase activity and levels of hTERT are associated with the 
immortal phenotype (McGregor et al., 2002). The telomerase holoenzyme 
consists of two main components, a catalytic domain with telomere-specific 
reverse transcriptase activity (hTERT) and an RNA template (hTR). There is 
much controversy in the literature as to the relative importance of these 
subunits in the regulation of telomerase activity. Direct measurement of 
telomerase activity may be assessed using the Telomerase Repeat 
Amplification Protocol (TRAP) assay. As this requires protein from the cells or 
tissues, it was not possible to assess telomerase activity in this manner. 
4.3.1 hTERT 
Splice deletions and insertions in hTERT transcripts result in a variety of 
alternative forms, which may vary in their activity (Yi et al., 2000). These 
various forms are surnmarised in Figure 4.5. Some of these alternatively spliced 
forms may retain very little or no telomerase activity (Colgin et al., 2000). The 
insertion variants all insert a premature stop codon, resulting in a truncated 
protein. These were not assessed in this study. 
Initial experiments investigated the expression of all deletion and full length 
forms of hTERT using primers in a region common to all transcripts. Expression 
was assessed by semi-quantitative RT-PCR in the tissue and cultures (Figure 
4.6). Total cellular RNA was extracted from the cultures and fresh tissue frozen 
at the time the cultures were established. The PCR primers used avoided 
regions of splice deletion (Dome et al., 1999). GAPDH mRNA levels were also 
measured to ensure comparable amounts of starting RNA were used. As 
previously described, hTERT expression in the mortal cultures was very low or 
absent, with higher expression evident in the immortal cultures. A small amount 
of hTERT expression was noted in D17. However, whilst the pattern of hTERT 
expression showed good agreement for the tissues related to the immortal 
samples, expression of hTERT was also seen in the tissue of origin of two of 
the mortal samples, D41 and D48. 
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Figure 4.5 Genomic organisation of the hTERT gene 
The figure shows the domains and variants of human telomerase catalytic 
subunit hTERT gene. Six alternate splicing sites are present (green arrows = 
insertions 1-4 and yellow arrows = deletions a and fl). All four insertion variants 
generate premature stop codons. Adapted from Yi et al (2001) (Yi et al., 2001). 
The primers used for serniquanitative RT-PCR are marked in blue (Dome et al., 
1999). The primer set spans nucleotides 1789-1971 and does not amplify the 
region of either of the deletion variants of hTERT gene. It spans intron 4 to 
avoid analysis of contaminating genomic DNA. The primers used for analysis of 
the deletion splice variants are those described in Yi et al, (2001) and span 
nucleotides 2109-2531 (marked in red) (Yi et al., 2001). 
alternative splicing 234 
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Figure 4.6 Comparison of hTERT RNA expression in primary oral 
keratinocytes and their tissue of origin. 
Expression of hTERT was demonstrated by RT-PCR in a panel of mortal and 
immortal dysplasia cultures for which there was matched tissue RNA available. 
The figure shows 5% Acrylamide gel electrophoresis RT-PCR products stained 
with ethidium bromide. GAPDH mRNA was also amplified as a control. This 
data is representative of three experiments. Note that the tissue related to D17 
does show hTERT expression albeit at a very low level. 
100 
The reasons for hTERT expression in D41 and D48 tissues are not clear. As 
the tissue was not microdissected in this experiment, this may represent tissue 
heterogeneity within the area of dysplasia. Alternatively, the possibility of 
contamination from cells in the lamina propria cannot be discounted, as high 
levels of telomerase activity have been reported in activated lymphocytes 
(Hiyama et al., 1995). However, the H&E stained tissue sections related to D41 
and D48 did not reveal a prominent lymphoctyic infiltrate in the upper lamina 
propria. Additionally, as there is little evidence of contamination from other cell 
types in relation to p16 expression, contamination is an unlikely cause. Work to 
be described later shows that these two cultures have a gene expression profile 
more like normal cultures than the other mortal dysplastic cultures. Additionally, 
these are the only mortal dysplastic cultures derived from the tissues of patients 
who were non-smokers. Due to the varying activity of the deletion variants, the 
possibility that the expression of hTERT in these tissue samples may not relate 
to telomerase activity had to be assessed in some manner. 
4.3.2 hTERT splice variants 
As there was no possibility of direct assessment of telomerase activity using the 
TRAP assay, the deletion variants of hTERT were assessed. Admittedly, this 
only allows for inference of the likelihood of the hTERT expression in the tissues 
resulting in telomerase activity and the assessment is semiquantitative. RNAs 
isolated from HeLa and W138 cells were used as positive and negative controls 
respectively. The data show that whilst in all cases the dominant form present 
was the, 8 deletion (-, 8), full-length hTERT transcript was also present, the only 
exception being D17 tissue (Figure 4.7). The predominance of the fl splice- 
deletion form is in agreement with the work of other groups (Yi et al., 2000). 
Thus, the hTERT expression demonstrated in the initial analysis of D41 and 
D48 was not solely due to the expression of an inactive splice variant. 
However, the uniform pattern seen in the tissues is not surprising, as there is no 
evidence in the literature for regulation of hTERT activity by alternative splicing 
in keratinocyte neoplasia in vivo. 
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Figure 4.7 Agilent 2100 Bloanalyser "virtual gel" of hTERT mRNA deletion 
splice variants 
The primers used were designed to detect the deletion splice variants of 
hTERT. The figure shows semiquantitative RT-PCR products analysed using a 
RNA 6000 nanochip on an Agilent Bioanalyser. The output can be visualised 
as a virtual gel. This demonstrated the presence of all four deletion splice 
variants of hTERT. HeLa and W138 cells were used as positive and negative 
controls respectively. 
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4.3.3 hTR 
The expression of the telomerase RNA template (hTR) was assessed by 
serniquantitative RT-PCR in the tissue and cultures (Figure 4.8). Tissue RNA 
was extracted from fresh tissue frozen at the time the cultures were established. 
GAPIDH mRNA levels were also measured to ensure comparable amounts of 
starting RNA were used. This analysis demonstrated that there was very little 
variation in hTR levels in the cultures, whether mortal or immortal, as has been 
described previously (McGregor et al., 2002). The exception to this was D41. In 
the tissues, hTR expression was detected in most samples, but there was 
greater variation, with the highest levels present in two out of four dysplastic 
biopsies that gave rise to immortal cultures. The it mortal" tissues showing the 
highest hTR expression (D30 and D36) were not those that showed hTERT 
expression (D41 and D48). 
In cell culture, it has been demonstrated that telomerase activity is related to 
hTERT expression and that in alterations of telomerase activity hTERT reduces, 
whilst hTR remains constant (Shin et al., 2003). However, in vivo studies have 
shown hTR to be upregulated in some solid tumours. Our in vivo data supports 
these observations, as hTR was most highly expressed in two of the immortal 
dysplasias. However, the effect was not as clear as for hTERT. 
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Figure 4.8 Comparison of telomerase template component (hTR) RNA 
expression in primary oral keratinocytes and their tissue of origin. 
Expression of hTR was demonstrated by RT-PCR in a panel of mortal and 
immortal dysplasia culture for which there was matched tissue RNA available. 
The figure shows 5% Acrylamide gel electrophoresis RT-PCR products stained 
with ethidium bromide. GAPDH mRNA levels were also measured as a control. 
This data is representative of two experiments. 
104 
4.3.4 Discussion 
The expression of hTERT in the immortal cultures reflected that seen in the 
tissues of origin. This suggests that the normal repression of hTERT 
expression had been lost in the subset of dysplastic tissues that gave rise to 
immortal cultures and this was maintained in culture. In contrast, the subgroup 
of dysplastic tissues that gave rise to mortal cultures generally showed no 
hTERT expression both in vivo and in culture. Why a minority of dysplastic 
lesions express hTERT in vivo, but not in culture is not entirely clear. This may 
be due to the persistence of, for example, the putative telomerase repressor on 
chromosome 3p. This is a common site of LoH in immortal cultures and in 
HNSCC in vivo (Partridge et al., 1994). 
The reason(s) for the loss of hTERT expression in the mortal cultures are not 
clear. Other workers have shown that normal oral cells in culture lose 
measurable telomerase activity by passage 5 (Fujimoto et al., 2003). Kunimura 
and co-workers suggested that this relates to the rapid loss of a telomerase- 
positive cell subpopulation in culture (Kunimura et al., 1998). This work 
suggests that the apparent loss of hTERT expression on establishment of 
normal cell cultures may be due to dilution of the telomerase positive cells in a 
heterogeneous cell population. This hypothesis has not been rigorously 
demonstrated. Use of organotypic culture systems has also clearly 
demonstrated that telomerase activity reduces once cells are committed to 
terminal differentiation (Cerezo et al., 2003). However, as the monolayer culture 
system does not allow cells to differentiate to any degree, reduction of hTERT 
expression related to differentiation is an unlikely and in any case paradoxical, 
explanation for the phenomenon seen in our cultures. 
Telomerase activity in normal cells in primary culture has also been related to 
the cell cycle (Kunimura et al., 1998). Telomerase increases in S phase and is 
dramatically reduced after S phase. In contrast, in immortalized cell lines 
telomerase activity remains constant with respect to the cell cycle, indicating 
that telomerase activity is deregulated in immortal cells (Holt et al., 1997). This 
may explain the good agreement of immortal cultures with tissues in our panel. 
Thus, whilst mortal oral keratinocytes may express hTERT in vivo, it is possible 
that only a small fraction of the mortal cells in vitro may be in S phase and 
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indeed some cells, even at low passage, may be exhibiting features of 
senescence. The observation that telomerase activity and hTERT expression 
reduces as cultured normal oral keratinocytes approach senescence has been 
attributed to methylation of the hTERT promoter as expression of hTERT was 
re-established by application of 5'Aza-2'-deoxycytidine (Shin et al., 2003). 
The expression of hTR in vivo varies, with generally higher levels in the tissues 
that gave rise to the immortal cultures. This implies that the regulation of hTR 
expression may be different in culture from the in vivo situation. However, 
without direct measurement of telomerase activity, it is difficult to be sure of the 
relative importance of these subunits in vivo. 
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4.4 P53 
Mutation of p53 has a well established role in the development of many 
cancers, including HNSCC. Cells lacking wild type p53 do not show G1 arrest in 
response to DNA damage and this leads to the accumulation of genetic 
abnormalities and also harbour defects in apoptosis. Earlier work in the group 
has demonstrated that p53 mutation is associated with the acquisition of 
immortality (McGregor et al., 2002). 
4.4.1 p53 protein 
p53 protein expression was measured in the cell cultures using Western blotting 
(Figure 4.9, lower panel). Expression of total p38 was measured to assess the 
equality of loading in the gel. The pattern of protein expression confirms that 
previously described (McGregor et al., 2002). In general, the expression in the 
mortal cultures was low, with the exception of D1 7, which had an elevated level 
of p53 (shown to be wild type McGregor et al., 2002). Table 4.1 shows that the 
protein level seen in the immortal cultures relates well to the previously 
published mutations in p53 (McGregor et al., 2002). The highest levels were 
seen in D19 and D34, both of which have homozygous mutations, whereas the 
protein level in D4, which had a heterozygous mutation, was lower. The 
frameshift mutation identified in D35 resulted in a truncated protein, which was 
not detected in the Western blot. The level in D38, which has wild type p53, 
was similar to that seen in the mortal cultures. 
The expression of p53 protein in the tissues was assessed by 1HC (Figure 4.9, 
top panel). This showed that, excepting D17, the tissues that gave rise to 
mortal cultures demonstrated low intensity of staining which was restricted to 
the basal and immediately suprabasal layers of the epithelium. In contrast, the 
expression of p53 in the tissues which gave rise to immortal cultures was higher 
in intensity and extended beyond the immediately suprabasal cells into the 
more superficial layers of the epithelium. This must be interpreted with some 
caution, as basal cell hyperplasia (BCH) is a common feature seen in reactive 
and preneoplastic changes in oral epithelium. The spatial effect seen may 
merely be a function of an increased basal compartment in these tissues. 
107 
D30 
bleib 
6 
D19 
III&i 00 0, ,0 le 4,4 
total p38 
culture 
D47 
, 
0,. %; 
A, % -- ". " I 
D34 
::. ". ".  ';::; -: - 4. '" "s ' 
D17 (EL) 
. C. 4-f jr 
D38 
4g 
p 
"of 
IVa go 
00 
01,0'. t.. 
ý-A 
US -4 a-. * so 
"w 04 
S-- 
D17 D30 D36 D41 D47 D4 D19 D34 D35 D38 
mortal immortal 
Figure 4.9 p53 (DO-1) immunostaining in primary oral keratinocyte 
cultures and their tissue of origin. 
Upper panel shows p53 immunostaining in formalin fixed biopsy tissue from 
which the culture was derived. EL refers to the extended lifespan of D17. 
Negative controls (not shown), using IgG showed no staining. 
Lower panel shows Western blot of whole cell extract from cultured dysplastic 
oral keratinocytes using p53 antibody (DO1). p38 was also measured to assess 
loading of the samples. The mutation in D35 resulted in a truncated protein and 
is shown here as absent. Magnification x2O. 
p53 
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However, BCH is also present in many of the tissues that gave rise to mortal 
cultures and the p53 staining in the tissues is still restricted to the basal 
compartment. 
The expression of p53 protein in the tissues related to D1 7 and D38 showed an 
intermediate pattern of staining which does not fit either of the patterns 
mentioned above. This may reflect heterogeneity within the tissue or the loss of 
p53 functions by the presence of defects at other point(s) within p53 regulated 
pathways, but without the increase in staining seen in a mutated and stabilised 
p53. The p53 protein results are summarised in Table 4.1. 
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cultures biopsy 
dysplasia growth p53 gene status protein WB protein lHC 
D17 mortal wild type mod intermediate 
D30 mortal wild type low basal 
D36 mortal wild type low basal 
D41 mortal wild type low basal 
D47 mortal wild type low basal 
D4 immortal mutation, exon 5, stop mod upper layer codon 
D19 immortal mis-match mutation, high upper layer exon 5 
D34 immortal mis-match mutation, high upper layer exon 4 
D35 immortal frame-shift mutation, absent none specific exon 6 
D38 immortal wild type mod intermediate 
Table 4.1 A comparison of the in vitro gene status of p53 with p53 protein 
expression in vitro and in vivo. 
The cell culture p53 mutation data is from McGregor, Muntoni et al (2002) 
(McGregor et al., 2002). Protein expression in the cultures was assessed by 
Western blot (WB) as shown in Figure 4.9. 
Protein expression in the tissues was assessed by immunostaining of formalin- 
fixed biopsy tissue (IHC), as shown in Figure 4.9. 
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4.4.2 p53 expression in organotypic culture 
In order to assess the effect of reconstituting a stratified squamous epithelium 
on the expression pattern of p53, an organotypic culture system was developed. 
This used fibroblasts derived from an oral premalignant lesion (which also gave 
rise to the keratinocyte culture D19) set in a collagen gel matrix. The epithelial 
cells (2 mortal cultures and 2 immortal cultures), placed on collagen gels at the 
air interface, were fed from below. This resulted in the formation of a stratified 
squamous epithelium over about 11 days (Figure 4.10). Immunohistochemistry 
revealed that the organotypic cultures maintained the difference in their 
expression of p53 seen in monolayer culture, although it was not as clear as in 
the original tissues (Figure 4.10, compared with Figure 4.9). This demonstrated 
that the alterations in p53 expression were an intrinsic feature of the cells, as 
reconstitution of a stratified epithelium in organotypic culture showed a similar 
pattern of expression of p53 to that in the original biopsy. 
4.4.3 p53 gene status 
Sequencing of specific sections of the p53 gene was carried out in order to 
assess the genetic relationship between the immortal cultures and the biopsies. 
As p53 mutations had been previously described in the immortal cultures in 
vitro, sequencing of material from the in vivo samples was only conducted in 
these areas (McGregor et al., 2002). Initially clDNA derived from total cellular 
RNA by RT-PCR was sequenced. This demonstrated that the same mutation 
was present in the tissue related to D19, but was heterozygous (Table 4.2). 
The requisite mutation could not be demonstrated in D4. However, the mutation 
in D4 resulted in a stop codon and this may be removed by nonsense mediated 
mRNA decay (reviewed in Culbertson, 1999). There was insufficient RNA to 
gain satisfactory results from D34 and D35. 
DNA was extracted from laser capture microdissected (LCM) tissue from 
formalin fixed sections of the original biopsies (Figure 3.1). This allowed for 
sampling of phenotypically different areas of epithelium. The heterozygous 
mutation found in D4 in culture was present in the dysplastic area of the tissue 
section, but was absent from "normal" adjacent epithelium (Table 4.2). 
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Figure 4.10 Formalin-fixed tissue derived from organotypic cultures of 
clysplastic oral keratinocytes D19 (immortal) and D30 (mortal). 
Left panels formalin-fixed tissue stained with haematoxylin & eosin. 
Magnification x2O 
Right panels show p53 protein expression (immunostaining using antibody DO- 
1 with haematoxylin counterstain). Comparison with corresponding panels in 
Figure 16 shows that p53 expression in D30 extends more superficially in 
organotypic culture than in the tissue. However, on comparison with D19, a 
clear difference in expression pattern was maintained. Magnification x40 
,w 
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sample mutation zYgosity 
Same mutation 
as culture? 
D 19 biopsy RNA NT 488 C>A heterozygous yes* 
D4 biopsy RNA not detected N/A N/A 
D19 biopsy DNA NT 488 C>A heterozygous yes 
D4 biopsy DNA 
dysplastic 
NT 489 C>A heterozygous yes 
D4 biopsy DNA 
non-dysplastic 
not detected N/A N/A 
D9 biopsy DNA NT 1009 C>T heterozygous yes 
, D20 biopsy DNA NT 743 G>A heterozygous yes 
Table 4.2 Comparison of p53 mutations in vitro and in vivo in D4, D19, D9 
and D20. 
The mutations were initially detected in cell culture (McGregor et al., 2002). 
Primers were designed to detect the specific mutation found in the culture and 
sequencing was performed on cDNA derived from 
" total cellular RNA (from frozen tissue) - by RT-PCR 
" DNA (from laser capture microdissection) - by PCR. 
*Note: The fact that the mutation in the biopsy is heterozygous may indicate 
some level of stromal or normal epithelial contamination or heterogeneity within 
the sample. 
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The mutation found in D19 in culture was also seen in the tissue, but was 
heterozygous. This may indicate some level of stromal/normal epithelial 
contamination or heterogeneity within the sample. The mutations previously 
seen in D9 and D20 were also present in the original biopsy tissue. Analysis of 
D34 and D35 is ongoing. 
4.4.4 Summary and discussion 
This analysis demonstrates that the differences in p53 expression seen in the 
culture were present in the tissue of origin. Whilst others have demonstrated 
that suprabasal p53 expression in dysplastic oral epithelium is associated with 
an increased risk of progression to carcinoma (Cruz et al., 2002; Cruz et al., 
1998), this data is novel in that it relates the alterations in the intensity and 
spatial distribution of p53 staining to p53 mutation and immortality in cell culture. 
As the mutations seen in the cultures were also demonstrated in the tissues 
from which they were derived, this demonstrated a clear genetic relationship 
between the immortal cells in culture and their tissues of origin. 
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4.5 Retinoic acid receptor beta (RAR-fl) 
Retinoids can regulate gene expression and thus modulate differentiation and 
growth in cells (Lotan, 1996) and there has been much interest in the effects 
that deregulation of this system may have in carcinogenesis. Much interest has 
been expressed in their potential use in the treatment of dysplastic lesions; 
however, this modality has proven to be disappointing. Downregulation of RAR- 
,8 
has been reported in many cancers, including HNSCC (Lotan et al., 1995). 
We have previously described constitutive expression of RAR-fl in our mortal 
dysplastic cultures with complete loss of expression in our immortal dysplastic 
cultures (McGregor et al., 1997). 
Multiple isoforms of RAR--fl have been described. Among the four known RAR-fl 
isoforms, RAR-, fl2 is thought to be the key tumour suppressor in humans (Lotan 
et al., 1995; Toulouse et al., 2000), but the possibility remains that RAR-fll is 
also involved. The expression pattern of RAR-fll suggests it is a fetal isoform 
(Toulouse et al., 1996), but no direct tests of the effect of the latter on tumour 
cell phenotype have been published. It is very similar to RAR-fl3 which is not 
found in human cells. The fourth isoform, a truncated version of RAR, 82 named 
RARfl4, is associated with turnorigenicity in humans and mice, so it is unlikely to 
have a tumour suppressor activity (Berard et al., 1994; Hayashi et al., 2003) 
The structure of isoforms RARfl2 and RARfl4 is shown in Figure 4.11. 
Unfortunately, the commercially available RARfl primary antibodies appear 
neither specific nor reproducible in lHC or Western blot. Therefore, there is no 
data on the expression of RARfl protein in the cultures or the tissues. 
4.5.1 RNA 
The expression of RAR-fl2was assessed by semi-quantitative RT-PCR in the 
tissue and cultures (Figure 4.12). Tissue RNA was extracted from fresh tissue 
frozen at the time the cultures were established. GAPDH mRNA levels were 
also measured to ensure comparable amounts of starting RNA were used. The 
pattern of expression in the cultures agrees with the pattern previously 
described by Northern blotting i. e. constitutive expression in mortal cultures with 
no expression in immortal cultures, except D38 (McGregor et al., 1997). 
Howeverp 
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Figure 4.11 Diagram of RARfl2 and RARfl4 transcripts and RARfl2 protein 
functional domains 
The most recent annotation of the RARfl locus and various isoforms is outlined 
in Ensembl transcript ID ENST00000330688 (hftp: //www. ensembl. orq). Much of 
the literature refers to the mRNA sequence of RARfl as exons 5-12. This 
diagram adopts the numbering sequence assigned in the Ensembl annotation 
(exons 1-8). 
RARfll (and RAR, 83) differ from RARfl2 in their 5'UTR and A coding region. 
RARfl4 is generated by alternative splicing in exon 1 (Zelent et al., 1991). The 
RAR, 82-specific primers used were those published by Sirchia et al (Sirchia et 
al., 2000). The positions shown by the red arrows. 
The figure is adapted from Chen et al, 2002 (Chen et al., 2002). 
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Figure 4.12 Comparison of retinoic acid receptor, 82 (RAU2) expression 
demonstrated by RT-PCR in a panel of cultures derived from dysplastic 
oral epithelium and their tissue of origin. 
Expression of RARP2 was demonstrated by RT-PCR in a panel of mortal and 
immortal dysplasia cultures for which there was matched tissue RNA available. 
The figure shows 5% Acrylamide gel electrophoresis of RT-PCR products 
stained with ethidium bromide. GAPDH mRNA levels were also measured as a 
control. This data is representative of two experiments. 
Tissue expression of RARP2 matched expression in the mortal cell cultures to 
some degree, but the immortal cell cultures did not match at all. 
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whilst RAR-fl2was not expressed in the immortal cultures, it was expressed in 
three out of four dysplastic biopsies related to these cultures. 
Mesenchymal contamination is a possible explanation, as fibroblast cultures 
express high levels of RAR-fl in the presence of retinoic acid (Crowe et al., 
1991). However, this observation has not been confirmed in vivo, and as this 
effect should have been seen in the II mortal" tissues, such an explanation is 
unlikely. Alternatively, heterogeneity in gene expression resulting from the 
presence of mortal and immortal subpopulations in the tissues may be 
responsible. This explanation assumes that, whilst mortal and immortal cells 
were present in the tissue, the immortal cells preferentially grew in culture. 
However, the lack of heterogeneity of p16 and p53 staining, particularly in 
tissues related to D19 and D35 mitigates against this conclusion. A more likely 
explanation lies in the now well established relation of RAR-j8 expression to 
squamous cell differentiation (Lotan, 1996). Therefore, the discrepancy in the 
tissues of origin may be explained by changes in RAR-j8 expression associated 
with terminal differentiation in the tissues. Such changes may not be apparent 
in monolayer culture of immortal cells. 
4.5.2 RAR#2 expression in organotypic culture 
In order to assess the influence of differentiation on the RAR-fl2 expression in 
the immortal cell cultures, an organotypic culture system was utilised. The 
expression of RAR7,82 in the stratified squamous epithelium formed over a 
period of 11 days was assessed by serniquantitative RT-PCR of total cellular 
RNA (Figure 4.13). GAPIDH mRNA levels were also measured to ensure 
comparable amounts of starting RNA were used. The differences in expression 
of RAR7,82 between mortal and immortal dysplasias in monolayer culture were 
also seen in organotypic culture, indicating that a change in the activation of the 
terminal differentiation pathway did not result in the re-expression of RAR-fl2in 
immortal cells. Thus, a difference in differentiation state was not the sole 
reason for the poor agreement of the immortal culture findings with their tissue 
of origin. 
However, the organotypic culture system does not fully reconstitute in vivo 
conditions. Many other cell types are present within the lamina propria that may 
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Figure 4.13 
RARP2 
GAPDH 
dysplasia D25 D30 D4 D19 
RARfl2 expression in organotypic oral keratinocyte cultures 
assessed by RT-PCR 
Expression of RARP2 was demonstrated by 
(D25 and D30) and two immortal cell cul- 
organotypic culture system. The figur 
electrophoresis of RARP2 RT-PCR products. 
as an expression control. 
RT-PCR in a panel of two mortal 
ures (D4 and D19) grown in an 
I 
. snows o-/o Acryiamiae gei 
GAPDH mRNA was also amplified 
The figure shows that growth of these primary cultures in a system which allows 
differentiation to occur did not result in a change in the expression of RARP2 in 
the mortal or immortal cultures. 
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contribute to variations in the oxidative state. In addition, the serum used in the 
feeding medium contains an undefined level of retinoids. It may be interesting 
to repeat the experiment with varying concentrations of retinoids, in order to 
recreate a physiological retinoid gradient across the epithelium. 
4.5.3 Discussion 
The agreement of RAR-fl expression in the cultures and tissues was poor, 
particularly in the tissues that gave rise to immortal cultures. The reasons for 
this are unclear. As the pathways and interactions related to the role of 
differentiation and tumour microenvironment in the development of HNSCC are 
undoubtedly important, it is a disadvantage that these cannot be examined in 
monolayer cultures. Despite this caveat, organotypic culture showed that 
induction of differentiation did not result in the expression of RAR-fl in the 
cultures. The reasons for this are not clear 
These results have implications for the extrapolation of in vitro gene expression 
data to the in vivo state. Validation of the markers related to the pathways 
described above (and perhaps others) must be conducted with care, bearing in 
mind the possibility that the in vivo correlation of the expression of such genes 
with that in the monolayer culture may be poor. 
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Chapter Five: Microarray study 
5.1 Introduction 
Analysis of the global gene expression profile of the cell cultures, both mortal 
and immortal was conducted using the Affymetrix U133A and U133B 
genechips. This allowed further analysis of the differences in gene expression 
seen on comparison of cultured mortal and immortal dysplastic oral 
keratinocytes. This data was further augmented by analysis of normal oral 
keratinocyte cultures and those from carcinomas, both primary tumours and 
metastases, a full list of which is seen in Table 3.1. The range of samples 
analysed allowed for fuller characterisation of events at various stages of the 
development of oral squamous cell carcinoma. These results refer primarily to 
the differences associated with keratinocyte immortality. 
All preparatory work for the microarray analysis was carried out at the BICR. 
This included culture of the cells, harvest and isolation of RNA, and the various 
stages of analysis and labelling to produce the labelled, fragmented cRNA 
ready for hybridisation to the genechip arrays. The fragmented cRNA was sent 
to the Microarray Core facility at the Paterson Institute for Cancer Research, 
where the hybridisations and scanning were carried out. The RNA was only 
processed if the stringent quality controls set by the PICR were met (see 
materials and methods). A test array was used for at least one sample in every 
batch sent. The raw data was returned to the BICR for subsequent analysis. 
5.1.1 Transformation and normalisation 
All of the raw microarray data was analysed as shown in Figure 5.1. The matrix 
was log2 transformed to improve the data distribution. This allows easier 
assessment of the degree to which different genes alter their transcription. The 
data was normalized using the Robust Multichip Average (RMA) method 
(I riza rry et al., 2003) implemented in RMAExpress http: //stat- 
www. berkeley-edu/users/bolstad/RMAExpress/RMAExpress. htmi. 
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Figure 5.1 Schematic flow diagram of microarray data analysis 
This diagram shows the standardised process which was developed for data 
analysis for all samples in the main study. The entire group of filtered genes are 
hereafter referred to as "all present genes". 
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RMA performs the following operations: 
e Probe-specific background correction to compensate for non-specific 
binding using perfect match (PM ) values alone (mismatch (MM) values 
are not utilised). 
Probe-level multichip quantile normalization to unify PM distributions 
across all chips 
Robust probeset summary of the log normalized probe level data by 
median polishing, resulting in a single value for the probe set. 
As RMA is based on rank normalisation, the distribution in each sample 
becomes the same. This results in a compression of the dynamic range of the 
data. This may be limiting in terms of the statistical analysis of the data, but may 
be an advantage when using clustering algorithms. 
5.1.2 Filtering 
In order to filter the data and remove probe sets that were not contributing 
meaningfully to further analysis, the data was analysed using Affymetrix 
Microarray Analysis Suite (MAS) 6.0. This utilises both the PM and MM data 
from the array and on this basis assigns a present (P), marginal (M) or absent 
(A) flag to each probe set in a particular sample. These flags were used to filter 
the data, as only probesets which were judged "present" in 6 or more samples 
were used in further analysis. In the main study, this reduced the number of 
probesets forwarded to further analysis from 44930 to 23562. 
5.1.3 Data clustering 
Hierarchical cluster analysis was used to arrange genes according to similarity 
in pattern of gene expression. This uses standard statistical algorithms and the 
output is displayed graphically, conveying the clustering and the underlying 
expression data. Clustering methods can be divided into two classes, 
supervised and unsupervised. In supervised clustering, vectors are classified 
with respect to known reference points. In unsupervised clustering, no 
predefined references are used (as in hierarchical clustering). Eisen recently 
reviewed various methods (Eisen et al., 1998). 
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Hierarchical clustering is widely used to find patterns in multidimensional 
datasets, especially for microarray data. The object of this algorithm is to 
compute a cluster dendrogram that assembles all gene expression elements 
into a single tree. The dendrogram produced is a binary tree in which each data 
point corresponds to terminal nodes and distance from the root to a subtree 
indicates the similarity of subtrees - highly similar nodes or subtrees have 
joining points that are farther from the root. It must be remembered that at the 
highest levels of the hierarchy the branches are very dependent on the lower 
links, thus they are less reliable. Almost all hierarchical agglomerative 
algorithms are safe when the interest is placed on the small, low levels of the 
hierarchy, but they become unsafe at high levels. The groups of genes derived 
from the cluster analysis showed great similarity to clinical and biological 
knowledge of the cultures in terms of type (normal, dysplastic or carcinoma) and 
replicative fate (mortal or immortal). 
5.1.4 Statistical analysis 
Statistical differences in gene expression were assessed using the Statistical 
Analysis of Microarray (SAM) algorithm (Tusher et al., 2001). The multiple 
hypotheses tested on analysis of microarray data mandates control of the type I 
error rate (false positives). In SAM this is defined as the False Discovery Rate 
(FDR). SAM identifies genes with statistically significant changes in expression 
by assimilating a set of gene-specific t tests. Each gene is assigned a score 
(delta, A) based on its change in gene expression relative to the standard 
deviation of repeated measurements for that gene (permutations). Genes with 
scores greater than a threshold, A, are deemed significant. The threshold can 
be adjusted to identify smaller or larger sets of genes. The percentage of such 
genes identified by chance is the FDR. 
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5.2 Pilot study 
The pilot study assessed several important variables that may impinge on the 
gene expression profile. The 3T3 feeders are required for many of these cells 
to survive, but removal of the feeders may have differential effects depending 
on cell type, as some of the carcinomas will grow in the absence of an irradiated 
3T3 feeder layer. In addition, there was concern that an immediate stress 
response may alter the GEP, as the feeders were being removed using 
PBS/EDTA. Assessment of the effects of serum replenishment on the gene 
expression profile and of two different operators growing the cells, preparing 
and labelling the RNA, was also required. 
As it was unclear whether the method of preparation of the cells would have an 
effect on the gene expression profile, or affect the normal and SCC cultures 
differently, different protocols for the removal of the feeder cells were assessed: 
A. Removal of irradiated 3T3 feeders 24 hours prior to RNA extraction. The 
cells were fed for the intervening period. This allowed for much quicker 
extraction of RNA after removal of the medium, but cells may respond 
differently without feeders present. 
B. Removal of the feeders immediately followed by RNA extraction. This 
minimised variation in culture conditions, but increased the possibility of 
an immediate stress response. 
The cluster dendrogram in Figure 5.2 shows a clear difference between the 
gene expression profiles of the normal culture (FNB5) and carcinoma (BICR 56) 
as assessed by hybridisation to the Affymetrix U133A genechip. It also 
demonstrated that the agreement of the technical replicates was good, despite 
that fact that the labelling of the replicates was carried out by two different 
operators (the author and Janis Fleming). On this basis, the subsequent main 
microarray study used duplicate technical replicates. The good reproducibility 
of the GEP of the technical replicates in the pilot study was also seen 
throughout the main study (data not shown). The differences in the GEP seen 
due to alternative timings of feeder removal in prep method were greater than 
between different operators using the same protocol (Figure 5.2). 
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In order to establish whether any 3T3 feeders remained on the plate and were 
differentially contributing to the GEP, cRNA prepared from irradiated 3T3 
feeders was analysed on an Affymetrix U1 33A genechip and is also seen in the 
dendrogram in Figure 5.2. This shows that the gene expression profile of the 
irradiated 3T3s was very different from the keratinocytes, regardless of how 
they were prepared. The 20 highest expressed genes in the 3T3s are shown in 
Table 5.1, in comparison with the levels seen in FN135 and BICR 56 (by both 
methods of 3T3 removal). Very few genes were more highly expressed in the 
irradiated 3T3 feeders than in the keratinocyte cultures. Furthermore, only one 
of these genes (GNAS) showed any differential expression between the two 
methods of 3T3 removal. 
Application of SAM to the two timings of 3T3 removal yielded a list of 
consistently differentially expressed genes seen in Figure 5.3 (FDR = 1%, fold 
change ýt2). This list includes genes involved in cell-to-cell communication, 
such as interleukin 8, several interleukin receptors and also genes involved in 
adhesion, such as cadherin 11 and integrin alpha 2. Many of these genes have 
a role in communication between the fibroblasts and the keratinocytes, which 
may indicate a role in aiding the survival of the cultures. 
Using 2-factor ANOVA, a small group of genes was identified in which the 
different methods had a differential effect on the cultures. This showed that the 
effect on the normal cultures of early removal of 3T3s was greater than in the 
carcinoma culture, as the method A normal samples cluster differently to the 
method B normal samples (p<0.001). The group of genes differentially affected 
by the early removal of the 3T3s is shown in Figure 5.4. However, the group of 
genes is small and the fold changes of the genes involved were not large, so 
the differential effect is subtle. 
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Figure 5.2 Hierarchical cluster of the GEPs of cultures used in the of 
microarray pilot study. 
The cluster was constructed using the normalised gene expression data for all 
genes and the euclidean distance measure with complete linkage. The pilot 
study included 9 Affymetrix U133A genechips, including one irradiated 3T3 
sample. Three variables were assessed. 
1. Two operators (KH/JF) grew parallel cultures of each sample. 
2. Two methods of 3T3 feeder removal: 
A. removal of 3T3 and re-feeding with medium 24 hours prior to RNA 
extraction. 
B. removal of 3T3s immediately prior to RNA extraction. 
2121 
3. Two samples: one normal (FNB5) and one carcinoma (BICR56). 
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FNB5 FNB5 BICR56 BICR56 
Gene A B A B 3T3 
GNAS complex locus 893 340 1111 360 9617 
eukaryotic translation 
elongation factor 1 7221 6888 7706 7105 7393 
alpha 1 
tubulin alpha 6 7337 7084 7574 7605 7211 
tubulin, alpha, 
ubiquitous 
7411 6925 7925 7974 6546 
ribosomal protein S10 5530 4880 6383 6059 6515 
ribosomal protein S2 7029 6650 7921 7262 6342 
ubiquitin C 6539 6548 6953 6974 5934 
cofilin 1 (non-muscle) 4816 5028 4692 4464 5404 
ribosomal protein S27 2645 2470 2925 2641 5313 
ribosomal protein S10 4713 3951 5119 5136 . 5240 
poly(A) binding protein 
1 2847 2466 4013 3706 5052 
tumor protein, 
translational ly- 4390 4394 4411 
1 
4204 5016 
controlled 1 
eukaryotic translation 3166 2824 1068 593 4977 initiation factor 5A 
nuclease sensitive 
element binding protein 3019 2557 3630 3739 4829 
11 1 1 1 1 
ribosomal protein S12 1 4659 1 4545 1 4839 1 4520 1 4646 
Table 5.1 Assessment of contamination of keratinocyte cultures with 
possible 3T3 genes. 
This table outlines a comparison of the 15 most highly expressed genes in 
irradiated 3T3 feeders, with the expression of these genes seen in BICR56 and 
FN135, by both timings of 3T3 removal, A and B. The figures shown are the 
mean values for the technical replicates. 
Apart from one gene (GNAS) there was no systematic difference in the 
expression of these genes in the keratinocyte cultures. This indicated that 
differential 3T3 contamination was unlikely to be contributing to the GEP of the 
keratinocyte cultures. 
128 
- 
B 
normal carcinoma 
0+ 
3T3 A 
normal carcinoma 
method 
culture 
operator 
SERPIN B2 
IGFBP3 
EREG 
unknown 
ITGA2 
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Figure 5.3 Graphical representation of genes significantly differentially 
expressed between methods A and B. 
The figure shows the expression of those genes with red representing 
overexpression and green underexpression relative to the median expression of 
the gene across the dataset. Genes and samples have been hierarchically 
clustered using euclidean metric and complete linkage. 
Genes were selected using SAM (FDR 1% and fold change : ý-2). The official 
gene symbol is shown on the right. The genes selected are a group of genes 
whose pattern of expression is related solely to the timing of the removal of 3T3 
feeders. These genes are primarily related to cell to cell communication (16/28 
by Gene Ontology) and adhesion (7/28 by Gene Ontology). 
1 
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Figure 5.4 Graphical representation of genes significantly differentially 
expressed by sample type and by method. 
The genes shown were selected by 2 factor ANOVA (p<0.001). Genes and 
samples have been hierarchically clustered using euclidean metric and 
complete linkage. 
This demonstrates that a small number of genes show a pattern of expression 
which changes only in the normal cultures upon differing timing of feeder 
removal. Thus, the early (24 hour) removal of the 3T3 feeders has a small, but 
significant differential effect on the normal cells, but not the carcinomas. The 
genes perform various functions such as metabolism (12/21 by gene ontology), 
and cell growth and maintenance (5/21). The changes were not marked, but the 
list does include one potential marker of immortality (UPK1 B, see Table 5.5). 
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5.2.1 Discussion 
The pilot study demonstrated that there was little difference in GEP of the RNA 
isolated and prepared by the two operators. The larger differences in GEP 
resulting from different preparation methods clearly indicated a need for strict 
standardization of technique. There was no evidence that contamination from 
irradiated 3T3 feeders contributed significantly (either consistently or 
differentially) to the observed keratinocyte GEP. The different timing of removal 
affected expression of a small number of genes in the normal culture, with little 
effect on the carcinoma culture. 
Such analysis demonstrated the need for strict standardization of the culture 
and preparation protocols. The standard protocol for the preparation of all RNA 
used in the main microarray study was removal of 3T3 feeders immediately 
before RNA extraction. This was preferred because it avoided the differential 
effects on gene expression in the cultures that are more dependent on the 3T3 
feeder layer for survival. Such standardization also aligned the methodologies 
of cell culture and preparation of the cells for extraction of protein for the 
validation steps later and allowed for direct comparison with the earlier 
published data that had been gained from cells grown using this protocol. 
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5.3 Main study 
The main microarray study utilised Affymetrix U133A and B genechips. Gene 
expression profiles were gained from cell cultures derived from all stages of 
SCCHN development - normal, dysplastic, primary carcinomas and 
metastases. This included a number of cultures (both mortal and immortal) 
derived from biopsies where the patient subsequently developed a carcinoma at 
the same site. The clinical and biological details of all cultures used in the study 
are in Table 3.1. The cells were grown to a standardized protocol (see pilot 
study) and harvested at approximately 60% confluence. 
5.3.1 Comparison of normal cultures with all carcinomas cultures 
A cluster dendrogram of the normal cultures and all of the carcinomas, both 
mortal and immortal, is shown in Figure 5.5. The cluster was constructed using 
the mean value of gene expression in the two technical replicates since the 
agreement between the GEPs of the two technical replicates was good (see 
pilot study and Figure 5.2). The dendrogram demonstrated a clear difference in 
the gene expression profile of mortal and immortal carcinomas. The normal 
group displayed the least heterogeneity, with the mortal carcinomas closely 
related to the normal cultures, but forming a distinct group. The immortal 
cultures clustered together, again demonstrating some heterogeneity. The 
culture in crisis, BICR7, was related to, but distinct from, the immortal 
carcinoma cultures. 
Application of SAM to compare the mortal and immortal carcinoma groups 
yielded a list of 1251 genes expression differences significant at a FDR of 1% 
and fold change ýt2 (Table 5.2). In contrast, comparison of the normal with the 
mortal and immortal carcinomas gave lists of gene expression differences of 
472 and 716 genes respectively (using the same parameters). Surprisingly, the 
overlap between the latter two lists of gene expression changes was only 11 
genes, indicating that the mortal and immortal carcinoma cells may have arisen 
via divergent pathways. However, such seeming large numbers of differences 
in gene expression may also occur in relation, for example, to a change in 
activity of a single transcription factor or additional chromosomal material 
gained by passage through crisis. 
132 
NT 
NB9 
FNB5 
FNB6 
FNB3 
BICR80 
BICR30 
BICR66 
BICR37 
BICR7 
BICR68 
BICR3 
BICR56 
BICR22 
BICR31 
normal 
mortal carcinoma 
carcinoma - crisis 
immortal carcinoma 
Figure 5.5 Hierarchical cluster based on the gene expression profile of 
normal and carcinoma keratinocyte cultures. 
The cluster was calculated using the mean of two technical replicates for each 
cell culture, all present genes, and using the euclidean distance measure with 
complete linkage. The similarity/difference between two samples is based on 
the total distance travelled on the horizontal plane. 
The normal samples cluster together, with the mortal carcinomas most closely 
associated. The immortal carcinomas are quite different in terms of GEP. 
BICR7 (in crisis) does not cluster closely with any of the samples 
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Further analysis using more stringent criteria (1% FDR and a fold change of > 
5) reduced the list from 1251 to 155 differences, as shown in Figure 5.6. These 
genes clearly distinguished not only the mortal and immortal carcinomas, but 
also the mortal and immortal dysplastic cultures, although some heterogeneity 
was present, particularly among the mortal samples (Figure 5.6). In general, the 
genes fall into two groups - those more highly expressed in mortal carcinomas 
and those in immortal carcinomas. The pattern of gene expression within the 
mortal samples showed that, for many of the genes, there was also a difference 
between the normal and mortal carcinomas. Thus, genes underexpressed in the 
normal cultures showed a further reduction in expression in the mortal 
carcinomas and vice-versa. This phenomenon further illustrated the possibility 
of divergence in the pathways to immortal and mortal carcinomas. 
5.3.2 Comparison of normal and dysplastic cell cultures 
Figure 5.7 shows the cluster dendrogram for comparison of the GEPs of normal 
cultures and all the dysplastic cultures, both mortal and immortal. The main 
difference in gene expression was related to the acquisition of the immortal 
phenotype. Compared with the carcinomas, there was a greater level of 
heterogeneity in relation to the dysplastic cell cultures, particularly amongst the 
mortal samples. Two samples (D41 and D48) consistently clustered with the 
normal samples. These were the only mortal dysplastic cultures derived from 
non-smokers, whilst the others were derived from smokers. One mortal sample 
(D17) clusters with the immortal samples. Whilst this culture senesces, it only 
does so after an extended lifespan. In addition, it demonstrates some of the 
features associated with immortal cells, namely loss of p16 and RAR-fl. Clearly 
in addition to these changes, it had an overall GEP similar to the immortal 
cultures (see comments later). Within the immortal samples, D35 was 
somewhat different in pattern of gene expression. This patient subsequently 
developed a carcinoma at the same site within six months of the initial biopsy. 
Thus, it is possible that invasive SCC was present in another part of the lesion 
at the time of initial assessment. The GEP of the other immortal cultures from 
patients who developed a carcinoma at the same site (D19 and D20) did not 
cluster consistently with the carcinomas. 
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Figure 5.6 Graphical representation of genes significantly differentially 
expressed between mortal and immortal carcinoma samples. 
Genes were selected using SAM (FDR :!! ý 1 %) and ýt 5 fold difference in 
expression between mortal and immortal carcinomas, giving a total of 155 
genes. The figure shows the expression of these genes in all samples (normal, 
dysplasia and carcinoma). Red represents relative overexpression and green 
relative underexpression as shown in the visual scale. Genes have been 
hierarchically clustered using euclidean metric and complete linkage. This 
demonstrates that some of the genes which differentiate mortal and immortal 
carcinomas also differentiate mortal and immortal dysplastic cell cultures. 
mortal immortal 
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Figure 5.7 Hierarchical cluster based on the GEP of dysplastic and 
normal keratinocyte cultures. 
The cluster was calculated using the mean of the two technical replicates for 
each cell culture, all present genes, and using the euclidean distance measure 
with complete linkage. 
The normal cultures cluster together along with D41 and D48. The other mortal 
dysplastic cultures cluster together except D17 (marked with a star) which 
clusters with the immortal cell cultures. 
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5.3.3 Cluster analysis of all samples 
Figures 5.8 and 5.9 show cluster dendrograms constructed using all the 
samples in the study. The matrix has been clustered using two different 
distance measures, euclidean distance (Figure 5.8) and cosine correlation 
(Figure 5.9). Euclidean distance is the most common method employed to 
measure differences between the points in n-dimensional space that represent 
gene expression values. It clusters based on absolute values of gene 
expression. However, a more appropriate metric for clustering of microarray 
data may be the cosine correlation, related to the angle between the vectors, 
since it allows comparison of trends in change of gene expression amongst 
samples rather than their absolute values (Causton et al., 2003). 
There were few differences in gene expression relationships identified by the 
different distance metrics, but some interesting points emerge. The euclidean 
metric placed immortal dysplastic cultures D4 and D38 with the mortal cultures, 
in close association with D17. However, the cosine correlation metric placed 
D17 with the immortal cultures closely associated with D38 and BICR7 (a 
carcinoma in 19 crisis"). This indicates that the patterns of gene expression in D1 7 
and D38 had some common features to that seen in immortality and crisis, 
whilst in terms of overall gene expression levels it was more like the mortal 
cultures. There was also evidence that D4 changed in early pass culture, losing 
expression of RAR-fl (McGregor et al., 1997). This may indicate that D4 
progressed through crisis shortly after establishment in culture and may account 
for a similar effect in relation to its position in the different cluster dendrograms. 
However, on comparison with the dendrogram in Figure 5.7, it is clear that 
these effects were subtle, as D4, D17 and D38 clustered with the immortal 
samples, despite the use of the euclidean distance metric. The pattern in Figure 
5.9 also indicates that the gene expression patterns associated with crisis (as 
seen in BICR7) may have been present to some degree in D17 and D38. The 
euclidean metric clustered the mortal carcinomas close together, whereas with 
the cosine correlation, there was greater heterogeneity, particularly in the mortal 
carcinomas. 
The main difference in GEP seen in both clusters was associated with the 
acquisition of immortality. In addition to this, some consistent subgroups were 
identified within the mortal and immortal groups. 
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Figure 5.8 Hierarchical cluster based on the GEP of all samples using 
euclidean distance. 
The cluster is based on the mean values of technical replicates, using all 
present genes. Distance metric = euclidean, with complete linkage. The 
euclidean distance metric uses absolute values of gene expression to calculate 
the cluster dendrogram. 
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Figure 5.9 Hierarchical cluster based on the GEP of all samples using 
cosine correlation 
The cluster is based on the mean values of technical replicates, using all 
present genes. distance metric = cosine correlation linkage = complete. The 
cosine correlation metric groups samples according to trends/pattern of 
expression rather than absolute value. 
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5.3.4 Dysplasia progression 
The patients whose biopsies gave rise to D 19, D20, D35 (immortal), and E2, E4 
and E5 (mortal) all subsequently developed SCCHN. The carcinomas 
associated with D19, D20 and D35 arose at the same intra-oral site as the 
original dysplastic biopsy, whereas the clinical details of the carcinomas related 
to E2, E4 and E5 are less clear. Microarray analysis did not allow us to identify 
clear groupings of the dysplastic cultures derived from lesions that subsequently 
progressed to carcinoma. However, D35 consistently clustered with certain 
immortal carcinomas, but there was no consistent relationship of D19 and D20 
to the carcinomas (Figures 5.8 and 5.9). As a group, the erythroplakia cultures 
(Ell, E2, E4 and E5) did not show a consistent pattern of relationship to the 
carcinoma cultures, however El and E2 were closely associated with mortal 
carcinoma cultures, regardless of the distance metric used to construct the 
cluster dendrogram (Figures 5.8 and 5.9). However, as the clusters were based 
on the entire gene expression profile, this does not rule out the possibility that a 
"high risk signature" of gene expression in the dysplastic cultures that clinically 
progressed to carcinoma may be hidden in a subset of the data. Paul Drake, a 
Clinical Research Fellow in the group, is conducting further analysis of the data 
with the aim of identification of such a gene expression signature. 
5.3.5 Identification of the genes associated with the immortal phenotype 
Based on the groups derived from the cluster analysis and from clinical and 
biological knowledge, various groups of the cultures were selected for analysis 
by SAM. Statistical analysis was also performed using ANOVA, with good 
agreement of the list of genes selected by the two methods (Figure 5.10). The 
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number of statistically significant differences in gene expression between the 
groups selected is shown in Table 5.2 (upper and lower). The FDR of 1% was 
selected as this was deemed to give a working list of a manageable size, whilst 
maintaining a high level of stringency. In addition, the fold change cut off was 
set at ýt2 for practical reasons including limiting the size of the gene lists and 
allowing for some possibility of validation of the differences identified by 
independent methods. D17 was excluded from the mortal dysplastic group 
since, as indicated previously, this appears to have an overall GEP very similar 
to the immortal dysplastic samples (Figures 5.8 and 5.9). 
The method for selection of the genes associated with immortality is shown in 
Figure 5.11. This selected consistent differences in gene expression that are 
associated with the immortal phenotype, whether at the dysplasia or carcinoma 
stages. This required comparison of the normal cultures with the immortal 
dysplastic culture and the immortal carcinomas (comparisons 1 and 2). 
Additionally, these differences in gene expression had to be present on 
comparison of the mortal and immortal dysplastic cultures (comparison 3). Initial 
criteria also excluded genes that differed on comparison of the normal cultures 
and mortal carcinomas. On close inspection of the expression pattern of these 
genes this was seen to be inappropriate as the differences noted in many of 
these genes were paradoxical to the differences associated with immortality. 
Thus, these genes were retained in the list. Examples of genes retained 
include cdc20 and AF1Q in Figures 5.13 and 5.14. 
This analysis yielded a list of 55 Affymetrix probesets, representing 49 different 
genes (Figure 5.12). Of these genes, 27 were expressed at a higher level in 
immortal samples and 22 genes were expressed at a lower level in immortal 
samples than mortal. The mean expression level for the different biological 
groups (with standard error) is shown in Figures 5.12 and 5.13. This 
demonstrates the variability within the groups, even though the statistical 
stringency in the initial SAM analysis/ANOVA was high. Certain genes have 
extremely large standard errors, particularly within the mortal carcinoma group 
in Figure 5.13. As it was less likely that these genes would be good markers of 
the immortal phenotype, none of these markers was selected for the 
subsequent validation steps. 
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ANOVA SAM 
Figure 5.10 Comparison of the size and agreement of gene lists obtained 
by SAM and ANOVA 
This Venn diagram illustrates the agreement between ANOVA (p<0.01) and 
SAM (FDR 1%) in the comparison of normal v immortal carcinoma (in both 
cases fold change >2 fold). In this instance, the ANOVA list is almost 
completely a subset of the SAM list. 
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normal MD-D17 MDT IVIC ID IDT ic 
normal 192 32 472 124 693 716 
MD-D17 - 55 239 218 573 731 
MDT - 5 576 1056 1239 
Mc - 1196 1300 1251 
ID - 7 4 
IDT 
I 
- 0 
ic I - 
Normal all MD- D17 IVIC all ID Ic 
normal 36 472 264 716 
all MD-D17 - 75 unknown 764 
IVIC - 1358 1251 
all ID 30 
Ic -I 
Table 5.2 (upper and lower) Number of statistically significant differences 
in gene expression in comparison of all groups. 
The numbers of gene expression differences were generated using SAM at 
FDR1% and fold changes L-2. MD = mortal dysplasia, MDT = mortal dysplasia 
which progressed to carcinoma, MC = mortal carcinoma, ID = immortal 
dysplasia, IDT = immortal dysplasia which progressed to carcinoma, IC = 
immortal carcinoma. The allMD-D17 v all ID could not be completed due to a 
lack of sufficient computing power at BICR. 
D17 was left out of these analyses since, as previously indicated, this appears 
to have a GEP very close to the immortal dysplasias overall (Figures 5.8 and 
5.9 and comments in the text). 
The largest number of significant differences in gene expression were found on 
comparison of mortal carcinomas and immortal dysplasias which progressed to 
carcinoma . 
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dysplasias, FDR 1% 
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normal and immortal 
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clysplasias (-D17) and immortal 
dysplasias, FDR 1% 
Figure 5.11 Venn diagram illustrating the method of identification of 
genes associated with immortality 
Gene lists derived from the statistical analysis of comparisons of various groups 
were loaded into Genespring@. Only genes which showed consistent 
differences in the normal-immortal dysplasia and normal-immortal carcinoma 
comparisons and were also present in a comparison of mortal-immortal 
dysplasias were selected. The 55 probe sets identified relate to 49 individual 
genes (Figure 5.12). 
Differences between mortal 
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-0+ 
mortal immortal 
Figure 5.12 Graphical representation of expression of 55 candidates. 
The 55 probe sets were derived as shown in Figure 5.11. The diagram shows 
the genes and samples clustered using the euclidean distance metric and 
complete linkage. Red indicates relative overexpression, and green relative 
underexpression - see visual scale. 
The genes divided into two clear groups with reciprocal patterns related to the 
immortal phenotype. The samples clustered very similarly to that seen in earlier 
figures, however NT (marked) no longer clusters with the other normal samples. 
All of the immortal dysplasia cultures that progressed to carcinoma (D19, D20 
and D35) were closely associated with immortal carcinoma cultures. 
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Figure 5.13 Affymetrix U133A genechip expression levels of 27 genes 
overexpressed in immortal samples. 
Genes were selected as outlined in Figure 5.11. Expression level is the 
normalised mean Affymetrix expression level for each group with the standard 
error of the mean also shown. In addition to demonstrating overexpression in 
the immortal samples, many of these genes showed a reduction of expression 
on comparison of the normal and mortal samples. 
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Figure 5.14 Affymetrix U133A genechip expression levels of 22 genes 
underexpressed in immortal samples. 
Genes were selected as outlined in Figure 5.11. Expression level is the 
normalised mean Affymetrix expression level for each group with the standard 
error of the mean also shown. Whilst these genes demonstrate consistent 
underexpression in the immortal samples, the standard errors, particularly in the 
mortal samples were often large, indicative of the heterogeneity within these 
samples. 
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5.3.5.1 Functional and gene ontology annotation. 
The genes identified are shown in Tables 5.3 and 5.4, together with a brief 
description of their function. Some of these genes are related to p53, either as 
directly p53 responsive genes or indirectly through unknown intermediates. 
These genes include GOS2, ALDH1A3 and DDA3. 
Classification of the genes using the gene ontology (GO) is a useful method of 
classifying the genes related to biological process, molecular function or cellular 
component (Ashburner et al., 2000). However, the GO is not complete and 
many genes, particularly those whose function has not been fully investigated, 
do not have a GO annotation. This may introduce a certain amount of bias into 
the spread of gene ontology term seen. Statistical analysis of the relative 
overrepresentation of particular gene ontology terms using Fisher exact 
probability revealed several groups of genes that were over represented in the 
subset of genes associated with immortality (Tables 5.5 and 5.6). Many of the 
genes more highly expressed in immortal cells are associated with cell 
proliferation, but there are other genes whose biological function does not relate 
to this, for example HMMR, and GlP2. The genes that were more highly 
expressed in the mortal cells are a much more varied group. Many of these are 
associated with metabolism of various substrates (including alcohol, retinoids, 
lipids and proteins), whilst others are associated with the inflammatory response 
(e. g. CXCI-6). 
It is possible that the preponderance of genes related to the cell cycle amongst 
the genes overexpressed in the immortal cultures may be misleading. This may 
partly be due a greater growth fraction or higher proliferative rate than mortal 
cultures, as the doubling time is shorter for immortal cultures than for mortal 
cultures (data not shown). Alternatively, the mortal cultures may contain a 
senescent subpopulation even though the cultures were used at the earliest 
passage possible. However, there are many other genes in these lists that 
have not been linked to the cell cycle and these may prove to be proliferation 
independent markers of the immortal phenotype. However, the cells that are 
immortal may have consistent changes within the regulatory mechanisms of the 
cell cycle and as such, these genes may be important and should be assessed 
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Symbol Gene Name Alias Genbank Biological function 
acidic nuclear phosphor- function unclear, inhibits protein phosphatase 
ANP32E protein 32 family, member E LANP-L NM 030920 2A 
abnormal spindle-like, 
ASPM microcephaly associated NM 018123 microtubule-based process 
regulation of cell cycle - G2/M CCNB1 Cyclin 131 NM 031966 transition/mitosis, complexes with cdc2 
mitosis, protein amino acid phosphorylation, 
CDC2 cell division cycle 2 CDK1 NM 001786 start control point of mitotic cell cycle 
cell division cycle 20 regulation of cell cycle, ubiquitin-dependent 
CDC20 homologue p55CDC NM 001255 protein catabolism 
DNA replication and chromosome cycle, 
CENPF centromere protein F mitosin NM 016343 regulation of mitosis, chromosome separation 
differential display, activated CKS1 B, 
DDA3 
_ 
by p53 CDC28 NM 001826 regulation of CDK activity, cytokinesis 
DLG7 discs, large homolog 7 HURP NM 014750 cell-cell signalling 
FLJ30525 hypothetical protein NM 144584 function unknown 
interferon alpha-inducible 
G1 P2 protein IF115 NM 005101 cell-cell signalling, immune response 
GTF21RD2 GTF21RD2 AY312853 transcription factor 
chromosome condensation 
HCAP-G protein G CAP-G NM 022346 mitotic chromosome condensation 
hyaluronan-mediated motility 
HMMR receptor RHAMM NM 012485 cell motility 
cDNA for differentially 
HSJO01348 expressed C016 gene NM 017527 function unknown 
invasive growth microtubule-based process, 
IF144 interferon-induced protein 44 MTAP44 NM006417 response to viruses 
KIAA0186 hypothetical protein NM 021067 
mitotic arrest deficient-like 1 HSMAD2 mitotic chromosome segregation, mitotic 
MAD21_1 (yeast) MAD2 NM 002358 spindle checkpoint 
cytokinesis, meiosis, protein amino acid 
NEK2 NIMA-related kinase 2 NLK1 NM 002497 phosphorylation, regulation of mitosis 
RA-regulated nuclear matrix- 
RAMP associated protein L2DTL NM 016448 function unknown 
SIP Siah-interacting protein CACYBP NM 014412 centromere/kinetochore complex maturation 
structural maintenance of chromosome organization, condensation, and 
SMC4L1 chromosomes 4-like 1 CAP-C NM 005496 segregation, transport 
STK6 serine/threonine kinase 6 ALK NM 003158 mitosis, protein amino acid phosphorylation 
TOP2A topoisomerase 11 alpha NM 001067 DNA topological change 
TPX2, microtubule- 
TPX2 associated protein homolog NM 012112 mitosis 
ESK, mitotic spindle assembly and checkpoint, 
MPS1 L1, positive regulation of cell proliferation, protein 
TTK TTK protein kinase PYT NM 003318 amino acid phosphorylation 
Cyclin catabolism, mitosis, regulation of cell 
ubiquitin-conjugating enzyme proliferation, regulation of DNA repair, 
UBE2C E2C ubch1O NM 007019 ubiquitin-dependent protein catabolism 
ZIC2 Zic family member 2 HPE5 NM 007129 brain development 
Table 5.3 Functional annotation of 27 genes overexpressed in immortal 
cell cultures. 
The biological function noted is that designated by the gene ontology and is a 
composite from all three of the annotation networks of the gene ontology. 
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Symbol Gene Name Alias Genbank Biological functions 
ABCAl ATP-binding cassette, sub- CERP NM_005502 cholesterol metabolism, 
family A, member 1 phagoc osis, protein targeting 
ADAMTS1 a disintegrin-like and METH1 NM006988 integrin-mediated signalling pathway, 
metalloprotease with negative regulation of cell 
thrombospondin type 1 proliferation, proteolysis and 
motif, 1 peptidolysis 
AFlq ALL1 -fused gene from NM006818 cell growth and maintenance 
chromosome lq 
ALDHlA3 aldehyde dehydrogenase 1 ALDH6 NM000693 alcohol and lipid metabolism 
family, member A3 
ALDH4Al aldehyde dehydrogenase 4 ALDH4 NM003748 proline biosynthesis/catabo I ism 
family, member Al 
CXCL6 chemokine (C-X-C motif) GCP-2 NM002993 chemotaxis, cell-cell signalling, 
ligand 6 inflammatory response, signal 
transduction 
GOS2 putative lymphocyte GO/Gl NM015714 regulation of cell cycle 
switch gene 
GPX3 glutathione peroxidase 3 NM002084 response to lipid hydroperoxide 
IGFBP2 insulin-like growth factor IBP2 NM000597 regulation of cell growth 
binding protein 2 
IVIL involucrin NM005547 differentiation 
KLK7 kallikrein 7 NM005046 epidermal differentiation, proteolysis 
and peptidolysis 
KRT23 keratin 23 HAIM NM015515 cytoskeleton organization and 
biogenesis 
LCN2 lipocalin 2 (oncogene 24p3) NGAL NM005564 transport 
LOC91947 signal transduction, sensory 
perception 
PLAT plasminogen activator, T-PA NM_000930 blood coagulation, protein 
tissue modification, proteolysis and 
peptidolysis 
RHCG Rhesus blood group, C RHGK NM016321 transport 
glycoprotein 
Sl0OA9 S100 calcium binding CAGB; NM_002965 cell-cell signalling, inflammatory 
protein A9 MIF response 
sloop S100 calcium binding NM_005980 calcium binding, motility 
protein P 
SERPINBII serine proteinase inhibitor, MNEI; Pl NM_030666 regulation of proteolysis and 
clade B (member 1 2 peptidolysis 
SLC6Al4 solute carder family 6 ATB(O+) NM007231 amino acid metabolism, 
member 14 neurotransmitter transport 
SPRR3 small proline-rich protein 3 NM005416 cornfied envelope. differentiation 
UPM B uroplakin 1B NM006952 urothelial differentiation 
Table 5.4 Functional annotation of 22 genes underexpressed in immortal 
cell cultures. 
The biological function noted is that designated by the gene ontology and is a 
composite from all three of the annotation networks of the gene ontology. 
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GO biological process 
group 
I No. of 
genes 
I Fisher exact 
probability, p 
I examples 
cell proliferation 
cell cycle 15 3.7x10-14 MAD21-1 , cdc20 
mitosis 11 5.5xl 0-17 STK6, CAPG, 
G2/M transition 2 0.004 DDA3, CyclinB1 
G1 1 0.03 Cdc2 
metabolism 
protein modification 5 0.03 STK6, NIMA 
ubiquitin-dependent 
protein catabolism 
2 0.02 UBE2C, cdc20 
DNA metabolism 
regulation of DNA 
repair 
1 0.01 UBE2C 
DNA topological 
change 
1 0.01 TOP2A 
cytoskeleton 
organization 
3 0.02 
I 
ASPM, IF144 
I 
Table 5.5 Classification of genes upregulated at immortality by GO 
biological process. 
The analysis demonstrates several significantly over represented groups of 
genes, as assessed by Fisher exact probability. Only groups over represented 
with p<0.05 were considered significant. Groups are presented as a primary 
term (shaded pale blue) with "child" terms underneath. The primary term may 
not itself be significantly over represented. A particular gene with multiple 
functions may belong to more than one group. 
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GO biological No. of Fisher exact 
process group genes 
I 
probability, p examples 
metabolism 
I 
alcohol metabolism 2 0 04 
ALDH1A3 
. ALDI-14 
amino acid 2 0 03 SLC6A14 
metabolism . 
protein catabolism 4 0.02 KLK7, PLAT 
immune response 
inflammatory 2 0 03 CXCL6 
response . S10OA9 
Table 5.6 Classification of genes down-regulated at immortality by GO 
biological process. 
The analysis demonstrates several significantly over represented groups of 
genes, as assessed by Fisher exact probability Groups are presented as a 
primary term (shaded pale blue) with associated child terms underneath (if 
appropriate). The primary term may not itself be significantly over represented. 
The analysis demonstrates several significantly over represented groups of 
genes, as assessed by Fisher exact probability. Only groups over represented 
with p<0.05 were considered significant. 
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in the validation steps. The above provisos must be noted, particularly when 
validating these markers in vivo. 
5.3.6 Discussion 
The pilot study was vital in aiding our understanding of the effects that subtle 
changes in experimental protocol could have on the gene expression profile. It 
confirmed that strict standardization of the protocol was required. The pilot 
study also demonstrated the differential effect that the removal of irradiated 3T3 
feeders may have on the GEP, particularly on the normal cultures. 
Microarray analysis of samples from all stages of the development of HNSCC 
revealed that the main differences in gene expression were associated with the 
immortal phenotype. Within the main division of the samples into mortal and 
immortal, many of the samples clustered according to their clinical groups. 
Exceptions to this included the consistent clustering of D41 and D48 with the 
normal samples. It was noted earlier that these patients were non-smokers and 
that the tissues from which these cultures were derived expressed hTERT at a 
high level. This may indicate that these cultures are fundamentally different 
from the other mortal dysplastic cultures. Comparison with the expression of 
hTERT in the tissues related to the normal samples may shed some light on 
this. However, no tissue from the normal biopsies was retained (either frozen or 
formalin fixed), so this analysis is not possible. 
The microarray analysis allowed for the generation of a list of novel candidate 
genes associated with the immortal phenotype. Many of the genes that were 
overexpressed in the immortal cultures are related to control of the cell cycle. 
All these genes require to be validated to confirm the accuracy of microarray 
data and assess if the differences seen at the level of transcript are also seen 
after translation. 
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Chapter Six: Validation of microarray results 
6.1 Expression of well characterised markers 
Initial validation was restricted to the well-characterised markers in the cultures 
such as hTERT, RAR-fl, and p16. The expression of these markers is outlined 
in Figure 
6.1.1 hTERT 
The upper panel of Figure 6.1 shows the expression of hTERT as detected by 
the Affymetrix U133A genechip. Only one of the two hTERT probe sets on the 
U133A genechip passed the filtering level set in the initial analysis (i. e. ý! 6P). 
One culture, which had hTERT ectopically expressed by retroviral vector (D17 
EST) was added to this graph as a positive control. This demonstrates that the 
Affymetrix U133A probe set 207199at does detect hTERT, but only when 
present at a high level, such as follows ectopic expression. Otherwise, there is 
little discernable difference in the expression of hTERT in the mortal and 
immortal samples. There is no correlation between this result and that found by 
quantitative RT-PCR (McGregor et al., 2002). This indicates that the probe set is 
not sensitive enough to measure accurately the expression of hTERT in these 
keratinocyte cultures. 
6.1.2 RAR-fl 
The lower panel of Figure 6.1 shows the expression of RAR-, 8 as detected by 
the only one of three probe sets that passed the initial filtering criteria. This 
demonstrates a good agreement with the previously published Northern blot 
data (McGregor et al., 1997). The level of expression is low in D41 and D48, 
but this is appropriate considering their similarity to the normal cultures that has 
been demonstrated by the GEP. Unfortunately Northern blot analysis of RARfl 
expression in these samples has not been conducted. 
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Figure 6.1 Expression of "known" markers on Affymetrix U133A genechip 
Panel A shows expression of hTERT as measured by oligo-nucleotide probe set 
207199 
- 
at. D17 with ectopically expressed hTERT (D17EST) and the empty 
vector control (D1 7NEO) were included as controls. 
Panel B shows expression of RARfl as measured by oligonucleoticle probe set 
205080 
- 
at. The other RARfl probe set is not informative and was not passed 
as "present" in the initial filtering of the data. 
Two of the three p16 probe sets were designated as present in the initial 
filtering. However, the oligonucleoticle probe sets for the measurement of p16 
on the U1 33A genechip were not informative. 
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6.1.3 PI 6 
Blast analysis of the probe sets for p16 revealed that the probe sets which 
Affymetrix state measure p16 expression are located in exon 2 of the CDKN2a 
locus. Selection of probe sets in this location does not allow for differentiation 
of the expression of p16 and p14 (ARF) and thus the data generated is not 
informative. 
6.1.4 p53 
The complex regulation of p53 levels by modulation of p53 degradation means 
that expression of p53 mRNA does not necessarily relate to the protein level or 
the function of the protein. Thus, it is more informative to look at the expression 
of various p53 target genes. The Affymetrix gene expression for a selection of 
these is shown in Table 6.1. Many of these genes changed in a predictable 
manner related to the loss of p53 in the immortal cultures. However, others 
showed no change at all. 
6.1.5 Discussion 
The microarray expression of these well-characterised genes agrees well 
expression as assessed by other methods (see chapter 4). However, this 
analysis has highlighted the limitations of microarray analysis with regard to 
sensitivity, specificity and accurate design and annotation of the probe sets. It 
is also not possible to comment meaningfully on proteins for which expression 
level or activity is controlled mainly by post-translational events. 
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GENE Normal MD mc ID Ic 
p2lWAF1 836 ± 34 803 ± 37 1183 472 393 ± 38 197 154 
Cyclin G2 296 ± 30 261± 15 438 ± 81 166 ± 28 110 ± 17 
Ribonucleotide 
reductase MI 
322 ± 34 332 ± 21 156 ± 12 580 ± 86 596 ± 48 
Ribonucleotide 691 1130 1105 
reductase M2 130 
703 ± 93 102 ± 27 210 101 
GADD45 901 ± 634 ± 44 
1231 ± 490 ± 90 485 ± 78 119 132 
tp531P3 490 ± 607 ± 35 
1044 ± 351 ± 79 176 ± 30 104 93 
PERP 2109 1676 2230 ± 1655 1147 
185 133 106 217 96 
Table 6.1 Mean Affymetrix expression level of selected known p53 target 
genes in various groups of samples. 
The numbers shown in the table are normalised and represent the mean for the 
various groups with standard error of the mean also shown. MID = mortal 
dysplasia, MC = mortal carcinoma, ID = immortal dysplasia and IC = immortal 
carcinoma. No significant differences in expression of other p53 target genes, 
such as PUMA, MDM2, BAX, PIDD, FAS, were seen. 
157 
6.2 Validation of novel candidate markers of immortality in vitro by 
western blotting 
The candidate markers of immortality were validated by Western blotting. 
Ultimately, this was preferred to validation at mRNA level by quantitative RT- 
PCR as only markers that show differences at protein level can be considered 
to harbour gene expression changes that may alter the phenotype of the cell. 
Even so, many functional changes are post-translational and are unlikely to be 
identified by Western blotting. Additionally, the expression of some genes may 
be regulated by alterations in the pattern of degradation of the encoded 
proteins. The use of Western blotting restricted the validation process to those 
genes for which antibodies were commercially available. The Western blots, 
together with the Affymetrix expression data, for a selection of these validated 
are seen in Figures 6.2 (genes more highly expressed in immortal cells) and 
7.2.2 (genes more highly expressed in mortal cells). 
In general, the protein expression of genes which were more highly expressed 
in immortal cultures , agreed with the Affymetrix expression level. There was 
very little expression of these genes in the mortal cultures (Figure 7.2.1). The 
expression levels in the atypical mortal culture D17 were very similar to that 
seen in the immortal samples. This is in keeping with earlier comments on the 
pattern of gene expression in this culture. 
The heterogeneity within the mortal samples, which was alluded to earlier, was 
evident in those in the genes that were overexpressed in the mortal cultures 
(Figure 6.3). Additionally, low levels of expression of proteins encoded by these 
genes in the immortal cultures, as predicted by the Affymetrix expression level, 
were not uniformly seen. This seems to be particularly true for D9 and D34 
(bearing in mind that D38 is also atypical). The Western blots indicated that few 
of the markers showed an "all-or-nothing" loss or gain of the expression of the 
particular gene, as was the case with p16. 
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Figure 6.2 Validation of selected genes which were overexpressed in 
immortal samples. 
Western blots of whole cell extract from a panel of normal, dysplastic and 
carcinoma keratinocyte cultures. The Y-axis refers to the normalised Affymetrix 
expression level for the mean of the technical replicates. Bars in the graphs 
coloured green represent normal samples, red bars mortal 
dysplasia/carcinomas and blue bars immortal dysplasias/carcinomas. The 
expression of these proteins matches the RNA transcript level as assessed by 
microarray. The expression of some of these genes in D17 is similar to that 
seen the in immortal dysplastic cultures. This work was completed by the author 
and Dr J Thurlow. 
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Figure 6.3 Validation of selected genes which were underexpressed in 
immortal samples. 
Western blots of whole cell extract from a panel of normal, dysplastic and 
carcinoma keratinocyte cultures. The Y-axis refers to the normalised Affymetrix 
expression level for the mean of the technical replicates. Bars in the graphs 
coloured green represent normal samples, red ones mortal 
dysplasia/carcinomas and blue immortal dysplasias/carcinomas. The pattern of 
protein expression matched the RNA transcript level only to some degree. In 
particular, some of the immortal cultures (ID9 and D34) expressed more protein 
than the RNA analysis would indicate. This work was completed by the author 
and Dr J Thurlow. 
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6.2.1 Discussion 
Validation of a panel of markers showed good agreement in the RNA 
expression level and expression of protein in vitro. This confirms the accuracy 
of the microarray expression data. The heterogeneity seen in figures 6.2 and 
6.3 indicates that in the case of some of the markers, post transcriptional or 
post translational modifications may have modulated the levels of protein 
detected. 
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6.3 Validation of candidate markers of immortality in vivo by lHC 
The expression of some of the markers validated in western blot was also 
assessed in the original tissue sections by lHC in 10 of the carcinomas: four 
[I mortal", five "immortal" and one in "crisis". A selection of the markers validated 
in the carcinomas is shown in Figures 6.4 and 6.5. p53 was added to the panel 
as the p53 status of the culture had been fully investigated, with p53 mutation 
and alteration in expression showing clear association with immortality (Burns et 
al., 1993). The carcinomas were utilised in preference to the dysplasia tissues, 
as the difference in expression level of the novel immortality markers, as 
measured by the arrays, was maximal in comparison of mortal and immortal 
carcinoma cultures. Assessment of the expression of these proteins in vivo is 
subject to very similar caveats to those outlined for validation by western 
blotting, in addition to the subjective nature of assessing expression of proteins 
by lHC. 
The tissues from which the immortal carcinomas were derived showed relatively 
uniform staining of the markers of immortality particularly at the advancing edge 
of the tumour (Figure 6.5). In most cases, the tissues showed fairly uniform p53 
expression, together with strong Cyclin 131 expression, especially at the 
invading edge of the HNSSC nests. In contrast, these HNSCC nests showed 
only a small proportion of cells expressing S10OA9 or involucrin. There was, 
however, a measure of heterogeneity in all of these tumours. This was most 
pronounced in BICR56, which showed areas of well differentiated nests of 
tumour, which centrally showed a mortal staining pattern. However, the 
expression of the characteristically immortal markers was clearly present in the 
basal layer of these nests, indicating that they were not mortal in character, but 
immortal with retained ability to differentiate. In general, the more poorly 
differentiated the tumour, the more uniform the immortal staining pattern. 
BICR7, which has an overall GEP very similar to that of the immortal 
carcinomas showed a characteristically immortal staining pattern (Figure 6.5). 
The tumours that gave rise to mortal carcinoma cultures were much more 
heterogeneous, with varying proportions of characteristic mortal and immortal 
staining patterns (Figure 6.4). Thus, some areas showed staining 
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Figure 6.4 Validation of selected candidate immortality genes by 
immunohistochernistry in tumours which gave rise to mortal cultures. 
The panels show p53, Cyclin B1, Involucrin and S10OA9 immunostaining in 
formalin-fixed biopsy tissue from which the cultures were derived. Negative 
controls (not shown), using IgG showed no staining. The panels indicate the 
level of heterogeneity present in the tumours which gave rise to the mortal 
carcinoma cultures. One tumour, BICR25, showed a uniform mortal staining 
pattern. This work was conducted on adjacent sections where possible and 
completed by the author, Dr J Thurlow and Ms J Fleming. 
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Figure 6.5 Validation of selected candidate immortality genes by 
immunohistochernistry in tumours which gave rise to immortal cultures 
and in BICR7 (crisis). 
The panels show p53, Cyclin 131, Involucrin and S10OA9 immunostaining in 
formalin-fixed biopsy tissue from which the cultures. was derived. Negative 
controls (not shown), using IgG showed no non-specific staining. Whilst the 
pattern of staining of the markers of immortality was relatively consistent, there 
was still some level of heterogeneity, most evident in BICR56. The pattern of 
expression in BICR7 (in crisis in vitro) was similar to that of the other immortal 
tumours. This work was conducted on adjacent sections where possible and 
was completed by the author, Dr J Thurlow and Ms J Fleming. 
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patterns very similar to that found in most of the immortal carcinomas (see 
above), whilst others showed staining more characteristic of the mortal cells in 
vitro (very little p53 and Cyclin B1 staining, and high expression of involucrin 
and S10OA9). One tumour, BICR 25, was composed almost entirely of nests of 
cells with a mortal phenotype. 
6.3.1 Discussion 
These lHC data indicate that the in vitro mortal and immortal phenotypes exist 
in HNSCCs in vivo. Also, it is clear that both may exist within the same tumour. 
Thus, the extensive gene expression differences associated with immortality in 
vitro also contribute to HNSCC heterogeneity in vivo. These findings have clear 
implications as to identification of the source cells within the tumours that grew 
in our cultures, as the immortal cells appear to be less differentiated, whilst the 
cells with a characteristic mortal phenotype are more differentiated. The factors 
that dictate which type of cell grows from a mixed cell population are not known. 
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Chapter Seven: General Discussion 
7.1 The culture model 
Whilst this study has largely centered round the use of microarray technology 
for the assessment of the GEPs of the various cell cultures, the ultimate clinical 
usefulness of the data is dependent upon the ability of the cell culture model to 
replicate the pattern of gene expression seen in vivo. The initial experiments 
outlined in this thesis indicated that the limited panel of molecular changes 
previously reported as having association with immortality (McGregor et al., 
2002) was present to a large degree in the tissue from which the cultures were 
derived. In particular, this was true for changes in expression and activity of 
those genes that control the cell cycle and are involved in the replicative 
barriers of senescence and crisis. Generally, this is in keeping with the original 
observations of Rheinwald and coworkers, who indicated that serial cultivation 
with irradiated 3T3 fibroblasts, gave rise to a genetically stable cell population 
that corresponded well to the tissue of origin (Rheinwald & Beckett, 1981). The 
subsequent demonstration of good in vivolin vitro correspondence of the novel 
markers of immortality further supports the culture system as a reasonable 
model of HNSCC development in vivo. This not only included proliferation 
markers but also markers of differentiation and motility, such as involucrin and 
S1 OOA9. 
The poor correlation of the expression of RAR-fl in the cultures and tissue 
serves to indicate that the 3T3 culture system does not fully replicate the in vivo 
state. The observation that RAR-, 8 was expressed in the immortal tissues 
requires explanation. It is likely that all of the dysplastic lesions, whether giving 
rise mortal or immortal cultures, allowed terminal differentiation to occur, but in 
the immortal cultures control of differentiation might have been either defective 
or occurring in a smaller proportion of cells. Additionally, the monolayer culture 
method does not allow the cells to establish an interaction with fibroblasts and 
other stromal cells. Such interactions have been shown to be of great 
importance in the development of neoplastic lesions as stromal cells have been 
shown to exert a significant effect on the gene expression profile of the 
neoplastic population (TIsty, 2001; TIsty & Hein, 2001). The further use of 
organotypic models, either as described earlier (Figure 4.10) or use of the more 
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sophisticated model recently described (Andriani et al., 2004) may improve this, 
but faithful reconstitution of the in vivo state may not be possible in vitro, due to 
its complexity. 
To further explore the relationship between the cultures and tissues, a fuller 
exploration of the gene expression patterns in some of the matched tissue and 
culture samples has now been conducted using microarray analysis, as funding 
for this has become available since the completion of the laboratory work for 
this thesis. Analysis of the data may give further insight into the changes in 
gene expression on establishment in culture. 
In terms of the pattern of gene expression related to proliferation and growth, 
the good agreement of in vivo and in vitro gene expression and the continued 
clear separation of the mortal and immortal samples laid a basis upon which the 
microarray study could proceed. There was a reasonable expectation that at 
least some of the changes in gene expression in culture would be identified in 
the tissue of origin. The identification of the atypical gene expression profiles of 
D17 and D38 in their related tissues was further evidence of the 
appropriateness of this tissue culture model, as is the extensive heterogeneity 
in gene expression in D4. This was initially a mortal culture, from which 
emerged an immortal cell line (McGregor et al., 1997). 
The in vivo validation of the novel markers of immortality utilised 
immunohistochernistry, which allowed the variability of expression of the 
markers to be assessed. Heterogeneity in gene expression was noted in all the 
carcinomas, but particularly in the turnours that gave rise to mortal cultures. A 
possible alternative method of in vivo validation would have been microarray 
analysis of the original tumours. As there was no fresh frozen tissue from the 
original turnours, the only material available was formalin fixed. Whilst the 
advances in microarray technology now allow microarray analysis of RNA 
extracted from formalin fixed material, the interpretation of such data is difficult. 
In many ways, immunohistochernistry is superior to this, as it allows 
assessment of the final product i. e. the protein, together with visualisation of 
any variability in expression within the tumour. In the context of microarray 
analysis, this could only be achieved by the examination of morphologically 
different areas within the tumour, each captured by LCM. The variation in 
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staining seen in the primary tumours in this study indicated that "bulk" analysis 
of tumours might obscure important patterns of heterogeneity of gene 
expression within the tumour. Microarray analysis of HNSCC in many other 
publications is often based on the bulk analysis of tumours (Cromer et al., 2004; 
Kuriakose et al., 2004; Lemaire et al., 2003; Roepman et al., 2005). 
7.2 The gene expression profiles 
The most striking differences in the GEPs were the large number of differences 
upon comparison of the mortal and immortal carcinomas and also comparison 
of the mortal and immortal high risk dysplasia cultures (Table 5.2, upper and 
lower). The large number and pattern of these differences indicated that there 
may be two separate, perhaps divergent, pathways to the development of the 
mortal and immortal carcinomas, with intermediates much in keeping with the 
clinical history of the individual dysplastic lesion. Thus, it may be possible to 
identify low and high risk dysplastic lesions, with the high risk lesions having a 
very similar GEP to the SCC cultures. This was borne out by the relatively 
small number of differences when comparing the mortal and immortal dysplasia 
cultures with their respective carcinomas. However, the hierarchical clustering 
did not allow for the clear identification of these various groups in terms of their 
GEP. There were very few consistent differences in gene expression on 
comparison of the high risk immortal dysplastic lesions and the immortal 
carcinomas. This indicates that these cells had gained additional changes in 
their GEP that were not present in the low risk immortal dysplastic cultures. 
The fact that they clustered very closely with the immortal carcinomas indicated 
that they may have gained almost all of the immortal carcinoma related changes 
in gene expression, but had not yet acquired that ability to invade (Figures 5.8 
and 5.9). In this respect, this is very similar to the findings of Ha and coworkers 
(Ha et al., 2002b), who found that most moderate/seve rely dysplastic lesions 
had a GEP very similar to HNSCCs. 
Due to certain limitations of hierarchical clustering in its ability to demonstrate 
the differences in the GEP of the various groups we have recently employed 
more sophisticated clustering techniques, such as spectral clustering (Kluger et 
al., 2003) in collaboration with Dr G KaIna and Dr D Higham in the Department 
of Mathematics at the University of Strathclyde. This method of clustering is 
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based on singular value decomposition (SVD) which may be used to assign one 
or more numerical values to each gene and each sample. Spectral clustering 
has been demonstrated as a useful tool for analyzing microarray data from well 
characterized cancer types, for example, it correctly identifies known subtypes 
of leukemia, lymphoma, breast cancer and brain cancer (Higham et al., 2005; 
Kluger et al., 2003), which has proved difficult with other methods. Application 
of spectral clustering to the data allows for a clearer separation of the different 
groups of cultures and this can be demonstrated on several different 
dimensions, not merely the 2D relationship which is dictated by the use of 
hierarchical clustering algorithms (for example, Figure 5.8). The delineation of 
groups of cultures relates to the known clinical features the lesions (Figure 7.1). 
The main groups of samples, based on both clinical and gene expression 
pattern, are shown in Figure 7.2. The number of gene expression differences 
for selected comparisons is also shown in this diagram and the pair-wise 
comparisons suggest that two pathways for the development of HNSCC exist- 
a mortal pathway and an immortal pathway. These can be observed in distinct 
patterns of gene expression. The number of changes in gene expression within 
each arm of the diagram was small when compared to the difference in gene 
expression between the mortal and immortal cultures. However, the 
interpretation of such a diagram must be treated with caution, as the cultures 
were derived from different individuals and not sequential biopsies taken during 
HNSCC development in a single patient. The demonstration of similar gene 
expression changes occurring in the development of an HNSCC within a 
dysplastic lesion from the same patient would allow such lineage relationships 
to be more surely established. 
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Figure 7.1 Analysis of the gene expression profiles by spectral clustering 
Analysis of the GEPs of dysplasias by spectral clustering in relation to primary 
HNSCCs, SCC recurrences, metastases and normal mucosa. See discussion 
text for an explanation of the basis of spectral clustering. The diagram shows 
the components of vectors V2 and V3 for each sample as the horizontal and 
vertical coordinates, respectively. Samples that were close in this two- 
dimensional ordering can be viewed as similar in GEP. This method 
demonstrates an enhanced separation of the cultures utilising the different 
vector components. This data is reproduced courtesy of Dr G KaIna and Dr D 
Higham, Department of Mathematics, University of Strathclyde. 
N= normal, MD = mortal dysplasia, MDT = mortal dysplasia which progressed 
to SCC MC mortal carcinoma, ID = immortal dysplasia, IDT = immortal 
dysplasia which progressed to carcinoma, IC = immortal carcinoma, M 
metastases (mortal or immortal), R= recurrence (all immortal). 
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Figure 7.2 Possible pathways of oral cancer progression based on 
similarities in gene expression between normal oral mucosa, clysplasias 
and SCCs 
Relationships of dysplasias to carcinomas revealed by gene expression 
profiling. The model demonstrates how the two types of HNSCC may be 
derived from intermediate dysplasias. Solid lines indicate likely routes of 
progression via mortal and immortal pathways, based on modest differences in 
gene expression between low and high risk dysplasias and SCCs. Dashed or 
dotted lines indicate possible alternative pathways; those indicated by dotted 
lines would involve much bigger gene expression changes. The numbers 
represent the number of statistically significant difference in gene expression, 
as also shown in Table 5.2 (upper and lower). 
171 
The possibility of two pathways in the development of HNSCC raises interesting 
questions in relation to the gene expression pattern of the two carcinomas. The 
classical markers of invasion and metastasis were predominantly found in the 
mortal carcinoma cultures and were absent from the immortal cultures. These 
included elevated expression of MMPs, collagens and laminins, CEACAM1, 
certain integrins and components of the urokinase plasminogen activator 
pathway. Alterations in the TGF-, 8 pathways were also present in the mortal 
cultures. It would seem likely then that these carcinomas invade using the 
mesenchymal method, either as individual cells or collectively and this might 
have involved EMT (See Figure 2.1 and Friedl & Wolf, 2003). As the immortal 
cultures downregulate the expression of these genes, it is less clear how the 
immortal HNSCCs became invasive. 
The alternative method of amoeboid movement does not require the alterations 
in proteolytic enzymes and intercellular attachments characteristically 
associated with cancer invasion and metastasis (see chapter 2). The 
overexpression of RHAMM (Dr J Thurlow, personal communication), an 
alternative hyaluronan receptor, might be indicative of changes that allowed 
cells to move in this way. RHAMM has been identified as a cell surface 
receptor involved in cell motility, but recent work suggests that it is more likely to 
act as an intracellular hyaluronan-binding protein interacting with both 
microtubules and actin filaments (Assmann et al., 1999). Investigation in other 
cancers has found overexpression of RHAMM at the invasive edge of lobular 
breast cancer and demonstrated a relationship between RHAMM expression 
and risk of nodal metastases in breast cancer and with clinical aggressiveness 
in pancreatic cancer (Abetamann et al., 1996; Wang et al., 1998). Thus, 
RHAMM over expression in immortal HNSCCs could be responsible for the 
invasiveness of immortal HNSCCs. 
Amoeboid migration has also been related to increased signalling via 
Rho/ROCK (Croft et al., 2004; Sahai & Marshall, 2003). Although our immortal 
HNSCCs did not show significant changes in expression of Rho family 
members, my colleague Dr J Thurlow has recently shown that they did over 
express ECT2, a Rho GEF (Miki et al., 1993). ECT2 has been implicated in 
cytokinesis and in the activation of Cdc42 in mitosis (Oceguera-Yanez et al., 
2005), but it also interacts with the polarity protein complex, Par6/Par3/PKCý 
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and localises at sites of cell-cell contact as well as in the nucleus (Liu et al., 
2004). ECT2 also interacts with the Kelch-like protein, KLEIP, which co- 
localises with actin at cell-cell contact sites (Hara et al., 2004). Thus, ECT2 
could also play a role in immortal HNSCC motility. Further work is required to 
test these alternative hypotheses and to explain immortal HNSCC motility. 
7.3 Gene expression profile and prognosis 
Such profound differences in the GEPs of the mortal and immortal carcinomas 
might also have clinical importance. It was noted in the Chapter 2 that the 
ability to establish as a cell line in culture has been related to poor prognosis 
and lymph node metastases (Shimada et al., 2003). Although univariate 
analysis of immortality in culture showed correlation with nodal status, p53 
pathway defects (elevated p53 or MDM2 expression), p2l WAR and p27 KIP1 
expression and reduced FHIT expression, in multivariate analysis, p53 pathway 
defects were the main independent predictors of cell line establishment and of 
propensity to lymph node metastasis. This is compatible with the GEP seen in 
our immortal cells and suggested that acquisition of immortality was associated 
with future propensity of primary SCCs to metastasise to lymph nodes. 
The link between immortality in cell culture and poor prognosis is borne out to 
some extent by our follow-up data. The small number of patients, the extensive 
co-morbidities in these patients and incomplete follow-up information - the 
clinical case notes for some of the patients have been lost or destroyed - places 
severe limitations upon this analysis. Another factor was stage at presentation, 
as those tumours that gave rise to immortal cultures tended to be more 
advanced. Of primary HNSCCs that gave rise to immortal cultures, five of 
seven were T4, whereas only three of eight primary mortal HNSCCs had a 
tumour of this size. In terms of the presence of nodal metastases, five of seven 
immortal turnours were node positive, whilst only three of eight mortal tumours 
had nodal metastases at diagnosis. Despite these caveats, none of the patients 
whose tumour gave rise to a mortal carcinoma has died in circumstances 
directly attributable to their HNSCC diagnosis. However, at least five of the 
patients who produced an immortal culture died from causes attributable to their 
HNSCC diagnosis, often after a protracted clinical course. 
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7.3.1 Other microarray studies 
Interpretation of the results of microarray studies in the published scientific 
literature is greatly hindered by the variety of study designs and methodologies 
employed. In some studies, statistical analysis of the data is not ideal, as 
correction for multiple hypothesis testing has not been performed (Al Moustafa 
et al., 2002; Ha et al., 2003). In others, where appropriate corrections were 
made, the list of genes was very small, even allowing for a large FDR (Nagata 
et al., 2003). Interestingly (and perhaps not surprisingly in view of this), 
comparison of the GEPs of some of the early gene expression studies 
has produced agreement of around 7% in the lists of genes proposed as 
important in the development of HNSCC (see 
hftp: //www. upstate. edu/microb/shillite/Microarray Oral Cancer Genes. HTM). 
Many recently published in vivo gene expression profiling studies have utilised 
various classification methods to subdivide HNSCCs into groups with GEPs that 
may be linked to different prognoses. Generally, these in vivo studies measure 
gene expression differences in the whole tumour cell population, not just the 
malignant epithelial component, as in our study. Whilst some studies have 
utilised LCM technology to select a pure epithelial tumour sample for analysis, 
none has attempted to select and analyse morphologically different areas, or to 
sample areas with differing patterns of differentiation. The merits of such bulk 
analysis of tumours are debatable, as the tumour heterogeneity alluded to 
above cannot be assessed. The presence of other types of cell in the sample 
analysed can vary extensively, particularly as the intensity of the immune 
response to the tumour differs between patients. One study has demonstrated 
that this can have a marked effect on the overall GEP, particularly with relation 
to immune system-related markers (Ginos et al., 2004). Others argue, 
however, that it does not matter if some of the markers are stromal or 
immunoregulatory elements (Roepman et al., 2005). That argument can only 
be valid if the sole aim is a clinically relevant set of molecular predictors - 
analysis of the GEP in terms of cellular and molecular biology of the tumours is 
compromised by inability to distinguish the relative contribution of the various 
cellular elements. 
The study of 25 primary HNSCCs, 16 locally recurrent HNSCCs and 13 normal 
oral mucosa samples by Ginos and coworkers found a gene expression 
174 
signature correlating with local recurrence (Ginos et al., 2004). This included 
proteins involved in extracellular matrix interactions, such as certain laminins 
and integrins, proteins implicated in EMT, (such as SNA12), and the MET 
oncoprotein. With the exception of MET, this molecular signature of recurrent 
disease strongly resembles the GEP of our mortal SCCs. A different study of 
60 HNSCCs categorized the tumours into two main groups, one of which could 
be further subdivided (Chung et al., 2004). The main group, which was not 
further subdivided, was associated with increased local recurrence and 
displayed a gene expression signature which was both consistent with that 
demonstrated by Ginos and coworkers and resembled that of our mortal SCCs: 
e. g. LAMA3, B3 and C2, P-cadherin, desmocollin 2, keratin 14, kallikrein 10, 
SKALP and TGF-fl. 
Three recent in vivo studies have reported HNSCC GEPs associated with high 
risk of lymph node metastasis (Chung et al., 2004; Cromer et al., 2004) 
Roepman et al, 2005). The studies reported by Chung et al. and Cromer et al. 
also suggest that the gene expression changes associated with lymph node 
metastasis are different from those associated with local recurrence of 
HNSCCs. Despite the long lists of genes generated by these studies, there 
appears to be no overlap between the published profiles of high risk of 
metastasis of HNSCC. This may partly be explained by the use of different 
microarray platforms and variations in the design of the studies including the 
use of different reference samples. However, there is greater overlap between 
the GEPs predictive of lymph node metastasis in Chung et al and Cromer et al 
with our immortal HNSCC signature than with our mortal HNSCC signature. In 
contrast, the metastasis associated GEP identified by Roepman and coworkers 
which was based on 82 heterogeneous HNSCCs does not seem to have any 
particular bias in relation to our HNSCC immortality markers (Roepman et al., 
2005). 
The study by Chung and coworkers identified a gene expression signature of 
primary HNSCCs that predicted future lymph node metastasis with 80% 
accuracy (Chung et al., 2004). The lymph node positive signature included 
known proliferation associated genes and many other genes that were more 
highly expressed in our immortal SCCs, for example ECT2, UBE2C and STK6. 
The lymph node positive predictor signature derived by Cromer et al. based on 
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34 hypopharyngeal HNSCCs also shows greater similarity with our immortal 
SCC gene expression profile than our mortal signature, whereas the lymph 
node negative signature resembles our mortal SCC profile much more closely 
(Cromer et al., 2004). Overall, these various in vivolin vitro comparisons and 
the observations of Shimada and coworkers cited above (Shimada et al., 2003), 
suggest that the HNSCCs that only recur locally may have a GEP similar to our 
mortal SCCs; whereas HNSCCs that metastasise to lymph nodes tend to have 
an immortal phenotype. 
It is clear that, despite the efforts in standardization (including MIAME) the 
variation between microarray studies is still large. At present, it is difficult to see 
clinical utility of such data if these disparate studies, purporting to assess the 
same biological event, arrive at completely exclusive lists of genes (Chung et 
al., 2004; Cromer et al., 2004; Roepman et al., 2005). As the number of 
suggested useful markers grows, it is not going to be possible to test all of the 
candidate genes in properly constituted clinical studies. Perhaps a more 
rigorous validation of the markers in such studies is required, for example by 
immunohistochernistry in the original tumours. Obviously, this also has its 
limitations. 
7.4 The possible origins of HNSCC 
The establishment of cultures from HNSCCs with different replicative 
characteristics and the distinctive gene expression patterns seen in our analysis 
may reflect differences in origin. Two theories have been proposed regarding 
the derivation of such neoplastic cells. The selection hypothesis proposes that 
squamous neoplasia arises from pre-existing telomerase proficient stem cells 
(Owens & Watt, 2003). Stem cells are responsible for the continual 
replacement of cells within a tissue and in squamous epithelium under steady 
state conditions, it is likely that these cells are relatively quiescent and do not 
express telomerase. In contrast, the remainder of the cells in the proliferative 
compartment of squamous epithelia do express telomerase at a low level, but 
this is rapidly lost upon establishment in cell culture, as was demonstrated in 
Figure 4.6. However, when stem cells enter the cell cycle, it is likely that they 
too will express telomerase. These cells are obvious candidates for the origin 
of squamous neoplasia, as they are present within the tissue over a long period 
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and as such would have the opportunity to accumulate the required number of 
mutations for the establishment of neoplastic disease. As they are telomerase 
proficient in vivo, they should possess long telomeres and be genetically stable. 
In some respects, the mortal HNSCC phenotype bears such features. These 
cells lack telomerase activity when cultured in vitro, have WT p53 and are 
relatively genetically stable. Tumours bearing these features have been shown 
to have a better prognosis in vivo. However, comparison with the microarray 
analysis of epithelial stem cells by Blanpain and coworkers, shows there is no 
consistent relationship of a suggested stem cell gene expression pattern to any 
of our groups of keratinocytes (Blanpain et al., 2004). Admittedly, the stem cells 
in this study were from hair follicle, and as such, analysis of stem cells from oral 
mucosa must be compared with our data before the hypothesis is dismissed. 
Additionally, the fact that the mortal tumours in our study appear to be more 
highly differentiated than the immortal tumours may also mitigate against this 
hypothesis. Recent telomere length studies indicate that, in general, the 
immortal cultures have short telomeres whilst the telomere length of mortal 
cancers is more variable (data not shown). This may indicate that both arose 
from telomerase deficient cells. Therefore, mortal HNSCC may simply be 
tumours that for stochastic reasons have not completed a sufficient number of 
cell divisions to precipitate senescence and telomeric dysfunction, and as such 
have retained the ability to differentiate. 
An alternative viewpoint suggests that epithelial neoplasms may arise from 
differentiated, telomerase negative cells. The observation that keratinocytes 
lacking stem cell properties can be immortalised by adenovirus EIIA supports 
this (Barrandon et al., 1989). Such telomerase deficient cells should 
demonstrate shorter telomeres with telomeric fusions, deregulated telomerase 
and mutation of p53, together with appreciable genomic instability. These cells 
would be expected to demonstrate aneuploidy, extensive LoH and unbalanced 
chromosomal translocations. The immortal HNSCCs (and dysplasias) display 
these characteristics. If this is so, the telomerase deregulation hypothesis 
predicts that cells which have bypassed senescence, but not crisis, should also 
be identifiable in developing lesions. One of our cell cultures, BICR7, displayed 
the features of crisis in vitro and in vivo analysis of HNSCC tumours has 
demonstrated several of these features (Gordon et al., 2003). Similar findings 
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have also been reported in other cancer models. In our study, these cells had 
also lost molecular markers of terminal differentiation. 
The presence of intermediate features in vivo (D1 7, D38) and in vitro (Gordon et 
al., 2003) raises the possibility that conversion of mortal tumours to immortal 
may be possible. However, the data presented here indicates that such an 
effect requires extensive changes in gene expression. The observation that 
most of the turnours show heterogeneity of expression of mortal and immortal 
markers, may reflect such interconversion. The variation was present in all of 
the tumours which gave rise to the mortal cell cultures. Thus, in the carcinomas 
which had a uniformly immortal phenotype in vivo, the development of 
immortality may have been an early effect, perhaps at the dysplasia stage. The 
existence of atypical transitional forms of dysplasia cell culture (D1 7 and D38) is 
evidence which supports this. Alternatively, these tumours may have been at a 
more advanced stage of conversion from a predominantly mortal HNSCC 
phenotype to a predominantly immortal one. 
The turnours which gave rise to the mortal carcinoma cultures have been shown 
to be very heterogeneous, containing areas with both the mortal and the 
immortal HNSCC phenotype (Figure 6.4). This may indicate that invasion 
predated the development of immortal clones within the tumour. As the 
immortal phenotype has been associated with poor prognosis, this presents a 
plausible explanation for the better prognosis if turnours have a population of 
mortal cells at the time of diagnosis i. e. late development of the immortal cell 
population. However, this advantage may be time-limited if the tumour 
undergoes conversion from a mortal to an immortal phenotype. Thus, there is 
no implication that the mortal HNSCCs are indolent lesions, as it is likely that 
given time they too will spread and kill the patient. 
The establishment of both a retrospective and prospective analysis of dysplastic 
lesions may help in answering these questions. Both of these studies have 
received ethical approval from the relevant LRECs in Glasgow (KH in 
retrospective study as co-investigator, prospective study as main investigator). 
The retrospective study will utilise the issue archives in the Department of Oral 
pathology at Glasgow Dental Hospital and School. The pathology database 
contains 27 patients with a biopsy-confirmed dysplastic lesion who have 
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subsequently developed a SCC at the same site. The prospective study, 
designed to collect a patient's first diagnosed dysplastic lesion, has been 
recruiting for two years. Whilst the recruitment rate has been disappointing, 
around 50 biopsies have been stored, with the availability of both fresh and 
formalin fixed material. 
7.5 Consistent changes unrelated to proliferative capacity 
There are surprisingly few consistent gene expression changes common to all 
HNSCC cultures, regardless of proliferative fate. Genes such as this may be 
good candidates for therapeutic intervention, as they are altered in the 
carcinoma cultures. Gene such as Creatine kinase B, SIX and FOXQ1 are 
upregulated in the HNSCC cultures when compared with normal cultures; whilst 
ZNF185, CUGBP2, PLCID4, HOP and CYP27131 are all downregulated. All 
these gene expression changes still require to be validated by another method. 
There is evidence for the involvement of some of these genes in other cancers, 
but how these changes might contribute to HNSCC development is unclear. 
For example, FOX members are known to be deregulated in various cancers 
(Katoh, 2004). SIX1, is believed to stimulate proliferation via activation of Cyclin 
Al (Coletta et al., 2004). It is overexpressed in breast cancers, particularly 
metastases and is also involved in determination of the metastatic phenotype of 
rhabdomyosarcomas (Yu et al., 2004). CUGBP2/ETR-3 is a regulator of 
nuclear and cytoplasmic RNA processing events (Ladd & Cooper, 2004) and 
has been implicated in translational silencing of COX-2 during radiation induced 
apoptosis (Mukhopadhyay et al., 2003). CYP27131 is increased in skin SCCs 
(Reichrath et al., 2004) and colon cancers (Reichrath et al., 2004), whilst HOP 
is a potential transcription cofactor, downregulated in hypopharyngeal 
carcinoma (Lemaire et al., 2004). 
7.6 Markers of immortality 
Our previous work has shown that p53 mutations are closely associated with 
immortality in the dysplasia and carcinoma cultures. Some of the 
dysplasia/HNSCC immortality markers are known p53 target genes, for 
example, ALD1A3 (Okamura et al., 1999). Other known p53 target genes also 
differ in expression level between mortal and immortal HNSCCs or clysplasias. 
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The pattern of these differences in gene expression varies, but in general, p53 
target genes that show differences between mortal and immortal HNSCCs are 
involved in the control of the cell cycle, replication or cell cycle arrest, whereas 
those that show little change are often those genes whose function may be 
related to apoptosis. Loss of expression of RAR-, B is also strongly associated 
with immortality, although its level of expression is barely detectable in the 
microarray experiments (Figure 6.1). 
Many of the novel markers of the immortal phenotype seen in our cultures have 
been related to cancer biology in some way in the literature. What is most 
striking is the extent of over-representation of cell cycle associated genes 
amongst those more highly expressed in the immortal cells. These cells are 
proliferating faster, and this is reflected in a shorter doubling time in vitro (data 
not shown). However, there are some genes which have been relatively under- 
investigated, including GOS2, Keratin 23 and RHCG, amongst others. 
Microarray analysis of mortal cells as they approach senescence has been 
conducted in many cell types, including normal oral keratinocytes (NHOKs) 
(Kang et al., 2003: 13aek, 2003 #365). These analyses have shown that the 
gene expression profile of NHOKs as they approach senescence does in some 
respects mirror that seen in our mortal cultures when compared with the 
immortal cultures. In the paper by Kang et al, there is profound downregulation 
of cell cycle genes, and upregulation of some MMPs and collagens, amongst 
others (Kang et al., 2003). The analysis by Baek et al shows a similar pattern of 
changes, but with less overlap of the gene expression profile in our mortal cells 
(Baek et al., 2003). This raises the question of the extent to which genes 
associated with senescence influence the overall GEPs. 
Microarray analysis of luminal mammary epithelial cells before and after 
immortalisation with SV40, demonstrated a spectrum of changes in gene 
expression with some overlap with our immortality markers (Park et al., 2004). 
Indeed many of the over expressed genes in the immortalised cells are related 
to cell cycle and mitosis, as in the immortal cultures. Similarly, those genes 
whose expression falls on SV40 immortalisation include genes related to 
differentiation and some which also are downregulated in our immortal cells, 
such as ALIDWA3. Although the particular genes altered only overlap to some 
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extent, presumably as the cells are of different tissue type and the process of 
SV40 immortalisation is different from that occurring in our cultures, it appears 
that very similar pathways have been affected. This indicates that the 
distinctive GEP of the immortal cultures is not solely due to the presence of 
senescent cells in the mortal cultures. 
The profound downregulation of many markers related to differentiation may be 
of clinical note as it is known that poorly differentiated tumours tend to behave 
more aggressively. If the basis for this is closely linked with immortalisation, 
this analysis provides an underlying biological explanation for how tumours may 
become poorly differentiated, and for the link between loss of differentiation and 
poor prognosis. Rheinwald and co-workers showed that all cell lines derived 
from HNSCC have a subnormal rate of commitment to terminal differentiation in 
suspension culture when compared to normal cells (Rheinwald, 1982). Whilst 
all the cell lines in the study by Rheinwald and co-workers did eventually enter 
terminal differentiation, it is clear that their ability to do so was greatly 
compromised. 
The capability of some of our immortal cultures to differentiate was tested in 
growth as xenografts in nude mice (data not shown). This demonstrated a 
variation in the capability of these cultures (mostly immortal carcinomas) to 
undergo terminal differentiation; BICR56 and BICR31 formed large keratin filled 
cysts whereas BICR22 grew as solid nests with no keratinisation evident. In 
addition, the fact that the expression of RAR-, 8 in the immortal dysplasia 
cultures (either in monolayer or in organotypic culture) did not match that in the 
corresponding tissue, suggests that the link between immortality and a lack of 
differentiation may neither be strong nor causal and may be profoundly affected 
by the microenvironment and/or time. This requires further work, perhaps 
utilising more sophisticated organotypic culture systems, for example with 
tumour fibroblasts and other stromal elements, to attempt a more complete 
recapitulation of the microenvironment, as indicated earlier. 
7.7 Markers of high risk in clysplastic lesions 
A GEP of dysplastic lesions in relation to progression to carcinoma has not 
been reported in the literature. The first published data on the gene expression 
profile of PMLs in comparison to HNSCCs was that by Ha and coworkers (Ha et 
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al., 2003). However, there was no follow-up data given in this study to allow for 
assessment of "high risk" markers of transformation to HNSCC. This analysis 
suggested that the gene expression pattern of the dysplastic lesions became 
progressively more like that of HNSCCS with increasing grade of dysplasia. 
Indeed, the number of significant differences in gene expression between the 
dysplastic and HNSCC samples was very small. Additionally, the GEP of 
clinically normal tissue adjacent to dysplastic lesions was very different for true 
normal tissue. However, in both cases, the number of samples was small. 
There are two possible explanations for these patterns of gene expression: 
heterogeneity due to large variation in the expression profiles of PMLs or little 
real difference. Despite the authors' emphasis on the latter, it is clear that there 
was appreciable heterogeneity in the dysplasia samples reported in the study. 
Despite the existence of outliers in the cluster analysis, it appears that all the 
dysplasia samples were used in the comparison with HNSCCs, presumably, as 
the numbers were too small to give any statistical significance without the 
inclusion of the outliers. Thus, the size of the final gene list, and the genes 
contained within it, may be a little misleading. Despite this, we have also found 
that the difference between the dysplastic and invasive samples (mortal or 
immortal) is much smaller than for comparisons of the same samples with 
normal cells. 
The completeness of follow-up data in the cases that progressed to carcinoma 
is vital in establishing a true relationship between each patient's dysplastic 
lesion and any subsequent malignant disease. In the case of the three immortal 
dysplastic cultures from patients who developed a carcinoma (D19, D20 and 
D35), the follow-up data clearly demonstrates that the original dysplastic lesion 
and the carcinoma were from the same anatomical site in the mouth. The 
provenance of these lesions as is progressors" is, therefore, good. However, it 
has not been possible to obtain follow-up data beyond one year for the mortal 
erythroplakia cultures and therefore the clinical history of the patients and the 
natural history of their lesions cannot be stated with any degree of certainly. 
This must be borne in mind when extrapolating from this data into the clinical 
situation. 
Analysis of the gene expression profiles of the cultures derived from the 
clysplastic lesions that progressed to HNSCC is ongoing. This work, presently 
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being continued by Dr Paul Drake, is attempting to identify a genetic pattern that 
is a signature of high risk of progression to carcinoma in a dysplastic lesion. 
This is complicated by the identification of the two possible pathways to HNSCC 
development, as described earlier. The small number of changes seen within 
the two pathways and the large number of differences between the pathways, 
as shown in Figure 7.2, means that consistent markers of high risk of dysplasia 
progression, regardless of proliferative lifespan, are unlikely to be identified. 
Thus, two different panels may emerge - one specific to the mortal lesions and 
another to immortal lesions. In practical terms, this would result in lesions first 
being screened for markers of the mortal or immortal phenotype, before the use 
of the appropriate high risk panel of markers. 
The small number of samples at our disposal is an obvious limitation of such 
analysis. However, the retrospective and prospective studies will be useful in 
the validation of any potential markers. The establishment of new dysplasia 
cultures may also be beneficial, but this is dependent on careful follow-up of 
lesions with no guarantee that the patient from whom the culture was 
established will develop a carcinoma, as only a small proportion of the lesions 
will progress to HNSCC. Thus, establishing whether high risk lesions are mortal 
or immortal (or mixed) may be important as a first stage in analysis of dysplastic 
lesions, with markers of high risk used subsequent to this. 
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7.8 Future work 
7.8.1 Completion of validation steps 
The future direction of the project depends largely on the completion of 
validation of the gene expression profiles and exploration of many of the 
possible hypotheses and molecular mechanisms outlined above. Validation of 
the selected novel immortality markers in dysplastic tissue related to the 
cultures is a vital step. Where commercial antibodies are not available, other 
gene expression changes of interest must be validated by quantitative RT-PCR 
and a decision made as to the necessity of raising antibodies for future 
immunoblotting and immunohistochemistry. The completion of this element will 
allow decisions to be made as to the future direction of the research. Whilst 
some of the basic functional experiments, such as knockout of RAFý8 from 
mortal cultures have also yet to be completed, the advent of RNAi in the interim 
period may allow such interventions to be accomplished more easily. 
7.8.2 Mechanism of invasion 
The possibility that different mechanisms of invasion are used by mortal and 
immortal cells requires further investigation. However, this will require the 
derivation of more mortal carcinoma cultures, as our current stocks are almost 
exhausted. New ethical approval for the collection of material for this purpose 
still requires to be obtained. It may be possible to immortalise some of the 
remaining stocks of mortal carcinomas and indeed, Ken Parkinson plans to 
attempt this by ectopic expression of hTERT in these cultures. However, it is 
not clear what effect this may have on the invasive properties of these cells. 
The use of Matrigel Invasion assays and scratch wound assays initially to 
assess the movement of the immortal and mortal (where possible) cells would 
be a useful starting point in the assessment of the different types of migration in 
these cells 
7.8.3 Tumour microenvironment 
Further organotypic culture experimentation with a more concerted attempt at 
reconstitution of the microenvironment is required. This is particularly important 
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as the mortal cultures do not appear to have the ability grow as xenografts in 
nude mice. It may also be possible to utilise the new dysplasia associated 
fibroblast cultures collected in the prospective study. This may help 
demonstrate the influence that the microenvironment has on the cultures. It 
may also be possible to gain permission for the derivation of new tumour 
associated fibroblast cultures when the prospective study for SCC samples is 
set up. 
In relation to the poor agreement of RAR-, 8 expression in the tissues related to 
immortal cultures, the role of RAR--fl in immortalisation requires further 
investigation. It may now be possible to knock out the expression of RAR-fl in 
mortal cultures, for example by use of RNAi, or ectopically express it in immortal 
cultures. 
7.8.4 Clinical studies 
As indicated above, retrospective and prospective studies have been 
commenced for the analysis of both dysplastic and invasive oral lesions. These 
will allow us to test many of these hypotheses regarding the different pathways 
and cells of origin in development of HNSCC. This material also forms an 
important part of the ongoing work of the group in terms of markers of high disk 
of dysplasia progression to carcinoma. 
Retrospective study 
Markers validated at RNA and protein level in the cultures will be tested in a 
retrospective study. All patients since 1990 who have developed a squamous 
cell carcinoma at the same intraoral site as a previous dysplastic biopsy will be 
included. At present 26 such patients have been identified for inclusion. These 
patients will be assigned three control dysplastic lesions that have not 
developed into HNSCC. This will be matched for: 
o age 
* sex 
risk factors (smoking and alcohol intake). 
The markers will be assessed in formalin fixed, paraffin embedded tissue 
sections by immunohistochemistry, with attention paid to staining location, 
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intensity and proportions of cells stained, using the Quickscore method (Detre 
et al., 1995). This will form part of Dr Paul Drake's project. 
Prospective study 
Markers which look promising in the retrospective study will then be forwarded 
into the prospective study. This removes the unavoidable bias of a 
retrospective study, can allow for the effect of clinical intervention and will also 
allow a large enough study sample to be collected to allow conclusions to be 
drawn despite the presence of clinical variables. Ethical approval for this 
project has been obtained. Both fresh and formalin-fixed material will be 
collected and consent for access to medical records (including ISID cancer 
registration data) will be obtained. Funding will be sought for a new microarray 
study on this material. Patients recruited must: 
have a clinical indication for an biopsy of a white or red patch. 
be 20-70 years of age 
have no history of previous HNSCC 
a confirmed diagnosis of dysplasia and no other concurrent oral 
pathology (e. g. candidosis and immunological diseases are excluded). 
Assuming 10% progression over 10 years, the study requires to recruit 250 
patients to detect a significant (p<0.05) difference in a single marker with 80% 
power. The patients will be followed for at least 5 (hopefully 10 years) and 
approached for donation of another sample if a biopsy is clinically indicated. 
For the purposes of the study, follow-up will be censored once a patient 
develops a SCCHN at the same site as the original biopsy. Results will be 
analysed using the Cox's proportional hazards model and Kaplan Meier survival 
curves. 
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